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The extracellular envelope glycoprotein (gpl35) of
maedi-visna virus interacts with cellular receptor molecules
and is the major target of neutralising antisera in vivo.
Antigenic drift of gpl35 may have an important role in viral
persis tence.
In order to begin to investigate the roles of different
regions of gpl35, yeast and bacterial expression systems were
used to generate recombinant protein and gpl35 was expressed
as 3 overlapping fragments. There have been no published
reports of expression of recombinant gpl35 proteins.
By using the proteins to screen sera from infected
sheep it was shown that sheep vary in the regions of gpl35 to
which they mount an antibody response detectable in this
system. At least 3 epitopes on gpl35 are recognised by sera
from infected sheep.
The recombinant proteins were used to investigate
interactions of gpl35 with cellular molecules, and as
immunogens to raise gpl35-specific sera. Possible future
experiments using these reagents are suggested.
gpl35 fragments derived from different viral stocks of
the British isolate of maedi-visna virus were sequenced, to
obtain a preliminary estimate of the extent of the
variability of the gene. The data suggested the presence of
both relatively conserved and variable regions in gpl35.
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1.1 Brief Historical Background To Maedi-Visna Virus
Maedi-visna virus (MVV) was initially isolated and
characterised as a consequence of an epidemic of a
progressive pneumonia ("maedi"), accompanied in some cases
by progressive paralysis ("visna") which arose in
Icelandic sheep flocks between 1939 and 1952. The disease
had not previously been recognised. 150,000 animals were
lost due to the disease and a further 650,000 destroyed in
a successful attempt at disease control (Sigurdsson,
1954a). Transmission of the disease to healthy animals
via selected tissue preparations from affected sheep was
demonstrated (Sigurdsson, 1954a : Sigurdsson e_t al. ,
1957) and in 1967 a single virus was shown to be the
causative agent of both sets of symptoms (Gudnadottir &
Palsson, 1967).
The outbreak of maedi-visna disease on Iceland has
been traced (Sigurdsson, 1954a) to the importation in 1933
of twenty sheep of the Karakul breed from Germany. From
the epidemiology of the subsequent outbreak it would
appear that at least two of the imported animals were
infected with MVV, which had never been seen to cause any
disease in Germany. The reasons for its dramatic spread
in Iceland probably included the more intensive conditions
under which sheep tended to be housed, and its
introduction into a sheep population which had been
effectively isolated from mainland Europe for hundreds of
years.
MVV and the disease which it causes has now been
recognised in numerous countries, including the
Netherlands where it is known as zwoegerziekte (De Boer,
1970), the United Kingdom (Watt e_t al., 1990), South
Africa (Querat e_t al. , 1990), the United States of
America, where it is sometimes known as ovine progressive
pneumonia virus (Cutlip & Laird, 1976), Greece (Seimenis
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£t a_I. , 1985) and Belgium (Biront and Deluyker, 1985). In
none of these cases has it had the same economic impact as
in the Icelandic outbreak although it can be of importance
in flocks with a high incidence of MVV infection.
MVV was used (Sigurdsson, 1954b) as a model for a
new form of virally-induced disease which Sigurdsson
defined as "slow", distinguishing this from a chronic
disease such as tuberculosis. Currently MVV has become a
focus of research interest because of the increasing level
of detection in commercial flocks, and due to its possible
use as an animal model for certain aspects of infection by
human immunodeficiency virus (HIV).
1.2 Classification Of MVV
MVV is the prototypic member of the Lentivirinae
subfamily of the Retroviridae family which includes HIV-1
and HIV-2, feline immunodeficiency virus (FIV) (Pedersen
et al., 1987), simian immunodeficiency virus (SIV) (Letvin
et al., 1985), caprine arthritis-encephalitis virus (CAEV)
(Crawford e_t a_l. , 1980), bovine immunodeficiency virus
(BIV) (Gonda £t al^. , 1987) and equine infectious anaemia
virus (EIAV) (Dreguss & Lombard,1954). With the exception
of EIAV in which disease episodes tend to be cyclical the
diseases caused by the lentiviruses are characterised by
their relatively slow onset and progressively debilitating
course.
In common with the other members of the subfamily,
MVV possesses a positive-sense single-stranded RNA genome
(ssRNA) (Brahic e_t al. , 1977), an RNA-dependent DNA
polymerase (reverse transcriptase) (Lin & Thormar, 1970)
and replicates via a DNA intermediate (Haase & Varmus,
1973). The lentiviruses are distinguished from the other
retroviruses by their more complex genome structure, which
in addition to the gag, pol and env genes contains a
number of small open reading frames (orfs) which code for
regulatory proteins. This results in a complex
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transcription pattern (Vigne et a_1. , 1990).
Phylogenetic comparisons of the lentiviruses differ
in fine detail, partially dependent on the gene and viral
strain studied. However there is reasonable consensus
that MVV is more closely related to the non-primate
lentiviruses than to the primate species (Olmsted e_t al. ,
1986 : McClure ejt a_l. , 1988), but the relationship between
HIV and MVV is closer than that of HIV with various
oncogenic retroviruses (Gonda ^t a_l. , 1985), thereby
acting as a further justification for the inclusion of
these viruses in the same subfamily.
1.3 The MVV Genome
Six MVV isolates have been sequenced; these represent
four variants of the 1514 Icelandic strain (Sonigo e_t
al. , 1985; Braun e_t al. , 1987; Staskus e_t , 1991),
South African-Ovine Maedi Visna Virus (SA-OMVV) (Querat £t:
al. , 1990) and the British isolate EV1 (Sargan e_t al. ,
1991). The genome structures derived are broadly similar,
albeit with some relatively minor differences. Figure 1.1
is a schematic representation of the MVV genome
organisation.
The genome size varies from 9202 bases for 1514 to
9256 nucleotides for SA-OMVV. The long terminal repeat
(LTR), divided into the U3, R and U5 regions, contains a
primer binding site complementary to that for tRNA^ys^ 2
and a polypurine tract which acts as the initiation site
for positive strand DNA synthesis. A well-defined TATA
box begins at nucleotide 438 and CCAAT consensus sequences
begin at bases 352 and 364 (Hess e_t al. , 1985). The LTR
contains target sequences which influence levels of
transcription of the genome (section 1.5) many of which
appear to be located within the 43base-pair tandem repeats
found in the LTRs of all isolates studied. However, while
SA-OMVV and 1514 contain two copies of the 43 basepair
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to contain only one such copy. The functional
significance of this is unknown.
The viral gag gene encodes the structural
nucleoproteins (section 1.4).
By analogy with other retroviruses the pol gene
encodes the reverse transcriptase, an
endonuclease/integrase and also contains the core sequence
of a viral protease, although this activity has not been
directly demonstrated for MVV.
The most 3' structural gene is the env gene which
codes for the external and transmembrane glycoproteins
(section 1.15). All isolates encode an Arg-Lys-Lys-Arg
which represents the cleavage site between the outer and
transmembrane glycoproteins. A predicted RNA secondary
structure within env functions as a cis-acting target
sequence for the Rev protein (Tiley e_t £l_. , 1990).
Of the proteins encoded by the small orfs Tat is
encoded by a single exon, unlike the situation in HIV
where transcription from two exons is required (Arya e_t
al, , 1985). Rev is coded for by two exons, at the 5' and
3' ends of the env gene, the 5' region being in the same
reading frame as env. An open reading frame with sequence
homology for HIV vif (Strebel (2t al. , 1987) is also
present.
There is an additional orf, termed W, in SA-OMVV
(Querat e_t al, 1990). There have been no reports of a
functional protein from this orf, and it does not appear
to display extensive sequence homology with any other
lentiviral orf.
There have been no reports of MVV orfs analogous to
the HIV-1 genes vpr (Ogawa e_t a_l. , 1989), vpu (Strebel ejl
al. , 1988), tev (Benko ^t a_l. , 1990) or nef (Ahmad &
Venkatesan, 1988) although an element homologous to a
functionally required HIV-1 Nef sequence has been
identified in EV1 (Sargan e_t al. , 1991).
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1.4 Proteins Of MVV
Initial studies of the proteins synthesised from the
MVV genome were hampered by problems in excluding cellular
proteins from the assays, and difficulties in the
determination of molecular weights, particularly for the
glycoproteins. Estimates for the number of polypeptides
in the virion ranged from eleven to fourteen (Mountcastle
et al., 1972), fifteen (Haase & Baringer, 1974) to twenty
five (Lin, 1978). With the advent of monospecific anti-
MVV sera, followed by molecular cloning advances, much of
this confusion was resolved.
The major precursor of the gag-encoded proteins is a
non-glycosylated molecule of 55kDa (Pr55§aS) (Vigne e_t
al. , 1982) which is cleaved to form the mature proteins
p30 (core protein) (occasionally referred to as p25), pl6
(matrix protein) and pl4 (nucleoprotein). Pulse-chase
experiments indicated that the processing and cleavage
occurred intracellularly. These are the major internal
structural proteins of MVV.
A 150Kda precursor molecule of the gag-encoded
products is also detectable in infected cells (Vigne e_t
al. , 1982). By analogy with other retroviruses this is
believed to be both a Gag and a Pol precursor; this
polyprotein is generated by a ribosomal frame-shifting
9 +
event. The MVV reverse transcriptase is Mg^ dependent
but has similar pH, substrate and temperature requirements
to the Mn^+-reverse transcriptases of the type-C
retroviruses (Lin and Thormar, 1970). Production of the
predicted integrase and possible protease proteins has not
been directly demonstrated, although reports of
integration of the MVV genome (Vigne e_t al_. , 1985), and
the cleavage of the Gag-Pol precursor molecules suggests
that both these functions may be present.
Only the env-encoded proteins (section 1.15) of MVV
have been shown to be glycosylated. Pulse-chase
experiments (Vigne e_t _al. , 1982) demonstrated that the Env
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glycoprotein is produced as a glycosylated 150kDa
precursor, which is subsequently processed to a 135kDa
form. The nature of this processing is unclear.
Glycosylation inhibitors indicated that the non-
glycosylated precursor to the 150kDa molecule had a
molecular weight not exceeding 105kDa, and theoretical
considerations suggested that the maximum size of the non-
glycosylated form of the Env molecule would be 95kDa
(Vigne e_t al. , 1982). Env is variously referred to as
gpl35 or gpl05.
The 1982 paper of Vigne e_t a_l. does not specifically
state whether gpl35 represents the entire env-encoded gene
product, or the extracellular region only. In addition to
the high molecular weight glycoprotein glycosylated
proteins with estimated molecular weights of 46kDa and
51kDa have been observed (Haase & Baringer, 1974) in viral
preparations. By analogy with other retroviruses, and the
fact that most analyses have been conducted using reducing
conditions, where the outer and transmembrane
glycoproteins would be expected to dissociate it is likely
that gpl35 represents the extracellular region of Env and
the transmembrane region is the gp46/gp51 glycoprotein.
For consistency gpl35 will refer to the outer membrane
glycoprotein, gp46 to the transmembrane glycoprotein, and
Env will be used when it is unclear from the literature
which region of the env-gene product is under discussion.
The rev gene encodes a 19kDa polypeptide (Mazarin e_t
al., 1990) necessary for the cytoplasmic expression of the
incompletely spliced env mRNA (Tiley e_t a_l. , 1990). HIV-1
Rev contains a region near the N-terminus of forty amino
acids, with a highly basic core, mutations of which affect
binding of Rev to the Rev-responsive element (RRE) (Hope
et al. , 1990) and a ten amino acid leucine-rich region
towards the C-terminus of the protein, mutations in which
have no effect on RRE binding, but which produce a
negative viral phenotype (Hope e_t al., 1990). These major
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functional domains are moderately conserved in MVV (Tiley
et al., 1991).
The tat gene encodes a protein of lOkDa (Davis &
Clements, 1989) or llkDa (Gourdou e_t a_l. , 1989)
characterised by the presence of a cysteine-rich domain.
Tat acts as a positive transactivator of viral
transcription; it has been shown (Gourdou et al., 1989) to
increase steady-state levels of LTR-directed mRNAs.
The vif gene encodes a 29kDa protein which is
detectable late in the lytic cycle in vitro (Audoly e_t
al., 1992). Vif is cytosolic in location and appears to
be absent from cell-free virions (Audoly _et _al. , 1992).
1.5 The MVV Life Cycle
In common with the other lentiviruses MVV
characteristically displays very different patterns of
transcription and replication in vitro and in vivo. In
permissive cells in vitro MVV causes extensive cytopathic
effect (CPE) with formation of multinucleated giant cells
and the release of free infectious virus into the culture
medium. This lytic cycle is usually complete in three
days (for strain 1514). In vivo however the viral life
cycle is interrupted and this has important consequences
for viral persistence.
The lytic cycle has been the more thoroughly
investigated and will be described first; the in vivo
infection will be described in terms of its variation from
the lytic process.
1.5.1 In Vitro
Binding of MVV to a cellular receptor (section 1.12)
is followed by viral fusion, entry and uncoating. Much
work remains to be performed on these early stages in
infection. The first stage in viral transcription and
replication is reverse transcription of the viral ssRNA to
form double-stranded DNA (dsDNA). The basic pathway is
thought to be similar to the reverse transcription of most
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retroviruses (review see Dahlberg, 1988), and initiated by
binding of tRNA^y3-^ 2 t0 primer binding site of the
LTR (Sonigo e_t al. , 1985).
By analysis of the low molecular weight DNA fraction
from MVV-infected sheep choroid plexus cultures it was
determined (Harris e_t a_l. , 1981) that the major
extrachromosomal form of MVV was a linear molecule,
comprising a full-length negative strand and a positive
strand that contained a gap of 300-500 base pairs just 3'
of the centre of the linear molecule. It has been
suggested (Sargan e_t a_l. , 1991) that the presence of a
polypurine tract in this region may act as an alternative
second strand primer site. While some authors have
reported that this gapped linear duplex DNA is by far the
predominant form in the infected cell (Blum £t: £l_. , 1985)
other workers (Vigne et £l_. , 1985) have suggested that it
forms no more than 20% of the viral DNA. The structure
has not been conclusively demonstrated in other
lentiviruses and its significance is not clear.
It has been claimed (Harris et a_l. , 1984) that there
was no detectable integration of MVV DNA into host
chromosomal DNA during a lytic infection. Closed circular
DNA is believed to be the topologically preferred form for
integration (Panganiban & Temin, 1984) and only 0.1% of
the molecules in MVV-infected choroid plexus fibroblasts
are in this form (Harris e_t _al. , 1981). However,
integration has been reported (Vigne £t^ ajL. , 1985) when
infecting ovine foetal cornea cells rather than choroid
plexus fibroblasts. Integration may therefore be more
likely to occur in cells with a higher divisive capacity,
or influenced by other cellular factors, but there is no
evidence to suggest that it is essential for the infective
process in vivo.
dsDNA serves as the template for transcription of
viral genes, and for the full-length genomic RNA which
will be packaged into virions. MVV has a complex
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temporally regulated pattern of transcription. Eight
hours after infection of ovine foetal trachea cells with
virus strain 1514 no viral RNA was detected (by Northern
blotting), presumably as a consequence of reverse
transcription of the input RNA (Vigne e_t aJL. , 1987). At
twenty four hours post-infection a low level of mRNA
species with apparent sizes of 1.2 to 1.6kb (subsequently
redefined as 1.4 and 1.7kb (Gourdou jet al_. , 1989) ) were
detectable and at seventy two hours post-infection these
were accompanied by species of 9.4kb, 3.7kb, 4.3 and
4.8kb. This suggested temporal regulation of expression,
with the small mRNAs expressed first, followed by the
larger species. A similar pattern has been reported
using the same virus strain to infect choroid plexus cells
(Sargan & Bennet, 1989).
These results contrast with those obtained by Davis
et al., (1987), using the same virus strain and cell type
as Sargan & Bennet (1989). Although Davis found a complex
transcriptional pattern it differed in a number of
details from the work outlined above. At six hours post¬
infection 9.4, 5.0, 4.3 and 1.8kb mRNA species were
detectable. By twelve hours post-infection a 1.5kb mRNA
was also detectable, at levels almost equivalent to the
1.8kb molecule, and both continued to increase up to at
least twenty-four hours.
All three studies suggested that the two smallest
mRNA species were multiply spliced, containing sequences
from the 5' end of the genome, the central region between
the pol and env genes and terminal 3' sequences. The 3.7
to 4.8kb mRNA species were singly spliced with sequences
from the 5' end of the viral genome being spliced to
acceptor sites 3' of the pol gene, and the 9.4kb molecule
was unspliced. The full-length message is believed to
code for the Gag-Pol precursor molecule, and the
intermediate molecules for Env, and also the sequences
homologous to Vif.
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Although they may differ in detail, some of which may
be due to experimental variations, all these studies
indicate there is complex temporal regulation of
expression of the different viral mRNAs, and it is
believed that the small, multiply spliced mRNAs play a
critical role in this temporal regulation.
The fully spliced transcripts are believed to encode
the tat (Gourdou e_t al., 1989) and rev messages (Tiley ej;
al. , 1990). Co-transfection into COS cells of a rev and a
LTR-beta globin construct showed that the rev construct
trans-activated the viral LTR sequences, either directly
or indirectly (Mazarin e_t a_l. , 1988) Experiments with
vectors encoding rev and env demonstrated that cytoplasmic
expression of the singly spliced env mRNA required
expression in trans of the rev gene product (Tiley e_t al. ,
1990) and demonstrated a RRE 3' to the transmembrane
protein cleavage site. The mechanism by which Rev
increases expression of the singly spliced mRNAs is
unclear, and has been referred to as "stabilisation" of
the mRNA (Vigne e_t al. , 1990).
In MVV infection therefore Rev appears to be at least
dual-functional; it can increase expression of mRNAs from
the LTR, and acts to allow the expression of singly
spliced env mRNAs in the cytoplasm, the appearance of
which is a critical event in progression of a lytic
infection in vitro. There is some dispute regarding the
cellular localisation of Rev protein in the cell. Mazarin
reports a predominantly cytoplasmic location (Mazarin e_t
al. , 1990) in MVV-infected ovine cells and a similar
pattern has been reported in COS cells transfected with a
rev construct (Vigne e_t a_l. , 1990). However, for a
similar construct also transfected into COS cells a
nuclear, and specifically nucleoli-based pattern of
expression similar to that observed with HIV has been
reported (Tiley et al., 1990). There is no clear
explanation of this discrepancy.
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Co-transfection experiments using Tat-expressing
constructs and MVV LTR-beta globin gene constructs showed
a dose-dependent steady-state increase in the levels of
beta globin mRNA with Tat (Gourdou £t al. , 1989). The
extent of the increase depended on the cell type
transfected, suggesting possible interaction(s) with
cellular factors. Unlike HIV (Feng & Holland,1988) no RNA
hairpin structure which acts as a target sequence for Tat
has been identified in the MVV LTR. It is not known if
the nuclear post-transcriptional activity observed with
HIV Tat (Braddock ejt al. , 1989) is present in MVV
Translation of the mRNAs, and subsequent processing
of the proteins is dependent on cellular enzymes and
organelles.
Lytic infection leads to massive amplification of
viral genomes with reports of cells containing in excess
of 4000 copies of viral RNA (Brahic e_t aj.. , 1977).
At the end of the lytic cycle the viral genomic RNA
and structural and polymerase proteins are packaged.
Early work suggested polyploidy of the packaged RNA
(Beemon e_t aX., 1976; Vigne ert a_l. , 1977) and by analogy
with other retroviruses MVV is now described as diploid.
Electron microscopic studies (Thormar, 1961 : Coward e_t
al., 1970) of MVV-infected cell cultures in vitro showed
MVV virions to have a size range of 65-110mu with a
centrally located osmiophilic core, separated from a
single outer membrane by a layer of low electron density.
The particles form by budding either from the surface of
infected cells or into macrophage vacuoles (Georgsson e_t
al., 1990)
1.5.2 In Vivo
While the basic pattern of reverse transcription and
gene expression is believed to occur by similar mechanisms
in vitro and in vivo the latter situation is subject to
much greater constraint. Virus cannot usually be
recovered from tissue homogenates from infected animals
- 12 -
but if these are explanted, or if the tissues are
maintained in culture with a permissive cell type then
infectious virus can be detected. This is consistent with
a block on viral replication in vivo which is relieved
under tissue culture conditions.
In choroid plexus tissue of experimentally infected
lambs proviral DNA was detected in 18% of the cells
examined by in situ hybridisation, at levels of 100-200
copies per cell. However the p30 protein was only
detected by immunofluorescence in 0.1% of these viral DNA-
containing cells (Haase ej: _al. , 1977). Similar
subsequent experiments (Brahic e_t a_l.., 1981) found that
only 1% to 3% of choroid plexus cells contained viral DNA,
at 60-70 copies per cell, and viral RNA was present at
levels two orders of magnitude lower than that seen in
permissive cells in vitro. This suggested that the
restricted expression of MVV in vivo was at least
partially due to a transcriptional block.
In contrast, it has also been observed that 15% of
alveolar macrophages of experimentally infected lambs
contained greater than 1000 copies of viral RNA, but that
only approximately 1% of the cells expressing viral RNA
produced virus (Gendelman e_t ad., 1985). The authors
suggested that this indicated a post-transcriptiona1 block
on viral replication. However, the experiments did not
involve immunological staining of the same cells which had
been assayed by the in situ hybridisation technique. It
was not therefore demonstrated that the macrophages which
were expressing very high levels of viral RNA were not
also expressing viral proteins, since the range of viral
RNA expression was from 50-1000 copies per cell.
Restricted replication in vivo has also been
demonstrated in monocytes taken from different anatomical
locations. Restricted viral RNA expression has been
reported in monocytes obtained from the lateral ventricles
of experimentally infected sheep (Peluso e_t a_l., 1985) and
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restricted viral RNA levels have been demonstrated in
monocyte/macrophage precursor cells in the bone marrow
(Gendelman et al., 1985). Viral genomes in precursor
cells may act as a "reservoir" of viral infection in vivo,
thereby contributing to viral persistence in the host
animal.
The molecular events controlling this restricted
replication and gene expression in vivo and release from
these restrictions in vitro remain to be fully elucidated.
Data suggests that viral gene expression increases during
the maturation of monocytes to macrophages (Gendelman e_t
al., 1986) and sequences in the viral LTR may be involved
in regulation of transcription in vitro in different cell
types.
The 43bp tandem repeats found in all MVV LTRs can act
as enhancer elements for a heterologous viral promoter
(Hess e_t al_. , 1985) and basal transcription levels in
sheep choroid plexus cells is highly dependent on
sequences within these repeats (Hess e_t al. , 1989). Each
repeat contains two copies of a site related to the AP-1
binding site and the LTR also contains a single AP-4
binding site (Gabuzda e_t a_l, 1989). In order to
investigate the role of cellular factors on activation of
the viral LTR mice transgenic for a LTR-CAT
(chloramphenicol acetyltransferase) construct were created
and LTR-driven CAT expression assessed in various tissues
(Small e_t a_l. , 1989). Expression in resident peritoneal
macrophages was low but these levels increased if the
macrophages were activated using thioglycolate. This
artificial situation may reflect the increase in viral
activity observed in the maturation of monocytes to
macrophages (Gendelman e_t a_l. , 1986). Perhaps
unexpectedly CAT expression was also observed in splenic
lymphocytes (Small e_t al. , 1989) but this was not up-
regulated during cellular activation, suggesting an
absence in lymphocytes of cellular factors required to
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activate the LTR. The AP-1 sites probably mediate the
serum responsiveness of the LTR (Hess e_t a_l. , 1989) and
the AP-1 site most proximal to the TATA box is probably
the most crucial in regulating induction of gene
expression from the LTR (Gabuzda e_t a_l. , 1989).
Although much remains to be discovered about the
restricted life-cycle of MVV in vivo it is probable that
interaction of cellular factors with the viral genome, and
perhaps particularly the LTR, may play a critical role
both in limiting viral replication under the majority of
in vivo conditions, and in relieving this block on the
viral life-cycle in tissue culture or when a latently
infected cell is activated.
1.6 Clinical Consequences Of MVV Infection
The extraordinarily long incubation period for MVV,
noted during the initial outbreak as one to three years or
more (Sigurdsson, 1954a) is followed by the onset of
disease symptoms with little subsequent regression and a
generally increasingly pathological course. Various organ
systems are affected and histopathologically the lesions
are characterised by their inflammatory nature.
The most commonly reported symptom is dyspnoea, which
becomes particularly obvious if the affected animal is
exercised. On post-mortem examination the lungs may be
two to four times heavier than normal with decreased
elasticity and a degree of fibrosis (Sigurdsson, 1954a).
Histologically the alveolar septa are thickened, due to an
accumulation of plasma cells, mononuclear phagocytes and
lymphocytes (Georgsson & Palsson, 1971). There is an
accompanying formation of lymphoid follicles with active
germinal centres (Lairmore e_t a_l. , 1986) and the regional
lymph nodes are enlarged. Interest in the condition has
been stimulated by its resemblance to the lymphoid
interstitial pneumonia observed in paediatric AIDS cases.
In animals with neurological infection gait is
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affected, with paresis of the hindquarters progressing
until paraplegia develops. The main histological lesion
is demyelination and destruction of white matter in the
brain, cerebellum and spinal cord (Sigurdsson e_t al. ,
1957). The lesions tend to be initiated periventricularly
and are inflammatory in nature. Primary lesions appear to
be focussed on the glia with little neuronal destruction
(Sigurdsson & Palsson, 1958), and ifection of
oligodendrocytes and astrocytes by MVV has been confirmed
in vivo (Stowring et al., 1985).
The mammary gland has also been shown to be affected
by MVV, resulting in a chronic indurative mastitis (van
der Molen e_t al^. , 1985) again characterised by marked
lymphoid hyperplasia and slight to moderate fibrosis.
Arthritis has been observed in MVV-infected sheep,
involving swelling and calcification of soft tissue,
fibrosis of the joint capsule and synovium and
perivascular lymphocytic infiltration (Oliver et al.,
1981). This is similar to the arthritis observed in CAEV-
infected goats (Crawford £t a_l. , 1980).
In certain flocks MVV is found in the same animal as
Jaagsiekte retrovirus, the causative agent of sheep
pulmonary adenomatosis (Payne jsJ; at, 1986). There have
been tentative suggestions of in vivo synergism between
the two retroviruses (DeMartini ^_t aT. , 1987), based on
accelerated development of lesions when both viruses are
present. Readily quantifiable data to support this has
not been presented.
In contrast to the oncoviruses there is no clear
evidence for any oncogenic action by the Lentivirinae
members. Although two early reports (Takemoto & Stone,
1971 : Macintyre e_t a/L. , 1972) suggested a causative role
for MVV in transformation of murine and human cells
respectively, these studies were marred by the use of cell
lines which showed a high tendency to "spontaneous"
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transformation. There are no confirmed reports of a truly
oncogenic effect of MVV in ovine cells.
1.7 Pathogenesis
One of the outstanding unsolved problems in
lentiviral diseases is the mechanism of pathogenesis. MVV
persists in the infected host despite a humoral and cell
mediated immune response (section 1.10) In vivo the
number of detectable productively infected target cells
is low; figures of 1 in 100,000 circulating leukocytes
have been quoted for MVV (assayed by virus isolation)
(Petursson £t a_l. , 1976). While this figure may show some
variation within different cell populations in different
target tissues it never reaches levels high enough to
account directly for the extensive lesions which develop.
There have been no reports in vivo of the directly virally
mediated formation of syncytia which are observed in
vitro.
The predominantly inflammatory nature of the lesions
in MVV-induced disease suggested that the disease
mechanism could be immunopathological in nature. Support
for this hypothesis was obtained from experiments
(Nathanson e_t a_l. , 1976) showing that immunosuppression of
sheep led to a major decrease in early central nervous
system lesions, but no demonstrable decrease in viral
replication.
There have been various reports of alterations in
immunological parameters in MVV-infected sheep, although
none are as dramatic as the depletion of CD4-positive
lymphocytes observed in HIV infection ( Gottlieb £t al. ,
1981). Elevated serum immunoglobulin concentrations have
been reported in MVV-infected sheep (Molitor e_t jQ. , 1979)
although the technique used was crude (zinc sulphate
turbidity) and did not distinguish between MVV-specific
and non-MVV-specific antibodies. If levels of MVV-
specific immunoglobulin were consistently elevated this
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could operate as an immunopathological mechanism, through
the formation of immune complexes and aberrant clearing of
these. There have however been no direct reports of such
a mechanism in MVV-induced disease.
Elevated numbers of cells (not identified) in the CSF
of experimentally infected animals have been reported
(Petursson e_t a_l. , 1976); this was generally most marked
in the first three months post-infection although most
animals continued to show an elevated level thereafter.
It has been reported (Lairmore e± a_l. , 1988a) that
bronchoalveolar lavage samples from experimentally-
infected lambs show a 1.5 fold increase of total
leukocytes, and a 4 fold increase of lymphocytes, over the
values found for uninfected lambs. 65% of these
lymphocytes were CD8-positive, compared with 25% for the
control animals. An increase in the absolute numbers of
CD8-positive lymphocytes in the circulation of a single
clinically affected sheep has also been reported (Kennedy-
Stoskopf e_t ad., 1989).
Bronchoalveolar lavage of lungs from naturally
infected sheep (diagnosed histopathologically)
demonstrated a doubling of total cell number but no
significant difference in the percentage of these cells
which were lymphocytes (Cordier e_t a_l, 1990). No
information was available on the clinical status of these
sheep (which were obtained from a commercial abattoir)
prior to slaughter. There was a significant increase (13%
against 5% for normal animals) in the percentage of
neutrophils in the lavage. The same paper also
demonstrated elevated spontaneous release of a neutrophil
chemotactic factor and fibronectin by macrophages obtained
from the infected lungs. This activity may play a role in
the recruitment of inflammatory cells to the lesion, and
in the fibrosis observed in affected lungs.
15.5% of alveolar macrophages from bronchoalveolar
lavage material from uninfected sheep expressed major
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histocompatibility (MHC) class II antigens but this level
was increased to 50.1% in the infected sheep (Cordier e_t
al. , 1990). Other workers have also reported increased
MHC class II levels on macrophages from infected animals
(Kennedy e_t , 1985) and have postulated that this is a
consequence of induction of an interferon after
interaction between lymphocytes and lentivirus-infected
macrophages (Narayan e_t al^. , 1985). Spontaneous release
of interferon by pulmonary leukocytes (Lairmore e_t al. ,
1988b) taken from lambs with severe lymphoid interstitial
pneumonia, but not from uninfected or asymptomatic
controls has been reported. It is not clear if the
interferon detected in these sets of experiments belongs
to the previously characterised classes of interferons or
is a novel molecule.
Much of the data described above for macrophages
suggests a possible "over-activation" of the cells, with
increased release of inflammatory mediators, which in turn
would attract inflammatory cells to a lesion. It is
possible that continual low level virus production in vivo
may act as a constant stimulus for this immunological
activity.
Interleukin-2 (IL-2) activity can be detected in
supernatants from lymph node-derived mononuclear cell
cultures, stimulated in vitro with concanavalin A. It has
been reported (Ellis & DeMartini,1985) that decreased
levels of IL-2 were released when the cultured cells were
derived from symptomatic naturally-infected sheep, but not
when they were obtained from asymptomatic or uninfected
animals. In contrast to the macrophage data this suggests
a decrease in immune responsiveness in clinically affected
animals.
A sequence homology over twelve amino acids (eight of
which are conserved) has been identified between the human
and sheep 21.5K myelin basic protein and the visna pol
gene product (Carnegie & Weise, 1987). It has been
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suggested that this could form the basis for an autoimmune
reaction in the demyelination observed in central nervous
system lesions. There has been no direct confirmation of
this mechanism.
Peptides derived from the gp41 and vif regions of the
MVV genome have been reported (Ruegg e_t a_l. , 1990) to
inhibit IL-2 or T-cell antigen receptor driven
proliferative responses in vitro. The significance of
this is unclear, particularly as immunosuppression has not
been identified as a major factor in MVV-induced disease.
Pathogenesis therefore appears to involve disruption
of the functioning of the immune system, with possible
inappropriate over-activation of effector cells having a
role in the observed lesions. While individual pieces of
data indicate regulatory dysfunction there is as yet no
coherent model for the means by which this dysfunction
arises (eg as a direct or indirect consequence of
macrophage infection) or precisely which components of the
immunological network are involved.
1.8 Phenotypic Variants Of MVV
Various strains of MVV differ in their pathogenicity
in vitro and in vivo. Both highly lytic and persistent
(in vitro) strains were isolated from naturally infected
sheep (Querat e_t a_l. , 1984), although only one type of
isolate could be recovered from an individual animal.
Intratracheal injection of either low passage (less than
ten passes) or high passage virus into lambs, with
sacrifice at various time points up to twenty eight weeks,
resulted in the development of histological and clinical
lesions only in those animals infected with low passage
virus (Lairmore e_t a_l. , 1986). However, since the high
passage isolate had not been derived from the low passage
isolate the authors' conclusion that in vitro passage
alters viral characteristics is not necessarily valid.
Two strains which caused a highly lytic infection of goat
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synovial membrane cells in vitro differed in their
cytopathic effect on alveolar macrophages in culture. One
isolate caused rapid and severe fusion, and this isolate
was also highly pathogenic in vivo. The other strain
showed little cytopathic effect on alveolar macrophages
and no pathogenic effects were observed in vivo (Lairmore
et al., 1987). While this study demonstrated a
correlation between in vitro and in vivo pathogenicity the
attempts to link this with the extent of previous tissue
culture passage were again inappropriate.
MVV strains have therefore been shown to vary in
their phenotypic characteristics. There is as yet no
clear data relating this to any particular MVV genes.
1.9 Transmission
The major route of transmission of MVV is horizontal
spread via the respiratory route, and is probably
exacerbated by close housing practices. In flocks in
which the length of exposure of lambs to infected ewes was
varied there was a rising incidence of transmission with
increasing periods of contact, rising to 81% of lambs
showing evidence of MVV infection when the flock was
maintained intact for one year (De Boer e_t a_l. , 1979).
Horizontal transmission between adult sheep has also been
demonstrated for flocks maintained under standard
management conditions (Houwers & van der Molen, 1987).
Concurrent MVV and sheep pulmonary adenomatosis (SPA) may
lead to increased transmission of MVV infection (Dawson e_t
al., 1990), possibly as a consequence of the increase in
volume of respiratory exudates caused by the SPA.
There is little clear evidence for vertical
transmission of MVV. Fifty lambs snatched from their
infected dams at birth (De Boer e_t al. , 1979) all remained
uninfected (only 80% of the dams may have been infected)
and no direct evidence for transplacental transmission
could be demonstrated in the experiments of Sihvonen
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(1980). However, in experiments with hysterectomy-derived
lambs from infected dams two out of eleven lambs from
infected ewes showed histological lesions compatible with
MVV infection (Cross ejt al. , 1975). It is possible that
the virus was transmitted during the surgical manipulation
and it is generally accepted that vertical transmission is
at best minor. However, as foetuses can be
experimentally infected in utero (Narayan e_t a_l. , 1974) by
direct injection of the virus into the foetus the lack of
natural vertical transmission may be due to the cell-
associated nature of the virus in the blood rather than a
lack of foetal susceptibility
Unlike CAEV, in which it has been clearly
demonstrated that maternal colostrum is a major infectious
route (Ellis £t al., 1983), such a mechanism has not been
unequivocally demonstrated for MVV, despite the presence
in ovine milk of cells from which virus can be
intermittently isolated (Sihvonen, 1980).
Transmission of virus has been reported from
faecally-contaminated drinking water (Sigurdsson, 1954a).
The importance of this as an infectious route is possibly
minor.
In contrast to HIV sexual transmission of MVV has not
been reported. There have also been no reports of an
invertebrate vector, such as that implicated in
transmission of EIAV (referenced in Narayan & Clements,
1989).
1.10 Host Immune Responses To MVV
Sequential studies using experimentally infected
sheep have demonstrated the generation of complement-
fixing and neutralising antibodies to MVV (Gudnadottir &
Kristindottir, 1967), the complement-fixing antibodies
arising one to two months post-infection and the
neutralising antibodies approximately six months after
infection. These results were extended to show early
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generation of MVV-specific antibodies in experimentally
infected sheep which were detectable using an indirect
immunofluorescence technique (De Boer, 1970). This
response rose more quickly than the complement-fixing
response, which again preceded the neutralising
reactivity. The minor discrepancies between the two
reports in terms of the absolute time-scales of response
may reflect differences in technique.
Variations in titre of complement-fixing antibodies
between different sheep have been reported (Petursson eX
al. , 1976), varying from 1/32 to 1/1024 and similar
variations were found for titres of neutralising
antibodies. The same report also suggested local
production of complement-fixing antibodies in the central
nervous system. Free MVV can be detected in the CSF in
the early stages of infection after intra-cerebral
inoculation; this local production of MVV-specific
immunoglobulin may be implicated in the subsequent
disappearance of free virus from the CSF (Petursson e_t
al., 1976).
With the exception of one report (Houwers & van der
Molen, 1987) in which two sheep in a naturally infected
flock became seropositive ( as determined by an ELISA )
and then seronegative again the papers referred to above
also show persistence of the MVV-specific antibody
responses.
Although sheep develop antibodies which are described
as neutralising this is often a reflection of an in vitro
assay technique involving prolonged prior incubation of
MVV with serum and may not be an accurate representation
of the in vivo activity of these immunoglobulins. In
vitro MVV binds to target cells within the first five
minutes of incubation, and virtually maximal attachment
occurs within the first fifteen minutes. Incubation of
MVV with neutralising antiserum for fifteen minutes
results in no detectable fall in virus infectivity. A
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possible consequence of this in vivo is that the rate of
virus binding to cells may be faster than the rate of
neutralisation (Kennedy-Stoskopf & Narayan, 1986).
Neutralisation in vitro has been shown to involve
immunoglobulin of the IgGl class and to be complement-
independent (Kennedy-Stoskopf & Narayan, 1986). This
contrasts with GAEV where in goats generation of
neutralising antibodies is virtually non-existent, and the
neutralising action of sera from immunised rabbits is
complement-dependent (Klevjer-Anderson & McGuire, 1982).
Neutralising antibodies prevent binding of MVV to the
surface of choroid plexus cells but act via a different
mechanism in simian virus 40 (SV40)-transformed
macrophages. Immune sera enhances binding and entry of
MVV in these cells, possibly via an interaction with Fc
receptors, but no viral reverse transcription occurs,
indicating a post-entry block on the viral life-cycle
(Kennedy-Stoskopf & Narayan, 1986). The antibody-
dependent enhancement of infection observed for HIV-1 at
sub-neutralising levels of antiserum (Takeda e_t a_l. , 1988)
has not been reported for MVV.
The viral proteins against which the humoral response
is mounted were determined in a longitudinal study of
experimentally and naturally MVV-infected lambs. By
immunoblotting it was shown that the first antibody to be
generated was anti-p30 followed by anti-gpl35, anti-pl6
and anti-pl4 (Kajikawa e_t £l^ , 1990), with some minor
variation between sheep. Anti-Env immunoglobulins are
likely to be the major neutralising antibodies as the Env
glycoprotein is external on the virion. Antibodies to the
llkDa Rev protein have subsequently been demonstrated in
experimentally-infected sheep (Vigne e_t , 1990).
However, the functional significance in vivo of the
reactivity to each of these viral proteins is unclear.
Much less data is available on the cell-mediated
response to MVV infection. An early cell-mediated immune
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response to MVV has been demonstrated within one week of
experimental intracerebral inoculation (Griffin e_t a_l. ,
1978). This declines to control levels four to six weeks
post-inoculation and is typical of the cell-mediated
response to an acute infection. However,a proliferative
response to virions and recombinant p30 protein,involving
CD4-positive and CD8-positive cells, has been consistently
demonstrated one to four years post-infection (Reyburn e_t
al., in press).
The available evidence therefore suggests that MVV
persists in an infected animal despite an active immune
response to the virus. The immune response appears to be
incapable of clearing the virus in the early stages of
infection, thereby permitting establishment of infection
in the host tissues, and virus continues to be produced
subsequently despite the continuing specific immune
response.
1.11 Tropism Of MVV
1.11.1 Species Tropism
MVV has been shown to infect sheep and also goats
(Banks e_t a_l. , 1983). It has been suggested (Houwers e_t
al. , 1989) that different sheep breeds may differ in their
susceptibility to MVV but there are difficulties in
distinguishing breed variations from inbred familial
effects.
In vitro MVV has been reported to infect cells from
other species (Gilden e_t a_l. , 1981), including those of
murine, bovine, guinea pig, dog, rat and human origin.
There have been no reports of in vivo infection by MVV of
any species other than sheep and goats.
1.11.2 Cellular Tropism
Although in vitro MVV replicates to high levels in
ovine fibroblasts this is not the major target cell
population in vivo. Macrophages were shown to be
infectable in vitro and macrophages from infected animals
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produced virus detectable by a co-cultivation assay with
fibroblasts (Narayan e_t al. , 1982). Cells of the
monocyte/macrophage lineage are the major target cell of
MVV in vivo. The more highly activated the cell the more
susceptible it is to infection, and transcription and
translation from the viral genome are dependent on the
maturational/activational status of the cell (Gendelman e_t
al. , 1986). Clusters of infected macrophage precursors
have been found in the bone marrow, which may act as a
viral reservoir (Gendelman e_t al. , 1985); this is
essential as blood monocytes and tissue macrophages are
relatively short-lived. There is selectivity in the
macrophage populations which are infected by MVV, for
example, there have been no reports of infection of liver
Kupffer cells or histiocytes. Restricted cellular tropism
in vivo may be related to cellular factors implicated in
viral regulation (section 1.5)
There are no convincing reports of MVV infection of
lymphocytes. In the description of viral antigens
detected in the central nervous system (CNS) of
experimentally-infected sheep the identification of
lymphocytes which were expressing viral core antigen was
based on morphological grounds only (Georgsson e_t a_l. ,
1989). This work also did not exclude the possibility
that the detected cells were actually B lymphocytes which
had bound MVV antigen via their immunoglobulin molecules.
A report of MVV infection of T-helper cells, accompanied
by a loss of MVV-specific activity (Jolly e_t a_l. , 1989)
has not been supported by any published data. Infection
of dendritic cells in vivo has recently been suggested
(Gorrell e_t al. , 1992).
1.12 The Cellular Receptor For MVV
Initial reports of susceptibility to MVV infection in
vitro in cells from a wide range of species (Gilden et
al., 1981) suggested that the viral receptor could be a
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fairly ubiquitous molecule. Subsequent work has not
confirmed this. MHC class II antigens have been reported
to bind MVV and soluble class II molecules were reported
to block infection of permissive choroid plexus cells
(Dalziel e_t al. , 1991). MHC class II molecules may
therefore be involved under certain circumstances in
interaction of the virus with a cellular receptor,
although expression of MHC class II on ovine cells is not
in itself sufficient to render these cells susceptible to
MVV infection. For example, B lymphocytes and activated
T lymphocytes express MHC class II molecules but do not
appear to be infected by MVV. Antibodies to an
unidentified 50kDa protein of sheep choroid plexus cells
block binding of MVV to these cells in culture (Crane e_t
al. , 1991a). This molecule may represent another
component of the cellular receptor for MVV.
1.13 Viral Attachment Proteins and Cellular Receptors For
Viruses
The first stage in viral infection of a cell is
attachment of the virus via a viral attachment protein
(VAP) to a cell surface molecule. These VAPs form either
the envelope or the capsid of enveloped and non-enveloped
viruses respectively. Major advances have been made in
recent years in the identification of viral receptors, and
in analysing the stages in viral entry subsequent to viral
attachment.
A wide range of cellular surface molecules have been
shown to act as viral receptors. These range from
relatively wide-spread molecules such as sialic acid
residues for influenza virus (Paulson e_t a_l. , 1979),
negatively charged phospholipids for vesicular stomatitis
virus (VSV) (Schlegel e_t a_l. , 1983) and heparan sulphate
proteoglycans for herpes simplex virus (HSV) (WuDunn &
Spear, 1987) to molecules with more restricted cellular
distributions. These include various members of the
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immunoglobulin gene superfamily, amongst them CD4 for HIV-
1 and HIV-2 (Dalgleish e_t a_l. , 1984; Klatzman ejt al. ,
1984), ICAM-1 for major group rhinoviruses (Greve e_t al. ,
1989; Staunton e_t al. , 1989), class I MHC molecules for
SV40 (Atwood & Norkin, 1989; Breau e_t al., 1992), a member
of the carcinoembryonic antigen family for mouse hepatitis
virus (Dveksler et: al. , 1991) and a molecule of unknown
physiological function for poliovirus (Mendelsohn e_t al. ,
1989). Other cellular molecules which have been
identified as viral receptors include the complement
receptor CR2 for Epstein-Barr virus (Fingeroth e_t al. ,
1984), a cellular basic amino acid transporter for murine
leukaemia virus (Kim £t al. , 1991; Wang e_t al. , 1991) and
aminopeptidase N for certain human and porcine coronavirus
strains (Delmas e_t a_l, 1992; Yeager e_t a_l. , 1992).
However, it is becoming clear that while in many
instances cellular receptors are necessary for viral
infection they may not be in themselves sufficient to
render a cell susceptible. For example transfection
experiments resulting in expression of CD4 on normally
CD4-negative human cells renders these cells susceptible
to infection by HIV. Murine cells expressing human CD4
remain non-permissive for infection, but virus can attach
to these cells and they will support viral replication if
the genome is introduced directly into the cell (Maddon e_t
al., 1986). This suggests a post-receptor block on viral
infection in murine cells, possibly at the stage of
membrane fusion or uncoating of the virus, which may be
dependent on accessory molecules present only on primate
cells.
Transcripts for the mRNA which encodes the poliovirus
receptor (Mendelsohn e_t a_l. , 1989) are found in a wide
range of cell types in vivo but viral replication is
restricted to the oropharyngeal and intestinal mucosa, the
Peyer's patches and motor neurons of the CNS. If
expression of mRNA correlates with expression of the
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receptor molecule on the cell surface this would also
suggest that the presence of a cellular receptor is not in
itself sufficient to ensure viral replication.
A virus may also be able to infect cells through a
molecule other than the primary characterised receptor.
HIV-1 for example has been shown to infect CD4-negative
cells (in an antibody-independent manner) (Harouse e_t al. ,
1989). Certain viruses eg West Nile flavivirus, can
subvert the host humoral response by binding to specific
immunoglobulin and so infecting macrophages, presumably
via their Fc receptors (Peiris & Porterfield, 1979).
VAPs are found in multiple copies on the virion and
therefore attachment may potentially involve high affinity
interactions or a large number of low affinity reactions,
which together generate a high avidity interaction.
Entry of viruses into the host cell can be classified
as pH-independent or pH-dependent. Viruses which are
internalised by endocytosis, where entry relies upon
fusion of the viral and endosomal membranes, are classed
as pH-dependent. For example, the influenza glycoprotein
precursor HAO is cleaved by cellular proteases to form HA1
(N-terminal, external glycoprotein) and HA2 (C-terminal
transmembrane) which remain associated via a disulphide
bridge and form homotrimers on the virion surface (Gething
et al., 1986). Upon acid-activation in the endosome there
is a configurational change in the homotrimer which
exposes a previously hidden hydrophobic domain in the HA2
subunits (Doms & Helenius, 1986) which is believed to
mediate fusion of the viral and endosomal membranes. This
pH-dependent change is crucial for the establishment of
the viral infection of the cell.
The separation of functions between different viral
structures during viral attachment and entry is a common
feature of viruses from many different families. The Env
glycoprotein of HIV contains separate epitopes for
receptor binding and fusion, predominantly localised to
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the external and cytoplasmic regions (section 1.14).
Unlike influenza virus HIV generally fuses with the plasma
membrane (Stein e_t a_l. , 1987), and the reaction is pH-
independent.
There is an increasing amount of data to show that
binding of a VAP to a cellular receptor results in changes
in either the VAP itself, or other viral constituents
which influence subsequent stages of the viral life cycle.
Binding of poliovirus to cells for example results in the
loss of the VP4 viral protein. It is possible that
occupation of the receptor binding site disrupts the viral
capsid leading to exposure of the N-terminus of VP1, with
a likely effect on viral attachment and release of viral
RNA into the cell (Hogle, 1988). HSV glycoproteins have
been shown to interact in a complex cascade during
cellular attachment and entry (Fuller & Lee, 1992).
Interaction of VAPs with cellular receptors is
therefore multifactorial and should not be viewed as an
isolated event in the viral life cycle. The interaction
cannot be considered in isolation as simply a targeting
mechanism, as it triggers a range of reactions critically
important for the outcome of the viral infection.
1.14 The Envelope Glycoprotein Of HIV
The envelope glycoprotein of HIV is the most
thoroughly characterised of all retroviral envelope
proteins and it is possible only to discuss some of its
major features in this introduction.
The env gene of HIV-1 encodes a precursor molecule of
856 amino acids (gpl60) which is processed to produce an
external N-terminal glycoprotein of 480 amino acids
(gpl20) and a transmembrane C-terminal glycoprotein of 345
amino acids (gp41) (Muesing £t a_l. , 1985). Minor
differences in amino acid number and protein size exist
between different isolates (Ratner £t^ a_l. , 1985; Sanchez-
Pescador et al. , 1985; Wain-Hobson e_t al. , 1985). In HIV-
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2 the processed forms are termed gpl25 and gp36.
A hydrophobic signal peptide is cleaved from the
precursor protein during envelope maturation (Allan e_t
al. , 1985). After cleavage of gpl60 to gpl20 and gp41 the
two glycoproteins may remain non-covalently associated, or
the gpl20 may be shed. Both C- and N-terminal regions of
gpl20 are involved in its interaction with gp41 (Helseth
et al, 1981; Ivey-Hoyle e_t al, 1991). Mature gpl20 is
heavily glycosylated, containing twenty-four (Muesing £t
al. , 1985; Ratner ejb al_. , 1985) to twenty-six (Sanchez-
Pescador e_t al. , 1985) potential N-linked glycosylation
sites. Gpl20 molecules form oligomers on the surface of
virions; however it is not clear if these are trimers
(Weiss e_t a_l. , 1990) or tetramers (Schawaller e_t al. ,
1989).
Comparisons of HIV-1 isolates have revealed high
sequence diversity in the env gene, particularly in the
extracellular region (Starcich e_t _al, 1986). Compared
with alterations in the gag and pol genes the env gene
changes were not only greater in number but involved a
disproportionately higher level of insertions, deletions
and non-silent single base changes. Nucleotide changes
were not randomly distributed throughout the gpl20 coding
region; after cleavage of the signal peptide five
hypervariable regions (VI to V5, labelling from the 5' end
of the gene) were identified, interspersed with well-
conserved sequences (figure 1.2). These regions of high
sequence diversity generally coincided with regions of
predicted high antigenicity (Starcich e_t a_l. , 1986).
The eighteen cysteine codons in the gpl20 coding
sequence were conserved between the five isolates studied
(Starcich e_t a_l. , 1986), indicating a maintained
"macrostructure" for HIV-1 gpl20, which may be a
consequence of functional constraints.
Although infection of cells via Fc receptors has been
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(McKeating et al, 1990) the binding of gpl20 to the CD4
antigen is a major determining event in viral infection
under most physiological conditions (Dalgleish e_t al. ,
1984; McDougal e_t al^ , 1986). The reaction is high
affinity with a dissociation constant of at least 4 x 10"^
M (Lasky ejt al. , 1987). Gpl20 and the natural
physiological ligand of CD4, the MHC class II molecule,
bind to different epitopes of CD4 (Lamarre e_t a_l, 1989;
Fleury e_t a_l. , 1991). Studies using soluble CD4 antigen
(sCD4) (Sattentau & Moore, 1991) have demonstrated that
binding of sCD4 to gpl20 results in conformational changes
in both gpl20 and gp41. These changes may be necessary
stages in the exposure of a predicted fusion epitope in
gp41 such as the highly conserved leucine zipper motif
reported to be critical for HIV membrane fusion and viral
entry (Dubay e_t al^. , 1992). Binding of sCD4 to gpl20 can
also result in dissociation of the non-covalently linked
gpl20 and gp41 (Sattentau & Moore, 1991). High level Env
glycoprotein expression on the surface of infected cells
may result in binding to CD4 antigens on uninfected cells,
thereby initiating cell fusion and leading to syncytium
formation and cell death (Lifson e_t a_l. , 1986; Sodroski e_t
al., 1986).
Various regions of gpl20 have been identified which
are involved, directly or indirectly, in binding to CD4.
Deletion mutants and anti-gpl20 monoclonal antibodies
demonstrated a critical role for amino acids within the
protein region 397-439 (Lasky e_t a_l. , 1987). Three non-
continuous regions of the C-terminal half of gpl20 were
also implicated in gpl20/CD4 binding (Kowalski ejt al. ,
1987), and a 25kDa fragment of the C-terminal portion of
gpl20 can bind CD4 (Nygren e_t a_l. , 1988). However,
residues in the N-terminal region of gpl20 have also been
shown to have a critical role in binding of gpl20 to CD4
(Syu e_t al. , 1990). The interaction of gpl20 with CD4
therefore appears to involve a number of sequence and
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conformational determinants within gpl20. This is
supported by data reported using a human anti-gpl20
monoclonal antibody which inhibits binding to CD4, but
which does not map to any of the previously defined
binding epitopes (Ho e_t aJ. , 1991).
Although a region within the second conserved domain
of gpl20 has been identified which is important in viral
infectivity (Ho eyt al. , 1988; Willey £t al. , 1988) the
epitope is probably not exposed under physiological
conditions, therefore recent research has been focussed
on the V3 domain of gpl20 as this may be a possible target
for neutralising antisera. A monoclonal antibody reactive
with an epitope located between amino acids 303 and 323
neutralised viral infectivity but had no effect on binding
of gpl20 to CD4 (Linsley et al., 1988). The same epitope,
putatively consisting of a loop between cysteine residues
at 296 and 331 ("the V3 loop") was shown to elicit type-
specific neutralising antibodies in chimpanzees (Goudsmit
et al. , 1988) and goats (Palker jij: a_l. , 1988). A peptide
spanning amino acids 307 to 330 can completely block
fusion inhibition by antisera reactive with the same HIV
gpl20 type (Rusche e_t al^. , 1988). This principal
neutralising determinant (PND) in the V3 loop of different
isolates consists of a generally conserved Gly-Pro-Gly-Arg
sequence at the tip of the loop, flanked by variable amino
acids (Javaherian e_t al. , 1989) which may account for the
type-specificity of the neutralising antisera.
Different HIV isolates vary in their preferred
cellular tropisms, particularly as to whether they
replicate more efficiently in monocytes, peripheral blood
leukocytes or T cell lines. A number of studies have
mapped these tropisms to regions of gpl20 which include
the PND (Liu £t al. , 1990; O'Brien e_t al, 1990; Shioda e_t
al. , 1991; Westervelt ejt a_l. , 1991) and two studies have
implicated residues within the PND itself (Hwang £t^ al. ,
1991; Takeuchi e_t a_l. , 1991). Direct evidence on the
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function of the PND in vivo is limited but it is not
believed to interact with CD4. Therefore the neutralising
ability of sera directed against the PND must be a
consequence of a post-receptor binding event. Mutations
in the V3 loop have no effect on Env glycoprotein
synthesis, processing or transport (unless one of the
conserved cysteine residues is mutated), nor do they
affect binding to CD4, but they have been reported to
abolish envelope-induced cell fusion (Freed ^t al., 1991).
In vitro various proteinases have been shown to cleave
gpl20 within the PND (Clements e_t al^. , 1991). Cleavage is
increased if the gpl20 is bound to sCD4 but blocked by
binding of neutralising sera. The authors have suggested
that cleavage by specific cellular or endosomal
proteinases may be a significant event subsequent to
binding of gpl20 to CD4. Peptides containing the
conserved Gly-Pro-Gly-Arg sequence inhibit a membrane-
bound serine esterase purified from a human CD4-positive
lymphocyte clone (Kido e_t a_l. , 1990) and a requirement for
cleavage by various cellular proteinases could act as a
mechanism by which variations in the PND affect cellular
tropism. It is probable, however that other regions of
the env gene also play a role in cellular tropism as a
CD4-binding region of gpl20 and the N-terminal portion of
gp41 affect the adaptation to growth of certain isolates
in tissue culture cell lines (Fujita e_t a_l. , 1992) in the
absence of any variations in the V3 loop.
The gl envelope glycoprotein has been implicated in
cellular tropism of pseudorabies virus (Card e_t al. ,
1992), indicating that this phenomenon is not restricted
to the lentiviruses. Conversely, among the lentiviruses
themselves it may not be the only determinant of cellular
tropism as it has been demonstrated in vitro that tropism
of EIAV is env-independent (Perry e_t al^. , 1992)
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1.15 Structure And Function of MVV Envelope Glycoprotein
Due in part to the lack of easily available well-
characterised gpl35, and the only very recent advances in
determining the cellular molecules with which it
interacts, information on the structure of gpl35 is
limited and there has been little progress in assigning
functional roles to different regions of the molecule.
The env genes sequenced from various MVV isolates
(section 1.3), display both sequence diversity (section
1.15) but also conservation of certain features (figure
1.3). The first hydrophobic region, which is presumed to
act as a signal sequence, does not occur at the N-terminus
of the protein but between amino acids 78 to 100 (Sonigo
et al., 1985) (the actual positions vary slightly between
isolates). This may be related to the utilisation of the
first forty eight amino acids to encode both Env and Rev.
A similar internal location of the hydrophobic signal
sequence has also been reported for FIV (Stephens e_t al. ,
1992). It is not clear if cleavage of this signal
sequence and the amino acids preceding it occurs in MVV,
as is found in HIV (Allan e_t &L., 1985) and FIV (Stephens
et al., 1992). By analogy with HIV the precursor protein
is believed to be cleaved into external and transmembrane
components (gpl35 and gp46); there is no data on the
regions involved in maintaining this presumably non-
covalent interaction post-cleavage.
Bromelain digestion experiments indicated that the
envelope glycoprotein formed "spikes" on the surface of
the virion (Mountcastle e_t al. , 1972). No data is
available on any oligomeric organisation of gpl35.
The external part of the Env protein encodes twenty
j V—> I
three N-linked glycosylation sites (Querat e_t a^. , 1989).
Sialic acid residues have been demonstrated on the surface
of MVV particles, presumably as terminal groups on
carbohydrates (August e_t , 1977). However, the levels




The envelope glycoprotein of MVV is shown
diagramatically. The full-length glycoprotein is
cleaved to form the extracellular region (gpl35) and
the transmembrane region (gp46). Approximate amino
acid positions are shown above the diagram.
Key
S = signal sequence
CS = cleavage site
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functional role has been assigned to them. This is in
contrast to CAEV where the residues are believed to have
an important role in protection of the virus from
neutralising antibodies, probably through steric hindrance
(Huso e_t a_l. , 1988).
Gpl35 has been identified as an antigenic target
during immune responses to MVV infection (section 1.10).
Immunisation of guinea pigs with lectin-purified gpl35
generated neutralising antisera, whereas antisera raised
against p30 had no neutralising effect (Scott e_t al. ,
1979). These experiments indicated that gpl35 was
probably the major target for neutralisation of virus
infectivity by specific antisera.
There is little information available on the
transmembrane region of Env. In CAEV antibody titres to
the transmembrane glycoprotein are high (McGuire et al. ,
1992) but such a response has not been reported in MVV. A
possible fusigenic epitope has been identified in MVV gp46
(Crane e_t a_l. , 1991b) (section 1.17).
1.16 Antigenic Drift And gp!35
Antigenic drift and consequent evasion of host
humoral responses has been reported in a number of disease
systems including EIAV (Kono e_t a_l. , 1973), human
influenza A virus (Laver & Webster, 1968) and rabies virus
(Wiktor & Koprowski, 1980). HIV shows sequence diversity
both in isolates from one individual, and between
different individuals (Hahn e_t al.. , 1986; Saag e_t al. ,
1988). While it is not disputed that antigenic variants
do arise during MVV infection there is controversy over
the frequency of such variants, their in vivo
significance, particularly for long-term persistence of
the virus in the presence of an active immune response,
and the role of neutralising antibody in stimulating the
generation of these variants.
1.16.1 Evidence For Antigenic Drift In MVV Infection
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Much of the data suggesting a role for antigenic
drift in MVV infection and persistence has been derived
from longitudinal studies of experimentally infected
sheep.
Four lambs were infected intracerebrally with plaque-
purified MVV strain 1514, blood samples taken thereafter
at regular intervals and virus isolations made from the
peripheral blood leukocytes (PBLs) of these animals
(Narayan ex a_l. , 1977). All sheep raised neutralising
antisera to the inoculating viral strain within six
months, but the sera all failed to neutralise another
strain of MVV, Dl-2, indicating strain-specificity in the
neutralisation response.
Four strains of virus isolated from leukocytes of the
four sheep at twenty two months post-infection were not
neutralised by sheep sera, whether collected before or
after virus isolation. This indicated the generation of
virus mutants which were not neutralised by the host's
antibodies. In vitro passage indicated stability of this
feature ie virus isolates which were neutralised by a
particular sheep serum were still neutralisable by the
same serum after a variable number of passages through
tissue culture (Narayan e_t a_l. , 1977).
This work was extended, partly to address the issue
of whether the mutant virus replaced the infecting strain,
or if the two co-existed. Sheep no. 1 from the experiment
described above was studied intensively. The original
neutralisation-resistant variant isolated was designated
LVf-i and six further isolates were obtained over the
following eighteen months (LV^_2 to LV-^y) (Narayan e_t al,
1978). All isolates including the parental infecting
strain 1514 were tested in neutralisation assays with
serum samples collected at different time points post¬
infection. On the basis of their neutralisation patterns
the viruses were placed into three antigenic groups - one
isolate had the same neutralisation profile as 1514, while
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the other six could be placed into one of two groups. The
isolation of a relatively late strain with the same
neutralisation profile as the infecting strain suggested
that parental and mutant virus strains could co-exist in
the same host. From their time-course data on this and
other experimentally infected sheep the authors concluded
that neutralisation variants did not arise until after the
development of antibodies capable of neutralising the
parental strain.
However, a sheep infected experimentally with plaque-
purified isolate produced antisera which neutralised
this infecting viral strain, but also neutralised 1514,
and at a higher dilution (Narayan £t al. , 1978). The
authors suggested that this represented some type of "one¬
way" cross-reactivity between the viral strains but it is
not clear that an isolate with similar properties to 1514
has not simply been generated during the infection.
It is also important to recognise that there is a slightly
arbitrary aspect to the particular strain which is
isolated at a given time point if more than one strain is
present in the circulating PBL population, particularly if
different isolates vary in the efficiency with which they
can replicate in tissue culture.
It was claimed (Scott e_t £l^ , 1979) that these
results were reproduced using guinea-pig serum raised to
lectin-purified 1514 gpl35, but the paper does not
actually show strain-specific neutralisation by this
serum.
Sera from infected sheep show a broadening of the
neutralising range with time (Narayan e_t a_l. , 1981). An
interesting aspect of the development of neutralising sera
is differential reactivity to "precursor" (ie viral stocks
from which an isolate was derived) and "future" (ie a
viral isolate which is obtained subsequently after in vivo
passage of a stock) viral mutants. The genealogy of
certain viral strains, through in vitro and in vivo
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passage is known. Longitudinal studies of experimentally
infected sheep show that the early sera of sheep
neutralised not only the input virus, but progenitors of
the input virus. However, the early sera did not
neutralise subsequent variants (Narayan £t a_l. , 1981).
For example, sheep inoculated with strain 1514 developed
almost as much antibody to the progenitor strain K1010 but
little to LV-^_^; sheep inoculated with strain
developed neutralising antisera to 1514. No clear
explanation of this phenomenon has been presented and the
authors claimed that their initial viral inocula were
clonal. However, subsequent data (Staskus et aJL. , 1991,
section 1.16.2) suggests this may not be a valid
assumption.
Other authors have questioned the frequency and
importance of antigenic drift in MVV infection. Six sheep
were inoculated intracerebrally with either the K796 or
K485 strain of MVV (both early progenitor strains of 1514)
and viral isolations made from PBLs at various time points
(Thormar e_t a_l. , 1983). Five of the sheep raised
neutralising serum antibodies against the inoculating
virus within four months of infection but a wide range of
variation in the isolation of different viruses was
observed. In one animal all isolates were identical to
the infecting strain while in each of the other sheep a
variant arose from one to three years post-infection. In
no case was replacement of the initial virus clearly
demonstrated, and the evidence generally indicated co¬
existence in vivo of different viruses. The authors
claimed that the results did not suggest a smooth
progression in the formation of viral isolates, as
postulated previously (Narayan e_t a_l. , 1978) and suggested
that in each animal only one distinguishable variant was
generated. They concluded that in vivo generation of
neutralising variants was a rare event.
In another study seventy six virus isolates were made
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over seven years from twenty sheep inoculated
intracerebrally with 1514 (Lutley e_t al^ , 1983). In six
of the sheep isolates not neutralisable by early sera
(which did neutralise the inoculating virus) were
obtained; in five of these sheep it was obvious that these
did not replace the inoculating strain. In the sixth
sheep the last six isolates were all different from the
inoculating isolate, although it is not clear if they are
identical to each other. In contrast to earlier results
(Narayan e_t a_l. , 1981) there was no consistent
neutralisation of a progenitor viral strain. The authors
concluded that only 16% of the isolates were antigenic
variants, and in only one sheep was there reasonable
evidence of antigenic drift, where this was defined as the
consistent isolation of variant viruses (Lutley e_t al. ,
1983).
Part of the controversy surrounding antigenic drift
in MVV is one of terminology. For instance, Lutley e_t ad^
(1983) claim that the figure of 16% quoted for variant
virus isolates is low, and indicates a relatively minor
role for antigenic drift in viral persistence whereas
Stanley e_t £l (1987) interpret the same data as indicting
a high frequency of viral variants. Given some of the
technical problems associated with the work which
suggested a significant role for antigenic shift (section
1.16.2) it is probably reasonable to assume that the
importance of the process was initially over-stated.
Certainly there is not the massive generation of variants
observed in EIAV infection, which can arise at intervals
of fourteen to sixteen days (Hussain e_t _al. , 1987) and
where a distinct virus population persists in each febrile
episode (Payne e_t al^. , 1987a).
1.16.2 The Role Of Antibody In Generation Of MVV Variants
Maintenance of neutralisation identity in vitro
indicated that variations seen in vivo might not simply
reflect random sequence changes (Narayan jet _al. , 1977).
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Viruses derived after five passages in vitro of plaque-
purified virus, in the presence of neutralising antisera,
showed significant differences from the parental strain
(Narayan _et a^. , 1977). Experiments comparing the mutants
which arose in tissue culture following treatment with
early or late sera (in which the neutralisation range was
broadened) demonstrated that variants arose only rarely
from the "late" cultures, and these were antigenically
very distinct (Narayan et al_. , 1981). This was taken to
imply that there is a range of "possible" variants, and
that selective pressure is applied by the specificities of
the neutralising sera.
This is almost certainly too simplistic a
proposition. It suggests an ordered progression in the
appearance of variants, the existence of which has been
disputed (Lutley e_t a_l. , 1983). The persistence of the
initial inoculating strain implies that virus isolates are
maintained by the host in the presence of an active immune
response, possibly in part due to the slow kinetics of
neutralisation (section 1.10). Given that the antibody
response is not effective in curtailing the spread of
virus it is difficult to envisage how it could operate as
an effective selective pressure.
The discovery that a viral stock derived from plaque-
purified virus, and subjected to six in vitro passages,
differed in nucleotide sequence and neutralisation
behaviour from the parental stock also suggested that
emergence of variants can be antibody-independent (Staskus
et al. , 1991) and that plaque-purification may not be a
successful procedure for isolating clonal populations of
MVV. Doubt can also be cast on the clonal identity of the
plaque-purified 1514 by the results obtained in a
subsequent paper (Crane e_t al. , 1988). A sheep
hyperimmunised with a concentrated plaque-purified 1514
preparation raised antisera which neutralised both 1514
and the variant isolate This may suggest either
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that the virus used as an immunogen contained variants or
that serum which neutralises 1514 can also neutralise a
"future" mutant of the parental stock, in contrast to the
results originally obtained with these isolates. Crane et_
al. ( 1988) do not discuss this discrepancy, indeed in
their discussion they repeat the assertion that
neutralisation of MVV is strain-specific despite the fact
that their data indicates otherwise. This result casts
some doubt upon the conclusions of the earlier work which
drew heavily upon postulated differences between 1514 and
LVi_i.
1.16.3 The Nature Of Gpl35 Variants
In the first formal demonstration that gpl35 was a
target for neutralising antibodies (Scott et al., 1979) it
was demonstrated that purified gpl35 glycoproteins from
neutralisation variants differed in their chymotryptic
peptide maps. No such differences were observed in the
chymotryptic digestion of core polypeptides. It was
suggested that the minor nature of the changes in the maps
implied that variants arose as a consequence of mis-sense
mutations, rather than deletions, insertions or
recombination events.
In similar studies RNA was isolated from parental and
variant strains (Clements e_t al. , 1980) and used in RNase
T1 fingerprinting studies. The observed changes were
clustered in the 3' region of the genome, consistent with
a location in the env gene. A further extension of this
work indicated that similar genetic changes occurred
during antigenic variation in two animals (Clements ^t
al., 1982).
Monoclonal antibodies have been raised against the
gpl35 of strain 1514 (Stanley e_t a_l. , 1987) and checked
for reactivity against the envelope glycoprotein of a
number of neutralisation variants (Narayan £t al.. , 1978).
Fifteen of these monoclonal antibodies were used in
epitope mapping studies; they defined five distinct
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partially overlapping epitopes, at least one of which was
conformational. The monoclonal antibodies all
distinguished the parental 1514 virus from the subsequent
isolates and distinguished two variant viral subgroups but
these did not correspond to the relationships found in the
neutralisation assays. The authors claimed that the
antigenic variations did not take the form of simple
deletions or additions of sites; rather it was suggested
that in the variants epitopes were altered in terms of
their "exposure" on the molecule; the variations in
binding of the monoclonal antibodies possibly reflected
alterations in the conformation of the gpl35, rather than
changes in linear amino acid sequence. This conclusion
was reached by assaying the monoclonal antibodies in
enzyme-linked immunosorbent assays against the different
viral isolates and analysing relative differences in
binding (all the monoclonals assayed reacted to a greater
or lesser extent with each isolate). It is not clear that
such an assay is really suitable for drawing such
conclusions. As none of the monoclonal antibodies
neutralised the virus it is possible that antigenic drift
involves variation in both neutralising and non-
neutralising viral epitopes. Variation in non-
neutralising epitopes in particular is unlikely to be
driven by pressure from neutralising antibodies but in
EIAV it has been suggested that some antigenic variation
may be due to immune recognition and destruction of
certain virus-infected cells, rather than antisera which
neutralises infectious virus (Carpenter e_t al^. , 1987). It
is not clear if such a mechanism operates in MVV
infection. The lack of any observed changes in the
antigenic structure of the major core protein, also using
monoclonal antibodies, indicates that alterations in the
env gene may be more readily tolerated than in the other
structural genes.
The sequence analyses of different isolates of MVV
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have yielded further data on variation in the env gene.
(There is some debate as to the actual identities of the
viruses sequenced by Sonigo e_t a_l. , 1985 and Braun e_t a_l. ,
1987. Unless otherwise stated the nomenclature used in
Staskus e_t al. , 1991 will be employed.) The 1514-based
isolates of Sonigo and Braun (Sonigo et al^. , 1985; Braun
et al. , 1987) showed 0.3% sequence diversity over the
entire genome and the distribution of mutations was
reported to be random except for one cluster of four
changes in the env gene (Braun e_t a_l, 1987) between
nucleotides 7864 to 7890. The likelihood of the cluster
arising by chance was calculated at 1 in 2000.
The env gene product of SA-OMVV exhibited 20%
mismatched predicted amino acids when compared with 1514
(Querat e_t , 1990), higher than the levels found for
gag and pol. All but one cysteine and two potential re¬
linked glycosylation sites were conserved between the
isolates (Querat e_t al.. , 1990). The variable region
previously reported by Braun (Braun e_t a_l. , 1987) was also
detected, as was an N-terminal region of gpl35 (coincident
with rev) and possibly the regions 7718 to 7753 and 7913
to 7979. Comparison with the EV1 isolate also
demonstrated the presence of conserved and variable
regions across the env gene (Sargan et aT. , 1991).
There has as yet been no convincing demonstration
that a particular variation in sequence leads to a
quantifiable alteration in neutralisation. The data does
indicate that the env gene can contain a
disproportionately high degree of variation, compared with
most of the rest of the viral genome. This can in turn
result in a level of amino acid sequence and antigenic
variation which is not necessarily reflected in changes in
neutralisation of the virus. Whether these changes
influence other aspects of viral infection is not clear;
it was claimed that sequential isolates varying in their
neutralisation patterns replicated as efficiently and as
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virulently in vitro as the parental stock, but this does
not necessarily preclude the presence of a subtle in vivo
effect.
1.17 Functionally Significant Regions Of MVV gp!35
Very little has been achieved in delineating
structure-functional relationships in MVV gpl35. Nothing
is known of the regions of gpl35 required for interaction
with the MVV cellular receptor. Studies using "fusion
from without" as an assay system have indicated that
immune sera contain two populations of antibodies, one of
which neutralises infectivity while the other prevents
fusion (Crane e_t _al. , 1988). The authors suggested the
presence of two epitopes on Env, one responsible for
fusion, and one for neutralisation. While the suggestion
that two regions of Env are involved in initial binding to
a receptor and subsequent fusion of virus with the cell is
probably reasonable the authors' contention that viral
infection may result from viral entry which is independent
of this "fusion" region is not. For fusion from without
to occur the virus must be added to cellular cultures at a
high multiplicity of infection. Antibodies which inhibit
fusion from without could do so by blocking enough sites
on the viral glycoprotein to prevent this critical level
of virus and cell membrane interaction from occurring,
while leaving enough of the "fusion" sites on the molecule
exposed to permit normal fusion of the virus with the
cellular membrane after receptor binding. The authors
also claimed that guinea pig serum raised against purified
gpl35 blocked virus-induced cell fusion and that therefore
both the neutralisation and binding epitopes must be
present on gpl35. However, as preparation of their
immunogen involved lectin-based affinity chromatography of
disrupted viral particles the possibility that the antigen
preparation also contained antibodies reactive against
gp46 cannot be excluded.
- 47 -
A twenty four amino acid peptide from the N-terminal
region of gp46 has been shown to induce fusion of goat
synovial membrane cells (Crane e_t al. , 1991b). Antisera
raised to this peptide blocked fusion from without, but
failed to neutralise virus infection. This region may
therefore be a candidate for a fusion domain in MVV Env.
Studies of cellular tropisms are not advanced enough
to demonstrate any correlation of env variants with
particular cellular targets.
It is unclear if antibodies to gpl35 are protective,
or if they may have a deleterious immunopathological
effect. In CAEV the titres of anti-gpl35 in the synovia
correlated directly with disease severity (Knowles e_t a_l. ,
1990); in studies of lambs experimentally infected with
MVV strains of different in vitro replication
characteristics the mean titre to gpl35 was three times
higher in lambs which developed lymphoid interstitial
pneumonia (Kajikawa et a_l. , 1990). Although this could
suggest a pathological role for anti-gpl35 antibodies it
might also simply indicate that viruses which replicate to
a higher titre in vivo generate more profound lesions, and
coincidentally also stimulate a higher level of anti-gpl35
antibodies by the presence of a greater antigenic dose.
In neither case was a clear cause-and-effect relationship
demonstrable and it is also possible that any
immunopathological effect of the immune response to gpl35
would depend on a balance of different antibody
reactivities eg neutralising against non-neutralising.
1.18 Summary
The interaction of virus and host in MVV infection is
complex and highly regulated. The Env glycoprotein is a
major determinant in the establishment of cellular
infection and a highly immunogenic target for the host
immune response. Antibodies directed against Env may be
involved in pathogenesis and viral persistence. However
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previous studies have been hampered by the lack of
availability of well-defined well-characterised reagents
with which to dissect the structural and functional
relationships affecting the glycoprotein.
1.19 Aims Of The Research Project
The gpl35 glycoprotein of MVV almost certainly plays
a major role in the viral life-cycle by acting as the
viral attachment protein. By analogy with other enveloped
viruses it is probable that gpl35 is involved in post-
receptor binding events and it may play a role in the fine
details of cellular tropism. It is also the major target
for neutralising antisera.
However, virtually no information is available on the
regions of gpl35 which are involved in these processes.
In order to begin to investigate this problem the env gene
region encoding gpl35 was inserted into expression vectors
in the form of 3 overlapping fragments. The expressed
recombinant proteins were used to determine if MVV-
infected sheep differ in their antibody responses to
various regions of gpl35. The recombinant proteins were
also used in an attempt to localise function to different
regions of gpl35 eg by inhibiting infection, binding to
the surface of susceptible cells, or binding to putative
receptor molecules. The recombinant proteins were also
used as immunogens in an attempt to raise antisera which
could also be used in localising function to regions of
gpl35, especially by attempting to generate neutralising
antisera. Such work has not been previously rigourously
attempted because of the lack of suitable recombinant
proteins.
An analysis of the sequence diversity of the gpl35
region of the env gene was also undertaken in order to





The EV1 British isolate of MVV (Sargan et al, 1991)
was used in all studies. Viral stocks described as "low
passage" had been passaged a maximum of five times in
vitro after the initial isolation, and stocks described as
"high passage" had been passaged in vitro at least twelve
times.
2.2 Cell Lines
Sheep choroid plexus cells (WSCP cells) were a kind
gift of M. Dawson, Central Veterinary Laboratory,
Weybridge, UK. 848 skin cells and YT40 skin cells were
obtained from sheep 848 and YT40 by the biopsy method of
Rheinwald & Green (1977) and were a kind gift of Dr B.
Blacklaws, Department of Veterinary Pathology, University
of Edinburgh.
2.3 Tissue Culture
Unless otherwise stated cells were maintained in
fully supplemented 8% DMEM, at 37°C/5% CC>2 as adherent
monolayers in plastic tissue culture flasks (Corning, UK).
Once confluence was attained cells were removed from the
flask by washing twice in versene, followed by incubation
with trypsin-versene at 18°C until the cells were no
longer adherent. The trypsin-versene overlaying the cells
was immediately diluted with an excess of medium and
approximately 25% of the cells re-seeded.
2.4 Propagation Of Virus
The medium was removed from T175 tissue culture
flasks containing 80% confluent WSCP cells and the
monolayer washed twice with 10ml aliquots of fully
supplemented 2% DMEM. Virus diluted in the same medium
was added at an MOI of 0.1 in a 5ml volume, and the flask
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incubated for 1 hour under the usual tissue culture
conditions. 30ml of fully supplemented 2% DMEM were added
to the flask, and the cells were maintained under the
usual conditions until syncytia formation became clearly
apparent. The medium was removed and pooled with that
from other flasks if appropriate. Cellular debris was
removed by centrifugation at 2500 x g and the supernatant
was stored in aliquots at -70°C.
2.5 Titration Of Virus
WSCP or skin cells were seeded into each well of a
flat-bottomed 96-well plate (Nunclon, Denmark) at a
density of 1 x 10^ cells/well in lOOul of fully
supplemented 8% DMEM. The plates were maintained under
the usual conditions until the monolayer was estimated to
be 80% confluent. The medium was removed and the cells
washed in lOOul of the same medium. Virus stock was
serially diluted in fully supplemented 2% DMEM and 50ul of
virus added to the appropriate wells, all dilutions being
tested at least in triplicate. Mock-infected controls,
incubated with fresh fully supplemented 2% DMEM or medium
removed from growing cells, were always included. The
plates were incubated with the virus for 60 minutes at
37°C/5% CO2 after which the virus was removed, and the
monolayer washed and overlaid with lOOul of fresh fully
supplemented 2% DMEM. The plates were incubated under the
normal conditions and stained with Giemsa's stain (section
2.19) to detect CPE. The 50% tissue culture infectious
dose (TCID50) was determined using the method of Reed &
Muench (1938).
2.6 Polymerase Chain Reaction
2.6.1 Template DNA
Hirt DNA (Hirt,1967) was isolated from 10^ WSCP cells
infected with various isolates of visna virus, and
harvested when the cell monolayer was displaying
significant syncytia formation. Hirt's technique was
followed by phenol-chloroform extraction, chloroform
extraction and ethanol precipitation. The DNA was
resuspended in lOOul of sterile distilled water (SDW) and
serial 10-fold dilutions used to determine the optimal
template concentration for each PCR reaction.
Where purified plasmid DNA was used as the PCR
template the plasmid preparation was diluted in SDW to a
DNA concentration of 5ng/ul.
2.6.2 Primers
Figure 2.1 shows the primers used to generate the
fragments of the gpl35 region of the env gene. The
primers were synthesised by Oswel DNA Service (Department
of Chemistry, Kings Buildings, West Mains Road, Edinburgh,
EH9 3JJ). Final primer concentrations ranged from 0.38uM
to 0.88uM.
2.6.3 PCR Conditions
Reactions were carried out in lOOul of 50mM KCl/lOmM
Tris-HCl (pH8.8)/l.5mM MgCl2/3mM dithiothreitol (Ohara,
1989) with 0.17mg/ml bovine serum albumin (BSA), IOOuM of
each dNTP (Pharmacia,UK) and 1.7 units Taq DNA polymerase
(Boehringer Mannheim) overlaid with lOOul of mineral oil.
Thirty cycles of PCR were performed using a Techne
Programmable Dri-Block PHC-1: denaturation at 95°C, 0.6
minutes; annealing at 55°C, 2 minutes; extension at 72°C,
2.5 minutes; final extension, 7.5 minutes.
Upon completion of the polymerase chain reaction 10%
of the DNA sample was analysed by gel electrophoresis and
the remaining 90% was phenol-chloroform extracted,
chloroform extracted and resuspended in lOul of SDW for
restriction digestion.
2.7 Restriction Digestion Of DNA Samples
DNA samples for analysis or for insertion into
plasmids were digested in a total volume of 20ul using a
minimum of 1 unit of enzyme per ug of enzyme site.
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Figure 2.1
PCR primers for generation of MVV gp!35 fragments
The primers shown were used as 3 pairs - (1 + 4), (2 +
5) and (3 + 6) to generate 3 overlapping fragments of
the MVV gpl35 gene.
The BamHI restriction site is underlined in each primer.
The terminal codon of the relevant env gene region is
shown in bold type for each primer.
The terminal MVV EV1 env gene region base is italicised
in each primer and the position of the terminal base in
the MVV EV1 sequence is shown.
The terminal MVV EV1 env gene region amino acid is shown
for each primer.




nt 5994, Met 1
2,
5' TCCCGGGATCCGAGGAAACAGGACATGCAC 3'
nt 6735, Glu 248
3,
5' TCCCGGGATCCGGATGTAATTGCTCAAGGTCAGG 3'
nt 7464, Gly 491
4,
5' ACACCCGGGAICCAGGACTCTTCTCGTCCTG 3"
nt 6929, Pro 312
5,
5' ACACCCGGGATCCCCCTATTCTGTCTAACGTGC 3'
nt 7652, Gly 553
6,
5" ACACCCGGGATCCTCACCAACCCTATGCCCCTC 3'
nt 8000, Val 669
Enzymes were obtained from Pharmacia UK or Northumbria
Biologicals Ltd UK and digestion was carried out in the
manufacturer's buffer. Reactions were incubated at 37°C
in a Techne Dri-Block DB-3 for greater than one hour.
Digested samples were analysed by electrophoresis.
When digesting a plasmid in order to insert a DNA
fragment 5ug were digested as described above, but in a
final volume of 50ul. After digestion incubation was
continued for a further 30 minutes in the presence of 1
unit of calf intestinal phosphatase (CIP) (Northumbria
Biologicals Ltd). A further 1 unit of CIP was added and
incubation continued for 5 minutes. The sample was
phenol-chloroform extracted twice, followed by chloroform
extraction and ethanol precipitation. The DNA was
resuspended in lOul of SDW and 10% of this analysed
electrophoretically.
2.8 Ligation Of Insert DNA Into Plasmids
Concentrations of digested fragments and plasmids
were selected such that the final amount of plasmid was
100-200ng and the fragment which was to be inserted was
present at approximately molar equivalence and at three¬
fold molar excess. Ligations were performed in a final
volume of 20ul for 16 hours at 18°C, using Amersham T4 DNA
ligase at 35 new units (1 new unit is the amount of the
enzyme which joins more than 90% of 6ug of lambda DNA
cleaved with Hindlll in 20ul for 30 minutes at 16°C) per
reaction, Amersham T4 RNA ligase at 0.1 units per
reaction, and the manufacturer's buffer.
2.9 Transformation Of Bacteria And Yeast With Recombinant
Plasmids
2.9.1 Generating Competent Bacteria
The JM83 and JM101 strains of E.coli (Pharmacia) were
rendered competent using the method of Cooke (H.Cooke,
Western General Hospital, Edinburgh, personal
- 54 -
communication). A pre-culture from a single colony was
grown in L-broth for 16 hours at 37°C with shaking. 400ul
of this pre-culture were inoculated into 40ml of Psi broth
and incubated under the same conditions until the optical
density at 550nm (OD550) of the culture was 0.3. 10ml of
this culture were added to 200ml of Psi broth and
incubated until an OD55Q of 0.48 was reached. The cells
were cooled briefly on ice and centrifuged at 3840 x g
for 5 minutes at 4°C. The cells were resuspended in 66ml
of ice-cold transformation buffer 1 (Tfbl) and kept on ice
for 10 to 15 minutes. The cells were centrifuged as above
and resuspended in 8ml of transformation buffer 2 (Tfb2)
and kept on ice for 20 minutes, after which 200ul aliquots
were transferred to 1.5ml Eppendorf tubes and frozen
immediately on dry ice. The competent cells were stored
at -70°C until required.
2.9.2 Transformation Of Bacteria
Competent bacteria were thawed on ice, incubated
with the ligated DNA for 30 minutes and then heat-shocked
at 42°C for 90 seconds. After brief cooling on ice, 800ul
of L-broth were added and the cultures incubated at 37°C
for 60 minutes. Typically the competent bacteria were
transformed with lOul i.e. 50 to lOOng of the ligated
material.
Bacteria transformed with pGEX-based plasmids were
spread onto L-broth/1.5% agar plates (w/v)
(Bacteriological Agar, Oxoid) containing ampicillin at
75ug/ml (L-broth/1.5% agar/amp) and incubated for 16 hours
at 37°C. Single colonies were picked into 10ml L-broth
containing ampicillin at 75ug/ml (L-broth/amp) and
analysed (section 2.12.1), or picked onto duplicate L-
broth/1.5% agar/amp plates for screening by colony
hybridisation (section 2.14.1).
Bacteria transformed with pTZ-based plasmids were
spread onto L-broth/1.5% agar/amp plates that had been
overlaid with L-broth/0.75% agar/amp containing 200ug/ml
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X-gal (5-bromo-4-chloro-3-indolyl-beta-D-galactoside,
Northumbria Biologicals Ltd)and 0.7mM IPTG (isopropyl-
beta-D-thiogalactoside, Northumbria Biologicals Ltd). The
plates were incubated for 16 hours at 37°C. Single white
colonies were picked into 10ml L-broth/amp and analysed
(section 2.12.1), or picked onto duplicate L-broth/1.5%
agar/amp plates for screening by colony hybridisation
(section 2.14.1).
2.9.3 Transforming Yeast
The BJ2168 strain of Saccharomyces cerevisiae
(auxotrophic for leucine biosynthesis) was used and
transformations were performed using the spheroplasting
method of Hinnen e_t al^. 1978, with the following minor
modifications. The yeast cells were washed once in 1M
sorbitol before incubation with 2% glusulase (v/v) (DuPont
Co., USA) for 2.5 hours after which the resulting
spheroplasts were washed once with 1M sorbitol and once
with 1M sorbitol/lOmM Tris-HCl pH7.5/10mM CaC^. The
spheroplasts were resuspended in 1ml of this solution and
divided into lOOul aliquots for transformation with either
a pOGS recombinant plasmid alone, or the recombinant
plasmid and the pUGS 41S plasmid together. The
spheroplasts and DNA were incubated for 15 minutes at 18°C
after which 1ml of 44% polyethylene glycol (PEG) 3400 was
added and incubation continued for a further 10 minutes.
The spheroplasts were sedimented by centrifugation at 2500
x g for 10 seconds, resuspended in 1ml of the
sorbitol/Tris-HCl/CaCl2 solution and 0.25ml aliquots added
to 20ml of molten regeneration agar. To select for
double-transformants, that is containing both the pOGS and
pUGS-derived plasmids, the spheroplasts were regenerated
in agar containing 0.002% L-tryptophan (w/v) (Sigma).
Each 20ml aliquot of regeneration agar containing the
transformed spheroplasts was poured into individual
sterile 90mm petri dishes. The plates were incubated at
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30°C until single colonies were clearly visible (3-6
days).
2.10 Sub-Cloning
For sequencing purposes sub-clones were made from the
original clones in pTZ19R. The env gene fragments were
excised using two restriction enzymes that cleaved at
sites in the multiple cloning site of pTZ19R on either
side of the inserted sequence. The fragment was then
purified by electrophoresis and the GeneClean II kit
(section 2.12.3) and ligated into pTZ18R cut with the
appropriate enzymes. Restriction enzymes were also used
to cleave a portion of the inserted gene fragment out of
the pTZ19R vector using the described protocol. The
plasmid plus partial insert that remained was purified by
gel electrophoresis, extracted using the GeneClean II kit,
and re-ligated to itself to yield a circular plasmid that
contained only a portion of the gene fragment of interest.
Where pOGS-based plasmids contained the fragment of
interest inserted in the 3' to 5' orientation, but no
recombinant plasmid containing the insert in the 5' to 3'
orientation had been generated, the 3' to 5' recombinant
plasmid was digested with BamHI to excise the fragment.
After phenol-chloroform extraction, chloroform extraction
and ethanol precipitation the mixture of fragment and
linearised plasmid were re-ligated as previously
described.
In all cases transformations were performed as
previously described.
2.11 Stocks Of Recombinant Transformants
Single colonies of E.coli JM83 and JM101 recombinant
bacterial clones were inoculated into 10ml L-broth/amp and
incubated for 16 hours at 37°C with shaking, after which
aliquots were mixed with equal volumes of sterile 40%
glycerol (v/v), transferred to -20°C for 2 hours and the
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clones then stored at -70°C. Cultures of BJ2168
recombinant yeast clones were grown in Sc-glc containing
0.002% L-tryptophan (w/v) (Sigma Chemical Company) (Sc-
glc/Trp) until the OD^qq was 1.0. Glycerol stocks were
made in the same manner as for bacterial clones.
2.12 Purification Of DNA
2.12.1 Small Scale Purification Of Plasmid DNA
Single colonies were picked from L-broth/amp plates
into 10ml of L-broth/amp using a sterile loop, and
incubated for 16 hours at 37°C with shaking. Plasmid DNA
was extracted using a modification of the alkaline-lysis
technique (Birnboim and Doly,1979). 1.5ml of the culture
were centrifuged at 9000 x g for 30 seconds and the
bacterial pellet resuspended in lOOul of 25mM Tris-HCl
pH8.0/10mM EDTA pH8.0/50mM sucrose containing 5mg/ml of
lysozyme and incubated on ice for 10 minutes. 200ul of
0.2M NaOH/1% SDS (w/v) were added and incubation continued
on ice for 10 minutes. 150ul of 3M sodium-acetate
solution pH4.8 were added and incubation on ice continued
for 10 minutes, after which the chromosomal DNA, protein-
SDS complexes and high molecular weight RNA molecules were
pelleted by centrifugation for 10 minutes at 9000 x g.
400ul of supernatant were transferred to a fresh microfuge
tube and 1ml of absolute ethanol added. After 30 minutes
at -20°C the plasmid DNA and remaining RNA were pelleted
as above, and the pellet resuspended in lOOul of 0.1M
sodium-acetate solution pH6.0. 200ul of ethanol were
added and after a further 10 minutes at -20°C the RNA and
DNA were pelleted, resuspended in lOOul of SDW containing
DNAase-free RNAase at lOug/ml and incubated for 30 minutes
at 37°C. After phenol-chloroform extraction, chloroform
extraction and ethanol precipitation the DNA was
resuspended in 20ul of SDW and 4ul were analysed by
restriction enzyme digestion followed by gel
electrophoresis.
- 58 -
2.12.2 Large-Scale Purification Of Plasmid DNA
A 10ml L-broth/amp pre-culture of recombinant E.cloi
JM83 or JM101 clones was incubated for 8 hours at 37°C
with shaking. The 10ml culture was added to 500ml L-
broth/amp and incubation continued for 16 hours. The
plasmid DNA was then harvested using pz523 columns (5
Prime-3 Prime,Inc), following the manufacturer's protocol.
This was followed by a further round of phenol-chloroform
extraction, chloroform extraction and ethanol
precipitation. The DNA was resuspended in SDW, typically
in a volume of 100 to 200ul and the OD250 an^ va-'-ues
and ratio for a diluted sample of the plasmid determined.
The conversion factor of 1 OD250 = 50ug/ml DNA was used.
Plasmid identity was confirmed by restriction digestion
analysis.
2.12.3 Gel Purification Of DNA Fragments
Following restriction digestion and separation of
fragments by gel electrophoresis, clean scalpel blades
were used to excise the relevant bands from the gel. DNA
was extracted from the gel slices using the GeneClean II
kit (Stratatech Scientific, UK) and resuspended in lOul of
SDW. 10% of this solution was analysed
electrophoretically to allow estimation of DNA
concentration.
2.13 DNA Sequencing
All sequencing was conducted using techniques based
on the dideoxynucleotide chain termination method (Sanger
et aT.,1977) using the Sequenase Version 2.0 kit (United
States Biochemical Corporation) with the supplied
Sequenase Version 2.0 T7 DNA polymerase.
All regions studied were sequenced at least twice.
Sequence data was analysed using the Genetics Computer
Group Sequence Analysis Software Package Versions 6.0 and
7.0 (Devereux et al, 1984).




The sequence to which each primer binds is shown below
the primer name. The terminal nucleotide positions in
each primer are shown.
Nucleotide positions for the MVV EV1 primers are from
Sargan et al., 1991.
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M13 Reverse Sequencing Primer
5' CAGGAAACAGCTATGAC 3'
pTZ19R/18R nt 267 nt 251
Tv Sequencing Primer
5' CAGGAGAAATCCGAGTG 3'
pOGS40/42 nt 2587 nt 2603
Primer 191L
5' TAATGCATAGGGAGATGG 3'
MVV EV1 nt 6692 nt 6675
Primer 193L
5' CTTGCACTCCAATACGG 3'
MVVEV1 nt 7135 nt 7119
Primer 415H
5' CCCACTGTTTATATTATGTCT 3'
MVV EV1 nt 7421 nt 7401
sequencing.
2.13.1 Single-Stranded DNA Sequencing
Single-stranded DNA from pTZ-based plasmids
transformed into E.coli JM101 cells was generated by
following the Pharmacia protocol with a few minor
amendments. 10ml of 2 x YT medium containing 150ug/ml
ampicillin (2 x YT/amp) were inoculated with transformed
JM101 cells and incubated at 37°C with shaking until an
ODsgo °f to 0*8 was reached. 400ul of this culture
were inoculated with M13K07 phage at a multiplicity of
infection (MOI) of 10. Incubation was continued for a
further hour after which 10ml of 2 x YT/amp, with
kanamycin at 70ug/ml were added, and the culture incubated
as above for 16 hours. After pelleting out the bacterial
cells by centrifugation at 2500 x g for 10 minutes, 2.5ml
of 20% PEG 3400/3.5M NaCl were added to the supernatant
and the sample incubated on ice for 30 minutes.
Precipitated phage was pelleted by centrifugation at
11,000 x g for 30 minutes at 4°C. The supernatant was
discarded and the phage resuspended in 500ul STE. After 2
phenol-chloroform extractions, chloroform extraction and
ethanol precipitation the ssDNA was resuspended in 30ul of
SDW. 7ul were used for each sequencing reaction.
Sequencing was performed according to the manufacturer's
protocol, each reaction being labelled with 7uCi of ^S-
dATP (specific activity of 400Ci/mmol). (For
electrophoresis see section 2.15.2.)
2.13.2 Double-Stranded DNA Sequencing
Very pure DNA is required for satisfactory double-
stranded DNA sequencing. Material obtained by pz523
column purification (section 2.12.2) of plasmid DNA was
suitable. The sequencing reagents from the Sequenase
Version 2.0 kit were used.
0.5-1.0 pmoles of DNA were mixed with 0.5 pmoles of
primer, and reaction buffer and SDW added to a final
volume of lOul. The samples were boiled for 5 minutes and
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placed on ice. The following reagents were then added;
DTT to 6.25mM, DMSO to 5% (v/v), lul of diluted labelling
mix, 7uCi ^S-dATP (specific activity of 400Ci/mmol) and
2ul of diluted Sequenase Version 2.0 enzyme. The
reactions were incubated for 2 minutes at 18°C and
subsequent stages were performed as for single-stranded
DNA sequencing. (For electrophoresis see section 2.15.2.)
2.14 DNA Analysis By Filter Hybridisation
2.14.1 Colony Hybridisation
Colonies were picked from the original plates using a
sterile loop onto a pair of duplicate L-broth/1.5%
agar/amp plates which were incubated for 16 hours at 37°C.
The colonies were then transferred to nylon filters and
processed by the method of Buluwela e_t aJL. (1989).
Briefly, dry nylon filters (Hybond-N Nylon, 0.45u, 82mm
diameter, Amersham UK) were positioned on the plates for
30 seconds and peeled off to remove the colonies. The
filters were placed face upwards on Whatman No. 3 paper
pre-soaked in 2 x SSC/5% SDS(w/v) for 2 minutes and then
microwaved for 2.5 minutes at full power (650W Matsui
microwave oven). After brief pre-wetting in 2 x SSC/0/1%
SDS(w/v) the filters were incubated in hybridisation
buffer for a minimum of 6 hours at 65°C, followed by
hybridisation with a -^P-dCTP-labelled probe in a minimal
volume of hybridisation buffer for 16 hours at 65°C.
Filters were washed 3 times at 18°C with
2xSSC/0.1%SDS(w,v) and twice at 65°C with
0.1xSSC/0.1%SDS(w/v). Filters were exposed for 16 hours
against Kodak X-omat S film at -70°C and developed.
Colonies reacting with the labelled probe were picked
into 10ml L-broth/amp and treated as for small-scale
plasmid preparations (section 2.12.1).
2.14.2 Labelling Probes Using Random Oligonucleotide-
Primed Synthesis
PCR fragments to be used as probes were generated as
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outlined and resuspended at an approximate concentration
of 50ng/ul. Radio-isotopic labelling was performed using
a modification of the technique of Feinberg and Vogelstein
(1983). Briefly, lul of PCR fragment was mixed with 20ul
of SDW, boiled for 3 minutes and cooled rapidly on ice.
6ul of 5x oligo-labelling buffer, 5 units of Klenow DNA
polymerase I (Northumbria Biologicals Ltd UK) and 20uCi of
•^^P-dCTP (specific activity of 400Ci/mmol) were added.
Labelling was carried out for 2 to 4 hours at 37°C and the
reaction stopped by the addition of 170ul of lOxTE. The
amount of radiolabel incorporated was assayed by
precipitating lul of the reaction mixture on glass fibre
discs in 5% trichloroacetic acid (w/v). Discs were placed
in 2ml of Optiphase Safe scintillant (LKB), activity
measured in an LKB Rackbeta Liquid Scintillation Counter
and specific activity calculated. With probes of
specific activity of approximately 1 x 10® cpm/ug 1.25 x
10® cpm were used in each hybridisation reaction. The
labelled probe was boiled for 3 minutes and then cooled
rapidly on ice before use.
2.15 Gel Electrophoresis
2.15.1 DNA Analysis Gels
DNA samples were analysed on 1% agarose (w/v)/TAE
gels containing lug/ml of ethidium bromide. Before
loading the samples were mixed with half their volume of
DNA sample buffer. Electrophoresis was carried out at a
constant voltage of 6.25V/cm^ and EcoRI/Hindlll-digested
lambda DNA molecular weight markers (Northumbria
Biologicals Ltd) were included on every gel.
2.15.2 DNA Sequencing Gels
All sequencing reactions were analysed on 6%
acrylamide (w/v) gels (acrylamide:N,N'-
methylenebisacrylamide ratio of 19:1) containing 8M urea
(all molecular biology grade reagents) in 0.5 x TBE buffer
using a Bio-Rad Sequi-Gen apparatus. Electrophoresis was
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conducted at a maximum voltage of 1212V/cmz from 2 to
hours. Gels were dried onto Whatman 3MM paper at 80°C for
2 hours under vacuum on a Bio-Rad Model 583 Gel Dryer and
autoradiography was carried out using Kodak X-omat S film.
Exposure was typically from 24 to 48 hours at 18°C for
single-stranded DNA sequencing, and 7 to 10 days for
double-stranded DNA sequencing.
2.15.3 SDS-PAGE Protein Gels
Polypeptides were analysed using a modification of
the dissociating discontinuous sodium dodecyl sulphate -
polyacrylamide gel electrophoresis (SDS-PAGE) method of
Laemmli (1970). SDS-PAGE was performed using the Bio-Rad
Mini Protean II slab gel apparatus, with 0.75mm spacers.
Either single concentration or gradient separating gels
were used, using a 30% acrylamide (w/v)/0.8%
bisacrylamide (w/v) stock solution and a final
concentration of 0.38M Tris-HCl pH8.7/0.1% SDS. The
stacking gel contained 3.48% acrylamide (w/v)/0.093% (w/v)
bisacrylamide/0.145M Tris-HCl pH6.8/0.12% SDS (w/v).
Samples were mixed with an equal volume of SDS-PAGE
loading buffer, boiled for 3 minutes and gels
electrophoresed in running buffer containing 0.05M Tris-
HC1/0.1% SDS (w/v)/0.37M glycine. Electrophoresis was
performed for 90 to 120 minutes at a constant voltage of
220V/cm^ and Pharmacia Electrophoresis Calibration Kit
markers (molecular weight range 14,400-94,OOOKDa) were
electrophoresed on every gel.
After completion of electrophoresis gels were either
stained to localise protein or the polypeptides were
electrophoretically transferred onto nitrocellulose
membranes for immunodetection (section 2.16).
2.15.3.1 Coomassie Staining Of Protein Gels
Routine staining was performed using 0.1% Coomassie
Blue R250 (w/v) (Sigma, UK) in 40% methanol (v/v)/15%
acetic acid (v/v) for 30 minutes followed by extensive
destaining in 20% methanol (v/v)/5% acetic acid (v/v).
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2.15.3.2 Silver Staining Of Protein Gels
Gels were fixed by a modification of the method of
Oakley e_t £^.,(1980). The gel was pre-fixed in 50%
methanol (v/v)/10% acetic acid (v/v) for 30 minutes and
then transferred to 5% methanol (v/v)/7% acetic acid (v/v)
for 30 minutes. The gel was fixed for 20 minutes in a 10%
glutaraldehyde solution (w/v) and washed in double-
deionised water for 16 hours. It was then incubated at
18°C for 15 minutes with shaking in a 0.1% (w/v) solution
of silver nitrate. Gels were developed in a 0.28M
solution of Na2C03 containing 0.05% (v/v) formaldehyde
until bands were clearly visible but before background
staining became too pronounced. The staining reaction was
halted by the addition of 1 to 2g of citric acid to the
solution. Staining was fixed by soaking the gels for 60
seconds in a 10% solution (v/v) of Ilford Hypam Fixer.
After staining gels were dried for 1 hour under
vacuum at 80°C on a Bio-Rad Model 583 Gel Dryer.
2.16 Western Blotting
Polypeptides separated by SDS-PAGE were
electrophoretically transferred onto nitrocellulose
membranes (Hybond-C, 0.45u, Amersham, UK) using a
modification of the original technique of Towbin e_t al. ,
(1979). Transfer was performed in 25mM Tris-HCl/20%
methanol using an Ancos Semi-Dry Electroblotter A,
operated at a constant current of 0.44mA/cm^. After
transfer the region of the nitrocellulose membrane
containing the molecular weight markers was removed and
the markers stained in 5% Amido Black (w/v) in 50% (v/v)
methanol for 30 minutes, and destained for several hours
in 50% methanol (v/v)/5% acetic acid (v/v).
Vacant sites on the nitrocellulose were blocked by
incubation at 18°C for at least 1 hour with 5% milk powder
(Sainsbury's) (w/v)/0.5% Tween 20 (v/v) (Sigma Chemical
Company UK)/sterile phosphate buffered saline (SPBS).
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Primary antibody was diluted in 5% milk powder/SPBS and
the blot was incubated with the antibody for 16 hours at
4°C. After 5 washes in the same diluent the blot was
incubated for 1 hour at 18°C with an alkaline-phosphatase-
conjugated second antibody, again diluted in 5% milk
powder/ SPBS. The blot was washed twice in the same
diluent and 3 times in 0.1M Tris-HCl pH9.5. The blot was
developed in NBT western blot development solution and the
reaction was stopped before background staining became too
pronounced by washing the blot in deionised water.
2.16.1 Preparation Of MVV Antigens From Infected Cells For
Western Blotting
Infection of a T175 flask of WSCP or skin cells was
carried out as for section 2.4 and the cells incubated
until significant synvytia formation was apparent. The
medium was removed and the cells dislodged from the flask
using sterile glass beads in 500ul of SPBS. An equal
volume of SDS-PAGE sample buffer was added and the samples
boiled for 3 minutes. Viral proteins were separated by
SDS-PAGE and analysed by western blotting.
2.17 Production And Purification Of Recombinant Proteins
2.17.1 Yeast (Ty-VLP) Expression System
2.17.1.1 Small-Scale Purification Of pi-Fusion Proteins
Single colonies from the agar plates were streaked
out onto Sc-glc-agar plates containing L-tryptophan at
0.002% (w/v) and incubated at 30°C for 3-5 days until
large single colonies were visible. A single colony was
picked into 50ml of Sc-glc/Trp and the culture incubated
with shaking at 30°C until it had reached an OD^qq of 0.5-
1.0. The cells were centrifuged at 1500 x g for 5
minutes and resuspended in 50ml of Sc-glc-gal containing
0.002% (w/v) tryptophan (Sc-glc-gal/Trp) and incubated as
above. Optimal induction time was determined by time-
course experiments. 15ml of the culture were centrifuged
at 1500 x g for 15 minutes and the cells resuspended in
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lml of TEN. lg of acid-washed and baked 40 mesh glass
beads (BDH,UK) was added, the cells vortexed for 1 minute
and then placed on ice for 1 minute. Cell breakage was
repeated three times. Cell lysates were mixed with an
equal volume of SDS-PAGE reducing gel buffer, boiled for 3
minutes and analysed on SDS-PAGE gels. For Coomassie-
stained gels 5ul of sample were loaded, and for Western
blot analysis l-2ul of sample were loaded.
2.17.1.2 Large-Scale Purification Of pi-Fusion Proteins
100ml of Sc-glc/Trp were inoculated with 2ml of a
glycerol stock of the appropriate yeast clone and
incubated with shaking at 30°C until the culture had
reached an OD^qq of 1. The 100ml culture was added to
500ml Sc-glc/Trp and incubation continued until the same
cell density had again been reached. The cells were then
split between 8 500ml aliquots of Sc-glc-gal/Trp and
incubation continued, the optimal induction time being
determined by previous time-course experiments. The cells
were harvested by centr ifugation at 3480 x g for 20
minutes at 4°C and resuspended in 20ml of SDW per litre of
original culture volume. The cells were spun at 1500 x g
and washed with SDW. This was repeated twice and followed
by one wash in TEN.
7.5ml of packed washed cells were processed using a
method based on that of Mellor e^ al.,1985b. Briefly, the
cells were broken open in 4ml of TEN containing protease
inhibitors (see Materials) to which 5g of acid-washed and
baked 40 mesh glass beads had been added. Cell breakage
was achieved by vortexing the cells for 3 one minute
intervals, interspersed with one minute intervals on ice.
The sample was spun at 1480 x g for 5 minutes at 4°C and
the supernatant stored on ice. The process was repeated
until greater than 80% breakage was apparent
microscopically. The pooled supernatant fractions were
centrifuged at 13300 x g for 20 minutes at 4°C to pellet
contaminating cellular debris and the supernatant was
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layered onto a 2ml 60% sucrose cushion (in TEN with
protease inhibitors) and centrifuged at 160,000 x g for 1
hour at 4°C. The layer of protein above the cushion, and
the cushion itself, were dialysed overnight at 4°C against
TEN and then layered onto a pre-formed 15-45% sucrose
gradient, underlayered with a 60% sucrose cushion. After
centrifugation at 100,000 x g at 4°C for 3 hours the
gradient was fractionated into 2ral samples and the
fractions analysed by SDS-PAGE and Western blotting.
2.17.2 Bacterial (pGEX) Expression System
2.17.2.1 Small-Scale Purification Of GST-Fusion Proteins
The protocol of Smith and Johnson (1988) was
followed. Briefly, 2ml of L-broth/amp were inoculated
with lOOul of a glycerol stock of the pGEX-based clones
and incubated at 37°C with shaking until the culture was
visibly turbid (typically 4 to 6 hours). IPTG was added
to O.lmM and incubation continued, typically for 2 to 3
hours. The cells were pelleted by centrifugation at 9,000
x g for 30 seconds and the pellet resuspended in 300ul of
ice-cold SPBS. A Dawe 2mm probe sonicator was used to
lyse the cells in 10 seconds with minimal frothing and
cellular debris was removed by centrifugation at 9,000 x g
for 5 minutes. 50ul of a pre-swollen 50% slurry of
glutathione-agarose beads (Sigma Chemical Company) were
added to the supernatant and the samples mixed gently at
18°C for 60 minutes. The beads were resuspended in 1.5ml
of SPBS and centrifuged at 9,000 x g for 10 seconds; the
supernatant was discarded and the washing procedure
repeated twice. The beads were resuspended in 50ul of
SDS-PAGE sample buffer and analysed by SDS-PAGE.
2.17.2.2 Large-Scale Purification Of GST-Fusion Proteins
100ml of L-broth/amp were inoculated with lOOul of a
glycerol stock of the pGEX-based clones and incubated at
37°C for 16 hours with shaking. This pre-culture was
diluted 1:10 with L-broth/amp and incubation continued
under the same conditions until an ODgQO value °f 0*6 was
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reached. IPTG was added to O.lmM and incubation
continued; the optimal point of induction, and the period
of induction were determined experimentally. Once
induction was complete the cultures were centrifuged at
4640 x g for 10 minutes at 4°C and the cells resuspended
in 15ml of ice-cold SPBS. A Dawe 2mm probe sonicator was
used to disrupt the cells in 3 one minute intervals of
sonication, with minimal frothing, interspersed with 2
minute intervals on ice. Triton X-100 (Sigma Chemical
Co. , UK) was added to a final concentration of 1% (v/v)
and the samples centrifuged at 10,300 x g for 5 minutes at
4°C to remove cellular debris. 1ml of a pre-swollen 50%
slurry of glutathione-agarose beads was added to the
supernatant and the samples mixed gently at 18°C for 60
minutes. The beads were resuspended in 50ml of SPBS and
centrifuged at 500 x g for 10 seconds; the supernatant was
discarded and the washing procedure repeated twice. The
beads were resuspended in 1.5ml of SPBS and stored at 4°C
until the fusion protein was eluted.
2.17.2.3 Elution Of Glutathione S-Transferase-Fusion
Proteins
The supernatant was removed from the glutathione-
agarose beads and the beads resuspended in the same volume
of 50mM Tris-HCl pH8.0/10mM reduced glutathione (Sigma
Chemical Co., UK). The samples were incubated for 2
minutes at 18°C, centrifuged at 500 x g for 10 seconds and
the supernatant removed. Elution was repeated twice and
the eluted protein stored in aliquots at -20°C.
2,18. Electron Microscopy
Yeast cultures were prepared for electron microscopy
by a modification of the protocol of Byers & Goetsch
(1975). Briefly, the cells from a 25ml culture were
pelleted at 2500 x g for 5 minutes at 4°C and resuspended
in 5ml of cacodylate/glutaraldehyde buffer. The cells
were incubated for 30 minutes at room temperature and
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pelleted as above. After resuspension in 10ml of
cacodylate/glutaraldehyde buffer the samples were
incubated for 16 hours at 4°G with rotation. The cells
were pelleted as above and washed twice in 10ml of pre-
treatment buffer. After the second wash the cells were
resuspended in 5ml of phosphate/citrate buffer containing
250ul of glusulase and incubated for 60 minutes at 30°C.
The spheroplasts were then washed in two changes of 10ml
of phosphate/citrate buffer and resuspended finally in 5ml
of the same buffer. The samples were post-fixed for 60
minutes at 0°C in 2% w/v osmium tetroxide in cacodylate
buffer, rinsed with SDW and incubated for 60 minutes at
20°C with 2% aqueous uranyl acetate. After dehydration
through a graded alcohol series and embedding in araldite
resin 60nm-thick sections were cut and examined on a
Phillips EM400 transmission electron microscope.
2.19 Giemsa Staining Of Cell Monolayers
Medium was removed from the wells of a 96 well plate
and replaced with lOOul of ice-cold acetonermethanol (1:1)
to fix the cells. After 10 minutes this was replaced with
lOOul of 1% potassium dichromate (w/v) solution for 30
minutes. This was replaced with lOOul of acetonermethanol
for 10 minutes, and the cells allowed to air-dry for 5 to
10 minutes. lOOul of Giemsa's stain (Gurr's Improved R66,
BDH,UK), freshly diluted 1:1 with tap water, were added to
each well for 5 minutes after which the stain was removed
and replaced by tap water for 60 seconds. Monolayers were
examined microscopically for cytopathic effects.
2.20. Immunofluorescent Staining Of Cells
2.20.1 Cell Monolayers
Sterile 10mm coverslips were placed singly in each
well of a 24-well plate (Nunclon). 1 x 10^ cells were
added to each well, in 500ul of fully supplemented 8% DMEM
and the plates were incubated at 37°C/5% CO2 until the
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desired level of cell confluency was attained. The medium
was removed and the monolayers washed once with 500ul of
SPBS, and fixed with 500ul ice-cold 0.15M NaCl/80% acetone
for 10 minutes. The coverslips were removed, dried with a
hair-dryer and stored dry in fresh plates at -20°C.
2.20.2 Cytospins
Efferent lymph (obtained by lymphatic cannulation of
the pre-femoral lymph node of a sheep, a kind gift of Dr J
Hopkins, Department Of Veterinary Pathology, University Of
Edinburgh) was diluted with SPBS until a cell
concentration of 2.5 x 10^ cells/ml was reached. Slides
coated with 1.25 x 10^ cells/cytospin were made using the
Shandon Cytospin 2, operated at 500rpm for 5 minutes.
After air-drying the cytospins were fixed and stored as in
section 2.20.1.
2.20.3 Immunofluorescent Staining
Fixed monolayers and cytospins were thawed at 18°C
and blocked for 30 minutes at 18°C with shaking in 250ul
of 10% normal species serum/0.01% Tween 80 (v/v)(Sigma
Chemical Company, UK)/SPBS. The normal species serum used
was from the same species as that in which the conjugated
antiserum was raised. After removal of the blocking
solution the samples were incubated for 60 minutes at 18°C
with shaking in 250ul of the primary antibody, diluted in
2% normal species serum/0.01% Tween 80/SPBS. The samples
were washed five times in 0.01% Tween 80/SPBS and
incubated with an anti-species antibody, conjugated to
fluorescein isothiocyanate (FITC) (Scottish Antibody
Production Unit), under identical conditions to the
primary antibody incubation. The samples were washed
three times in 0.01% Tween 80/SPBS, mounted in 2-3ul of
Citifluor (Citifluor Ltd., UK) and stored in the dark at
4°C until examined using a Leitz Ortholux II microscope.
2.21. Enzyme-Linked Immunosorbent Assay (ELISA)
Antigen was diluted in 0.1M NaHCO^ pH9.5 to an
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appropriate concentration and 75ul were used to coat the
wells of an ELISA plate (Dynatech UK) for 16 hours at 4°C.
The antigen was discarded and the wells blocked with lOOul
of 2% BSA (w/v)/SPBS for 45 minutes at 18°C. After
washing three times in 0.1% Tween 20 (v/v)/SPBS, 75ul of
first antibody, diluted in 2% BSA/SPBS, were added and the
plate incubated for 30 minutes at 18°C. The washing was
repeated and 75ul of the appropriate anti-species-
peroxidase-linked conjugate diluted in 2% BSA/SPBS were
added to the wells. After 30 minutes at 18°C the wells
were washed as above. 75ul of OPD substrate solution were
added to each well and the chromigenic reaction allowed to
proceed at 18°C. The reactions were stopped in all
wells by the addition of 50ul of 2M H2SO4. Absorption at
492nm was determined using a Titertek Multiskan.
Affinity-purified soluble ovine MHC class II antigen,
prepared by the method of Dalziel e_t a_l. (1991) was a kind
gift of Dr B.M. Dutia, Department Of Veterinary Pathology,
University Of Edinburgh.
2.22 Glycosidase Treatment Of Proteins
2ug of protein were adjusted to 0.75% SDS in a total
volume of 21ul and boiled for 3 minutes. The samples were
adjusted to 0.075% SDS/lOmM EDTA/lOmM Triton X-100 and
incubated at 37°C for 16 hours with 0.4U of N-glycosidase
F (Boehringer Mannheim ltd.) or 0.1U of endoglycosidase F
(Boehringer Mannheim ltd.). After digestion the samples
were precipitated with 5 volumes of acetone at -20°C for
16 hours and analysed by SDS-PAGE.
2.23. Immunisation Protocols
For the first immunisation antigen was diluted with
SPBS, and an equal final volume of Complete Freund's
Adjuvant (Sigma Chemical Co., UK) added. Samples were
emulsified using a Janhe & Kunkel Ika-Werk Ultra-Turrex
and stored at 4°C for 16 hours. Rabbits and mice (strain
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Balb/c) were immunised sub-cutaneously with 4ug of antigen
in 1ml (at two sites), and 1.5ug in 0.4ml (at two sites)
respectively. Subsequent immunisations were performed
under the same conditions but Complete Freund's Adjuvant
was replaced with Incomplete Freund's Adjuvant (Sigma
Chemical Co. UK).
Plain blood samples for analysis were obtained from
the ear vein (rabbits) or tail tip (mice). Samples were
allowed to clot at 4°C for 16 hours; the serum was removed
and stored at -20°C.
- 73 -
3. Analysis Of Sequence Variation In The gp!35 Gene Of MVV
Strain EV1
3.1 Introduction
In each lentivirus which has been extensively
studied significant degrees of variation between isolates
have been discovered in the env gene. In MVV this was
originally suggested by the isolation of neutralisation
variants after in vivo passage of the virus (section
1.16). There is still some debate concerning the
frequency with which such variants develop in vivo and the
role of neutralising antibodies in generating and
maintaining these variants. However it is becoming
apparent with the publication of the genome sequence of
different strains of MVV that there is significant inter-
strain variation in the env gene.
The greatest amount of detail on variation in a
lentiviral env gene has been accumulated for HIV.
Although an extensive discussion of the data for HIV is
outside the scope of this chapter the major salient points
will be discussed, particularly where they may have
relevance to the interpretation of sequence variations in
MVV.
An analysis of HIV variants isolated from
geographically distinct individuals demonstrated greater
levels of variation between the env genes of different
isolates than the gag or pol genes (Starcich e_t al. ,
1986). The maximum nucleotide disparity between two gag
genes was 5.9%, and 4.4% for pol genes. In contrast the
maximum disparity between the gpl20 regions of the env
genes was 14.0%.
Differences were also apparent in the type of
mutations present in different regions of the genome. In
the gag and pol genes nucleotide sequence changes were
almost exclusively individual point mutations. In env
however clustered point mutations, deletions, insertions
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and duplications were common (Starcich e_t a_l. , 1986). The
mutations in gag and pol were also less likely to result
in amino acid changes than the mutations in env. This
suggested a greater "tolerance" of alterations to amino
acid sequence in gpl20 than in the Gag and Pol proteins.
It also indicated a possible bias towards non-silent
nucleotide changes in env which may be a result of
interaction with host immune responses.
In individuals infected with HIV there is extensive
diversity of virus in vivo. While it is obviously
impossible under all except very rare circumstances to
monitor deviations from a clonal infecting isolate the
data suggests evolution of viral quasi-species in vivo.
Restriction mapping experiments on sequential isolates
from infected individuals found between 9 and 17 related
but distinguishable genotypes during viral isolation (Saag
et al., 1988) and by analogy with the data of Starcich et
al. (1986) the majority of the variation would be expected
to be found in the env gene. The insertion of different
env sequences, isolated from a single individual, into a
"background" viral strain demonstrated that the env gene
affected the growth capacity of the virus in different
cell types in vitro (Fisher £j: al^. , 1988) suggesting that
viruses may evolve in an individual host with different
cellular tropisms.
Mutations are not spread randomly throughout the env
gene (section 1.14) of HIV but are clustered into variable
regions (VI to V5), interspersed with relatively well-
conserved domains. The best characterised of these
variable regions is the V3 loop, which contains the PND.
Although high sequence variability is apparent between the
V3 loops from different HIV isolates it has been suggested
that certain structural features are maintained between
these variants (LaRosa e_t a_l. , 1990). The virus may be
under selective pressure for the kind of amino acid
substitution which is consistent with continued function,
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such that secondary structure may be maintained even in
the presence of primary sequence variation.
Studies on the V3 loop in sequential isolates from
children infected by a single plasma source have indicated
that the variants which arise during the course of an
infection may be host-dependent, as the consensus
sequences derived from viral isolations differed for each
individual (Wolfs £t al. , 1990). Fewer changes were
observed in the isolates from children in whom progression
to AIDS occurred most rapidly, suggesting that generation
of variants may be influenced by the immune system (Wolfs
et al., 1990).
Extensive variation in the V4 and V5 regions, both
between isolates from a single individual and between
isolates from different individuals infected from a single
source, has also been reported (Simmonds e_t al. , 1990).
This work confirmed that a number of env variants co-exist
in an infected individual.
Variation in the env gene of HIV has therefore been
extensively demonstrated in vivo and is believed to be
significant in viral persistence. The initial source of
variation is the intrinsically high error rate of reverse
transcriptase, due to its lack of a "proof-reading"
capacity, but the disparity in the accumulation of
mutations, both between genes and within the env gene
indicates selection pressures must be operating upon the
virus. It has been estimated for HIV that the rate of
O
_ O
viable genetic change is 10 i to 10 J substitutions per
site per year for env, but is tenfold less for gag (Hahn
et al. , 1986). Constraints also appear to limit the
evolution of variant sequences within an individual, as
variation of isolates within an individual is less than
variation between individuals (Hahn e_t _al. , 1986; Saag e_t
al., 1988).
Variation in the env gene has also been reported for
EIAV (Payne e_t al. , 1987b). This may be particularly
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significant as in EIAV it is possible to relate specific
disease episodes to the emergence of antigenic variants
(Montelaro e_t ad., 1984). In sequential isolates from
experimentally-infected ponies non-randomly distributed
mutations were present in the env gene, particularly in
the region encoding the extracellular gp90 (Payne ej; al. ,
1987b). Within the gp90 region one hypervariable and two
constant regions could be identified by comparison of
isolates. Approximately 40% of the amino acid
substitutions in gp90 of EIAV resulted in alterations in
asparagine residues, and therefore had the potential to
affect markedly the glycosylation pattern of the processed
glycoprotein (Payne ed _al. , 1987b). This may act in vivo
as a further means of protection from neutralising
antisera, by masking neutralisation epitopes on the viral
envelope.
Relatively little data at the DNA level is available
on the variants of MVV which exist in vivo. Section 1.16
summarised the data on sequential isolation of
neutralisation variants which arise in vivo. There is a
limited amount of data on variants of the 1514 strain of
virus, derived from in vivo passage of virus, and sequence
comparisons are also available for MVV isolates which have
been obtained from geographically distinct variants of the
virus. A pattern broadly similar to that seen in HIV is
beginning to emerge.
Restriction hybridisation experiments demonstrated
that homology between MVV and CAEV was predominantly
localised to the gag and pol regions of the genome (Pyper
et al. , 1984), with homology in env restricted to the 3'
region. Similar hybridisation results were obtained with
SA-OMVV, in which it was found that homology with the 1514
strain of MVV was greatest in the LTRs and the gag and pol
genes (Querat e_t a_l. , 1987), supporting the hypothesis of
relative variability of the env gene.
SA-OMVV was sequenced and compared with MVV strain
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1514 (Querat et_ al. , 1990). As anticipated from the
hybridisation data (Querat £t^ a_l. , 1987) much higher
diversity was observed for env than gag or pol (20% amino
acid mismatch, compared with 8.5% and 13% respectively).
The only orf in which greater sequence diversity was
detected was the rev gene, part of which is coincident
with the env orf. Sequence alterations were also
heterogeneously distributed within env, which may be
analogous to the distribution in HIV env.
A similar pattern was found for the British isolate
of MVV, EV1 (Sargan jet al. , 1991). Comparison of the env
sequences of EV1 and the previously sequenced isolates
confirmed that the env gene contained both relatively
conserved and variable regions. It has not yet proved
possible to relate these to functional determinants of the
molecule, such as receptor binding domains.
The same pattern may not however be immediately
apparent for sequential isolates from an initial viral
stock. An analysis of MVV strain 1514 and sequential
isolate 1LV1-1 revealed an almost random distribution of
mutations throughout the genome, except for one cluster of
mutations between nucleotides 7864 to 7890 which lies
towards the putative C-terminus of gpl35 (Braun al. ,
1987).
MVV strain 1514 was also used as the initial virus
stock for experiments in which infectious clones were
sequenced and compared (Staskus e_t al_. , 1991). Plaque-
purified 1514 was passaged in vitro and a progeny stock,
7/86 was obtained which differed from 1514 in its
neutralisation properties, suggesting that variations in
env may arise in the absence of selective antibody. Cells
were infected in vitro and the infectious clones obtained
from the Hirt DNA fraction. The two infectious clones
differed from the prototype 1514 sequence (Sonigo e_t al. ,
1985) by 0.978% and 0.793% but these changes were not
evenly spread throughout the genome. The env genes
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contained 53.33% and 64.38% of the changes respectively
(Staskus e_t al. , 1991). This supported the proposition
that even in the absence of selective pressure from a host
immune response the env gene is the region of the genome
which is most able to sustain mutations.
In order to begin to investigate the variability of
MVV strain EV1 a number of in vitro isolates were analysed
by DNA sequencing. Hirt DNA was used as the template for
PCR generation of env gene fragments. DNA sequencing of
these cloned fragments was performed in order to estimate
the type of variation observed in vitro for this strain,
and to investigate if any major differences were apparent
in the gene after long-term passage in tissue culture.
3.1 Cloning Of gp!35 Variants
In order to obtain variants of gpl35 the PCR was
performed using Hirt DNA isolated from a variety of viral
sources. The PCR primers shown in chapter 2 (figure 2.1)
were used to generate the overlapping fragments of env
which encode the protein regions shown in figure 3.1. The
fragments generated were inserted into the vector pTZ19R
for cloning and sequencing.
For each env region (envA, envB and envC) two clones
were sequenced after PCR generation from the Hirt DNA
preparation used in the sequencing of the EV1 British
isolate of MVV (Sargan e_t al. , 1991) (a kind gift of
D.J.Roy, Department Of Veterinary Pathology, University Of
Edinburgh). These are referred to in figure 3.2 as
"original clones".
One of each of these original clones for each env
region was subsequently used as a template in a PCR. The
resulting PCR fragment was inserted into the pOGS
expression vectors for generation of a recombinant fusion
protein (see chapter 4), and was also cloned into plasmid
pTZl9R for sequence analysis. These pTZ19R-based clones
are referred to in figure 3.2 as "duplicate clones".
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Figure 3.1
The regions of MVV strain EV1 gp!35 encoded by the
products of the PCR using selected primers
PCR primers 1 to 6 (chapter 2, figure 2.1) were used to
generate DNA fragments which spanned the coding regions
shown. The terminal amino acids of each encoded region















MVV strain EV1 gp!35 variant clones
Hirt DNA was used as the template for PCR with env-
specific primers, and the resulting fragments cloned as
in the text. The clone number is that which was
assigned to the original clone for each fragment in
pTZ19R.
Key
Original Template = low passage Hirt DNA as used
by Sargan jst a_l. , 1991.
Duplicate Template = purified plasmid DNA from
clones A46, BX10 or C45 as appropriate.
Low Passage Template = Hirt DNA from infection with
low passage EV1
















Hirt DNA isolated from viral stocks of EV1 which had
been passaged minimally in vitro (section 2.1) was used as
a PCR template. The resulting clones are referred to in
figure 3.2 as "low passage clones".
Hirt DNA from viral stocks of EV1 which had been
relatively extensively passaged in vitro (section 2.1) was
also used as a PCR template. The resulting clones are
referred to in figure 3.2 as "high passage clones".
In each case the fragments generated by PCR were
digested with BamHI, separated by gel electrophoresis and
purified using the Gene-Clean kit. Purified plasmid
pTZ19R was digested with BamHI and treated with CIP. The
purified digested PCR fragments and the digested plasmid
were ligated and the resulting DNA used to transform
E.coli strain JM101. Positive clones were initially
screened by ampicillin resistance and blue-white
selection.
For the original template Hirt DNA approximately 80
white colonies each resulted from the ligation of envA and
envC into pTZ19R. 12 of each were selected and screened
by small-scale purification of their plasmid DNA followed
by digestion with BamHI and analysis by gel
electrophoresis. 3 of the clones from the pTZ19R:envA
ligation contained a single insert of the expected
molecular weight and 2 of these were chosen arbitrarily
for sequencing (clones A46 and AX11). 7 of the clones
from the pTZ19R:envC ligation contained a single insert of
the expected molecular weight and 2 of these were chosen
arbitrarily for sequencing (clones C45 and CX7). 5 white
colonies resulted from the ligation of envB into pTZ19R.
Each clone was screened by analysis of purified plasmid
DNA and after BamHI digestion and gel electrophoresis 3
were found to contain a single insert of the expected
molecular weight and 2 of these were chosen arbitrarily
for sequencing (clones BX10 and BX11).
A similar procedure was followed where clones A46,
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BX10 and C45 were used as the PCR template to generate
"duplicate" sequences. 4 white colonies from each
transformation were analysed, and in each case the plasmid
contained a single insert of the expected molecular weight
in 3 of the clones. One of each was chosen arbitrarily
for sequencing (clones ADP1, BDP1 and CDP1).
For the "low passage" template Hirt DNA 22 white
colonies resulted from the ligation of envA into pTZ19R
and 32 white colonies from the ligation of envC.
Duplicate plates were made from these white colonies and
screened by colony hybridisation using the appropriate env
region probe. All the colonies hybridised to the env-
specific probes and 3 were selected for screening by
restriction digestion and gel electrophoresis of plasmid
DNA. After digestion with BamHI each of the selected
colonies was found to contain a single insert of the
expected molecular weight. One of each was chosen
arbitrarily for sequencing (clones DA3 and DC1). 2 white
colonies resulted from the ligation of envB into pTZ19R
and the plasmid DNA was analysed by restriction digestion
and gel electrophoresis. After digestion with BamHI one
clone was found to contain a single insert of the expected
molecular weight and this clone was sequenced (clone DB2).
For the "high passage" template Hirt DNA
approximately 75 white colonies resulted from the ligation
of either envA or envC into pTZ19R. These were screened
as in the paragraph above. All the colonies were positive
by colony hybridisation and 3 were further screened by
restriction digestion and gel electrophoresis of the
plasmid DNA. After digestion with BamHI each clone was
found to contain a single insert of the expected molecular
weight and one of each was chosen arbitrarily for
sequencing (clones VA1 and VC1). 7 white colonies
resulted from the ligation of envB into pTZl9R. These
were screened by restriction digestion and gel
electrophoresis of the plasmid DNA. After digestion with
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BamHI it was found that 2 clones contained a single insert
of the expected molecular weight and one was chosen
arbitrarily for sequencing (clone VB6).
3.3 Sequencing Of gp!35 Variant Clones
The various gpl35 clones were analysed by single-
stranded DNA sequencing using the dideoxynucleotide chain
termination technique, and each nucleotide was sequenced
at least twice. The sequencing primers used are shown in
chapter 2 (figure 2.2) and the basic strategies will be
outlined below.
The strategies for sequencing each clone are
summarised in figure 3.3. Each env fragment was initially
inserted in the 3' to 5' orientation (with respect to the
primer binding site) in pTZ19R and all clones were
therefore partially sequenced in pTZ19R using reverse
sequencing primer.
In order to reverse the orientation of the env gene
sequences with respect to the primer binding site the
fragments were excised from pTZ19R and ligated into
pTZ18R. The two plasmids differ only in the orientation
of the multiple cloning site within the plasmid. The envA
and envB fragments were excised from purified plasmid DNA
with the restriction enzymes EcoRI and Pstl. These each
cut the plasmid at one site only, one on either side of
the inserted DNA, and there are no EcoRI or Pstl site
within the envA or envB fragments. After excision the
fragment was purified in the normal manner, ligated into
pTZ18R which had been digested with the same pair of
enzymes and used to transform E.coli JM101. Colonies were
selected and screened in the same way as for the initial
transformations and one positive clone for each fragment
was arbitrarily chosen for sequencing (cloning data not
shown).
The envC fragment was excised from pTZ19R with EcoRI
and Hindlll. These each cut the plasmid singly on either
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Figure 3.3
Sequencing strategies for MVV strain EV1 gp!35 variant
clones
Single-stranded DNA was used for dideoxynucleotide chain
termination sequencing. Sequencing was in the direction
shown by the arrows and the terminal nucleotides for
each fragment are indicated (numbering as in Sargan e±
al. , 1991).
Key
R reverse sequencing primer
191L sequencing primer 191L
1931 sequencing primer 1931
415H sequencing primer 415H
19 fragment sequenced in pTZ19R
18 fragment sequenced in pTZ18R
19,X fragment sequenced in pTZ19R, after part of



















side of the inserted fragment, but there are no EcoRI or
Hindlll sites within envC. The fragment was ligated into
pTZ18R which had been digested with the same pair of
enzymes and cloning and screening performed as for envA
and envB.
The "reversed" clones were then partially sequenced
using reverse sequencing primer.
The envA sequence contains a unique Xbal site at
nucleotide 6494, and pTZ19R contains a unique Xbal site in
the multiple cloning site. Digestion of the pTZ19R:envA
plasmid DNA with Xbal resulted in excision of the envA
fragment between nucleotides 6494 and 6929 (all positions
refer to the nucleotide numbers in the published MVV EV1
sequence - Sargan e_t a_l. , 1991). The digested plasmid DNA
was re-ligated to itself, resulting in a plasmid
pTZ19R:envAX where envAX contained the envA fragment 5994
to 6929.
Internal sequencing primers were used in pTZ19R;envA
(primer 191L) and pTZ19R;envB (primers 193L and 415H).
The sequences generated for each clone were assembled
manually and subsequently analysed using versions 6.0 and
7.0 of the Genetics Computer Group Sequence Analysis
Software Package (Devereux ejt aJL. , 1984).
The nucleotide sequence of each cloned fragment is
shown in figure 3.4a-c, along with the published EV1
sequence (Sargan e_t _al. , 1991). The same name, for
example A46 is used to denote both the clone and the env
gene fragment itself. Positions at which the nucleotide
is variable between 2 or more clones are marked by
as terisks.
The predicted amino acid sequence for each clone was
derived from the nucleotide sequence and the results are
shown in figure 3.5a-c. Amino acids which vary between 2
or more clones are marked by asterisks. The single letter
amino acid code is used.
The percentage identity between each pair of clones
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Figure 3.4a
The nucleotide sequences of the MVV strain EVl gp!35
envA variants
The nucleotide sequence of each envA variant is shown,
including the published EVl sequence (EVl, from Sargan
et al., 1991).
Nucleotide positions variable between clones are marked
by asterisks.
The numbering below each line is derived from Sargan e_t
al., 1991.
The numbering above each line shows the nucleotide




VA1 ATGGCAAGCA CAAAGAGCAA GCCAAGCAGA GCAACCTGGG CAGACATGGA
DA3 ATGGCAAGCA CAAAGAGCAA GCCAAGCAGA GCAACCTGGG CAGACATGGA
AX11 ATGGCAAGCA CAAAGAGCAA GCCAAGCAGA GCAACCTGGG CAGACATGGA
ADP1 ATGGCAAGCA CAAAGAGCAA GCCAAGCAGA GCAACCTGGG CAGACATGGA







VAl GCCACCGCAA AAGGAAAAAT GGGGTCAAGT AGTACAAGAG TTGGTGACAG
DA3 GCCACCGCAA AAGGAAAAAT GGGGTCAAGT AGTACAAGAG TTGGTGACAA
AX11 GCCACCGCAA AAGGAAAAAT GGGGTCAAGT AGTACAAGAG TTGGTGACAA
ADP1 GCCACCGCAA GAGGAAAAAT GGGGTCAAGT AGTACAAGAG TTGGTGACAA








VAl GACAACAAAA C GAAGAGAGG CAGGGCTTGG TAACAGGTAA GAGAAAGCCA
DA 3 GACAACAAAA CGAAGAGAGG CAGGGCTTGG TAACAGGTAA GAGAAAGCCA
AX11 GACAACAAAA CGAAGAGAGG CAGGGCTTGG TAACAGGTAA GAGAAAGCCA
ADP1 GACAACAAAA CGAAGAGAGG CAGGGCTTGG TAACAGGTAA GAGAAAGCCA









VAl TGGGTAAGTA TTGAGATCCT GGGAACAAAT CATGATCAGG AAAAAGAAAA
DA3 TGGGTAAGTA TTGAGATCCT GGGAACAAAG CATGATCAGG AAAAAGAAAA
AX11 TGGGTAAGTA TTGAGATCCT GGGAACAAAG CATGATCAGG AAAAAAGAAA
ADPl TGGGTAAGTA TTGAGATCCT GGGAACAAAT CATGATCAGG AAAAAGAAAA







VAl GGTAAATGTC TGGGAACCAT GTGAAAAATG GTTTGGCCAA TTAGTATGGG
DA3 GGTAAATGTC TGGGAACCAT GTGAAAAATG GTTTGGCCAA TTAGTATGGG
AX11 GGTAAATGTC TGGGAACCAT GTGAAAAATG TGTTGGCCAA TTATTATGGG
ADPl GGTAAATGTC TGGGAACCAT GTGAAAAATG GTTTGGCCAA TTAGTATGGG








VAl TAACATATGG ATACTACAGA CTGGTGTTAT GGGGATGTCT CATATGGGAA
DA3 TAACATATGG ATACTACAGA CTGGTGTTAT GGGGATGTCT CATATGGGAA
AX11 TAACACTATG GTACTACAGA CTGGTGTTAT GGGGATGTCT CATATGGGAA
ADPl TAACACTATG GATGCTACAG CTGGTGTTAT GGGGATGTCT CATATGGGAA
A46 TAACACTATG GATGCTACAG CTGGTGTTAT GGGGATGTCT CATATGGGAA
EV1 TAACATCTAG
6244 ****
GTACATCAGA CTGGTGTTAT GGGGATGTCT CATATGGGAA
349
VAl ATGCAAAAAG AAAATAAGGG TCAATGTCAA GCAGAAGAAG TAATAGCGTT
DA 3 ATGCAAAAAG AAAGTAAGGG TCAATGTCAA GCAGAAGAAG TAATAGCATT
AX11 ATGCAAAAAG AAAGTAAGGG TCAATGTCAA GCAGAAGAAG TAATAGCATT
ADPl ATGCAAAAAG AAAGTAAGGG TCAATGTCAA GCAGAAGAAG TAATAGCATT
A46 ATGCAAAAAG AAAGTAAGGG TCAATGTCAA GCAGAAGAAG TAATAGCATT
EV1 ATGCAAAAAG AAAGTAAGGG TCAATGTCAA GCAGAAGAAT TAATAGCGTT
6294 k k k
399
VAl GATAGATGAC CCTGGAGGAT TCCAGAGAGT AAGACAAGTA GAGACAGTGC
DA3 GATAGATGAC CCTGGAGGAT TCCAGAGAGT AAGACAAGTA GAGACAGTGC
AX11 AATAGATGAC CCTGGAGGAT TCCAGAGAGT AAGACAAGTA GAGACAGTGC
ADPl GATAGATGAC CCTGGAGGAT TCCAGAGAGT AAGACAAGTA GAGACAGTGC
A46 GATAGATGAC CCTGGAGGAT TCCAGAGAGT AAGACAAGTA GAGACAGTGC




VA1 CAGTGACCTG TGTAACAAGA AATTTTACTC AATGGGGATG TCAGCCAGAG
DA 3 CAGTGACCTG TGTAACAAGA AATCTTACTC AATGGGGATG TCAGCCAGAG
AX11 CAGTGACCTG TGTAACAAGA AATTTTACTC AATGGGGATG TCAGCCAGAG
ADP1 CAGTGACCTG TGTAACAAGA AATTTTACTC AATGGGGATG TCAGCCAGAG
A46 CAGTGACCTG TGTAACAAGA AATTTTACTC AATGGGGATG TCAGCCAGAG
EV1 CAGTGACCTG TGTAACAAGA AATCTTACTC AATGGGGATG TCAGCCAGAG
6394 k
499
VA1 GGAGCATATC CAGATCCTGA GATAGAATAT AGAAATATAT CAAAAGAAAT
DA3 GGAGCATATC CAGATCCTGA GATAGAATAT AGAAATATAT CAAAAGAAAT
AX 11 GGAGCATATC CAGATCCTGA GATAGAATAT AGAAATATAT CAAAAGAAAT
ADP1 GGAGCATATC CAGATCCTGA GATAGAATAT AGAAATATAT CAAAAGAAAT
A46 GGAGCATATC CAGATCCTGA GATAGAATAT AGAAATATAT CAAAAGAAAT
EV1 GGAGCATATC CAGATCCTGA GATAGAATAT AGAAATATAT CAAAAGAAAT
6444
549
VA1 TCTAGAACAA GTGGATGGAC GAGACTGGCC ATGGAATACA TATCACTGGC
DA3 TCTAGAACAA GTGGATGGAC GAGACAGGCC ATGGAATACA TATCACTGGC
AX11 TCTAGAACAA GTGTATGGAC GAGACTGGCC ATGGAATACA TATCACTGGC
ADP1 TCTAGAACAA GTGTATGGAC GAGACAGGCC ATGGAATACA TATCACTGGC
A46 TCTAGAACAA GTGTATGGAC GAGACAGGCC ATGGAATACA TATCACTGGC
EV1 TCTAGAACAA GTGTATGGAC GAGACAGGCC ATGGAATACA TATCACTGGC
6494 k *
599
VA1 CTTTATGGCA GCTGGAAAAC ATGAAAAGCT GGATGAAAGA AAATGAAAAA
DA 3 CTTTATGGCA GCTGGAAAAC ATGAAAAGCT GGATGAAAGA AAATGAAAAA
AX11 CTTTATGGCA GCTGGAAAAC ATGAAAAGCT GGATGAAAGA AAATGAAAAA
ADP1 CTTTATGGCA GCTGGAAAAC ATGAAAAGCT GGATGAAAGA AAATGAAAAA
A4 6 CTTTATGGCA GCTGGAAAAC ATGAAAAGCT GGATGAAAGA AAATGAAAAA
EV1 CTTTATGGCA GCTGGAAAAC ATGAAAAGCT GGATGAAAGA AAATGAAAAA
6544
649
VA1 GAGAATAAGG GCAGAACAAA TAAAACAAAG GAAGATATAG ATGATCTTTT
DA 3 GAGAATAAGG GCAGAACAAA TAAAACAAAG GAAGATATAG ATGATCTTTT
AX11 GAGAATAAGG GCAGAACAAA TAAAACAAAG GAAGATATAG ATGATCTTTT
ADP1 GAGAATAAGG GCAGAACAAA TAAAACAAAG GAAGATATAG ATGATCTTTT
A4 6 GAGAATAAGG GCAGAACAAA TAAAACAAAG GAAGATATAG ATGATCTTTT
EV1 GAAAATAAGG GCAGAACAAA TAAAACAAAG GAAGATATAG ATGATCTTTT
6594 k
699
VA1 AGCAGGGAGA ATAAGGGGAA GATTTTGTGT TCCATATCCC TATGCATTAT
DA3 AGCAGGGAGA ATAAGGGGAA GATTTTGTGT TCCATATCCC TATGCATTAT
AX11 AGCAGGGAGA ATAAGGGGAA GATTTTGTGT TCCATATCCC TATGCATTAT
ADP1 AGCAGGGAGA ATAAGGGGAA GATTTTGTGT TCCATATCCC TATGCATTAT
A46 AGCAGGGAGA ATAAGGGGAA GATTTTGTGT TCCATATCCC TATGCATTAT
EV1 AGCAGGGAGA ATAAGGGGAA GATTTTGTGT TCCATCTCCC TATGCATTAT
6644 *
749
VA1 TAAAATGTGA GGAATGGTGT TGGTACCCCA CTGACATTAA TGAGGAAACA
DA 3 TAAAATGTGA GGAATGGTGT TGGTACCCTA CTGACATTAA TGAGGAAACA
AX11 TAAAATGTGA GGAATGGTGT TGGTACCCCA CTGACATTAA TGAGGAAACA
ADP1 TAAAATGTGA GGAATGGTGT TGGTACCCCA CTGACATTAA TGAGGAAACA
A46 TAAAATGTGA GGAATGGTGT TGGTACCCCA CTGACATTAA TGAGGAAACA
EV1 TAAAATGTGA GGAATGGTGT TGGTACCCCA CTGACGTTAA TGAGGAAACA
6694 * k
799
VA1 GGACATGCAC AAAAGATAAA GATAAACTGC ACAAAAGCAA AAGCTGTCTC
DA3 GGACATGCAC AAAAGATAAA GATAAACTGC ACAAAAGCAA AAGCTGTCTC
AX11 GGACATGCAC AAAAGATAAA GATAAACTGC ACAAAAGCAA AAGCTGTCTC
ADP1 GGACATGCAC AAAAGATAAA GATAAACTGC ACAAAAGCAA AAGCTGTCTC
A46 GGACATGCAC AAAAGATAAA GATAAACTGC ACAAAAGCAA AAGCTGTCTC




VA1 TTGCACAGAA AAGATGCCCT TAGCAGGAGT GCAAAGGGTA TATTGGGAAA
DA 3 TTGCACAGAA AAGATGCCCT TAGCAGGAGT GCAAAGGGTA TATTGGGAAA
AX11 TTGCACAGAA AAGATGCCCT TAGCAGGAGT GCAAAGGGTA TATTGGGAAA
ADP1 TTGCACAGAA AAGATGCCCT TAGCAGGAGT GCAAAGGGTA TATTGGGAAA
A46 TTGCACAGAA AAGATGCCCT TAGCAGGAGT GCAAAGGGTA TATTGGGAAA
EV1 TTACACAGAA AAGATGCCCT TAGCAGGAGT GCAAAGGGTA TATTGGGAAA
6794 ★
899
VA1 AGGAAGATGA GGAGAGTATG AAATTCATGA ATATAGAAGC TTGTACTGAG
DA3 AGGAAGATGA GGAGAGTATG AAATTCATGA ATATAGAAGC TTGTACTGAG
AX11 AGGAAGATGA GGAGAGTATG AAATTCATGA ATATAGAAGC TTGTACTGAG
ADP1 AGGAAGATGA GGAGAGTATG AAATTCATGA ATATAGAAGC TTGTACTGAG
A46 AGGAAGATGA GGAGAGTATG AAATTCATGA ATATAGAAGC TTGTACTGAG
EV1 AGGAAGATGA GGAGACGATG AAATTCATGA ATATAGAAGC TTGCACTGAG
6844 * *
936
VA1 TCAAAGTTAA GATGTGCACA GGACGAGAAG AGTCCT
DA3 TCAAAGTTAA GATGTGCACA GGACGAGAAG AGTCCT
AX11 TCAAAGTTAA GATGTGCACA GGACGAGAAG AGTCCT
ADP1 TCAAAGTTAA GATGTGCACA GGACGAGAAG AGTCCT
A46 TCAAAGTTAA GATGTGCACA GGACGAGAAG AGTCCT
EV1 TCAAAGTTAA GATGTGCACA GGACGAGAAG AGTCCT
6894 6929
Figure 3.4b
The nucleotide sequence of the MVV strain EV1 gp!35 envB
variants
The nucleotide sequence of each envB variant is shown,
including the published EV1 sequence (EV1, from Sargan
et al., 1991).
Nucleotide positions variable between clones are marked
by asterisks.
The numbering below each line is derived from Sargan et
al., 1991.
The numbering above each line shows the nucleotide




VB6 GAGGAAACAG GACATGCACA AAAGATAAAG ATAAACTGCA CAAAAGCAAA
DB2 GAGGAAACAG GACATGCACA AAAGATAAAG ATAAACTGCA CAAAAGCAAA
BX11 GAGGAAACAG GACATGCACA AAAGATAAAG ATAAACTGCA CAAAAGCAAA
BDP1 GAGGAAACAG GACATGCACA AAAGATAAAG ATAAACTGCA CAAAAGCAAA
BX10 GAGGAAACAG GACATGCACA AAAGATAAAG ATAAACTGCA CAAAAGCAAA
EV1 GAGGAAACAG
6735
GACATGCACA AAAGATAAAG ATAAACTGCA CAAAAGCAAA
99
VB6 AGCTGTCTCT TGCACAGAAA AGATGCCCTT AGCAGGAGTA CAAAGGGTAT
DB2 AGCTGTCTCT TGCACAGAAA AGATGCCCTT AGCAGGAGTG CAAAGGGTAT
BX11 AGCTGTCTCT TGCACAGAAA AGATGCCTTT AGCAGGAGTG CAAAGGGTAT
BDP1 AGCTGTCTCT TGCACAGAAA AGATGCCCTT AGCAGGAGTG CAAAGGGTAT









VB6 ATTGGGAAAA GGAAGATGAG GAGAGTATGA AATTCATGAA CATAAAAGCT
DB2 ATTGGGAAGA GGAAGATGAG GAGAGTATGA AATTCATGAA CATAGAAGCT
BX11 ATTGGGAAAA GGAAGATGAG GAGAGTATGA AATTCATGAA TATAGAAGCT
BDP1 ATTGGGAAAA GGAAGATGAG GAGAGTATGA AATTCATGAA TATAGAAGCT








VB6 TGTAATGCGT CACAGTTGAG ATGTGAGAAA GAAGATAAGA GTCCTGGAGG
DB2 TGTACTGAGT CAAAGTTAAG ATGTGCACAG GACGAGAAGA GTCCTGGGGG
BX11 TGTACTGAGT CAAAGTTAAG ATGTGCACAG GACGAGAAGA GTCCTGGGGG
BDP1 TGTACTGAGT CAAAGTTAAG ATGTGCACAG GACGAGAAGA GTCCTGGGGG
BX10 TGTACTGAGT CAAAGTTAAG ATGTGCACAG GACGAGAAGA GTCCTGGGGG
EV1 TGCACTGAGT CAAAGTTAAG ATGTGCACAG GACGAGAAGA GTCCTGGGGG
6885 * * * * * * * * k * * *
249
VB6 ATGTGTGCAA GGGTATCCGA TCCCCAGTAG GACTGAAATA ATACCTGAAA
DB2 ATGTGTGCAG GGATATCCGA TCCCAGTAGG GACTGAAATA ATACCTGAAA
BX11 ATGTGTGCAG GGATATCCGA TCCCAGTAGG GACTGAAATA ATACCTGAAA
BXP1 ATGTGTGCAG GGATATCCGA TCCCAGTAGG GACTGAAATA ATACCTGAAA







VB6 GTATGAAGCA TTTGAGAGGA AAGAAAAGCC CATATGGAGG AATAAAAGAT
DB2 GTATGAAGCA TTTGAGAGGA AAGAAAAGCC CATATGGAGG AATAAAAGAT
BX11 GTATGAAGCA TTTGAGAGGA AAGAAAAGCC CATATGGAGG AATAAAAGAT
BDP1 GTATGAAGCA TTTGAGAGGA AAGAAAAGCC CATATGGAGG AATAAAAGAT
BX10 GTATGAAGCA TTTGAGAGGA AAGAAAAGCC CATATGGAGG AATAAAAGAT
EV1 GTATGAAGCA
6985
TTTGAGAGGA AAGAAAAGCC CATATGGAGG AATAAAAGAT
349
VB6 AAGAATGGAG AATTAAAACT GCCTCTTACA GTAAGAGTCT GGGTAAGAAT
DB2 AAGAATGGAG AATTAAAACT GCCTCTTACA GTAAGAGTCT GGGTAAGAAT
BX11 AAGAATGGAG AATTAAAACT GCCTCTTACA GTAAGAGTCT GGGTAAGAAT
BDP1 AAGAATGGAG AATTAAAACT GCCTCTTACA GTAAGAGTCT GGGTAAGAAT
BX10 AAGAATGGAG AATTAAAACT GCCTCTTACA GTAAGAGTCT GGGTAAGAAT
EV1 AAGAATGGAG
7035
AATTAAAACT GCCTCTTACA GTAAGAGTCT GGGTAAGAAT
399
VB6 GGCGAATTTA TCAGGTTGGG TGAATGGAAC TCCCCCGTAT TGGAGTGCAA
DB2 GGCGAATTTA TCAGGTTGGG TGAATGGAAC TCCCCCGTAT TGGAGTGCAA
BX11 GGCGAATTTA TCAGGTTGGG TGAATGGAAC TCCCCCGTAT TGGAGTGCAA
BDP1 GGCGAATTTA TCAGGTTGGG TGAATGGAAC TCCCCCGTAT TGGAGTGCAA
BX10 GGCGAATTTA TCAGGTTGGG TGAATGGAAC TCCCCCGTAT TGGAGTGCAA




VB6 GAATGAATGG AAGCACAGGA ATAAATGGGA CCAGATGGTA TGGAATAGGA
DB2 GAATGAATGG AAGCACAGGA ATAAATGGGA CCAGATGGTA TGGAATAGGA
BX11 GAATGAATGG AAGCACAGGA ATAAATGGGA CCAGATGGTA TGGAATAGGA
BDP1 GAATGAATGG AAGCACAGGA ATAAATGGGA CCAGATGGTA TGGAATAGGA
BX10 GAATGAATGG AAGCACAGGA ATAAATGGGA CCAGATGGTA TGGAATAGGA
EV1 GAATGAATGG AAGCACAGGA ATAAATGGGA CCAGATGGTA TGGAATAGGA
7135
499
VB6 TCACTGCACC ATTTAGGGTT CAACATTAGT AGTAACCCTG AGCAGGGGAT
DB2 TCACTGCACC ATTTAGGGTT CAACATTAGT AGTAACCCTG AGCAGGGGAT
BX11 TCACTGCACC ATTTAGGGTT CAACATTAGT AGTAACCCTG AGCAGGGGAT
BDP1 TCACTGCACC ATTTAGGGTT CAACATTAGT AGTAACCCTG AGCAGGGGAT
BX10 TCACTGCACC ATTTAGGGTT CAACATTAGT AGTAACCCTG AGCAGGGGAT
EV1 TCACTGCACC ATTTAGGGTT CAACATTAGT AGTAACCCTG AGCAGGGGAT
7185
549
VB6 TTGCAACTTC ACAAAAGAAG TTTTGGTAGG AGGAGAAAAA TTCGAGTATC
DB2 TTGCAACTTC ACAAAAGAAG TTTTGGTAGG AGGAGAAAAA TTCGAGTATC
BX11 TTGCAACTTC ACAAAAGAAG TTTTGGTAGG AGGAGAAAAA TTCGAGTATC
BDP1 TTGCAACTTC ACAAAAGAAG TTTTGGTAGG AGGAGAAAAA TTCGAGTATC
BXIO TTGCAACTTC ACAAAAGAAG TTTTGGTAGG AGGAGAAAAA TTCGAGTATC
EV1 TTGCAACTTC ACAAAAGAAG TTTTGGTAGG AGGAGAAAAA TTCGAGTATC
7235
599
VB6 AGTATACACC CTCATGGAAT TGCTCGAAAA ATTGGACAGG ACATCCAGTA
DB2 AGTATACACC CTCATGGAAT TGCTCGAAAA ATTGGACAGG ACATCCAGTA
BX11 AGTATACACC CTCATGGAAT TGCTCGAAAA ATTGGACAGG ACATCCAGTA
BDP1 AGTATACACC CTCATGGAAT TGCTCGAAAA ATTGGACAGG ACATCCAGTA
BXIO AGTATACACC CTCATGGAAT TGCTCGAAAA ATTGGACAGG ACATCCAGTA
EV1 AGTATACACC CTCATGGAAT TGCTCGAAAA ATTGGACAGG ACATCCAGTA
7285
649
VB6 TGGCATGTAT TTAGATACCT AGATATGACA GAACATATGA CAAGCTATTG
DB2 TGGCATGTAT TTAGATACCT AGATATGACA GAACATATGA CAAGCTATTG
BX11 TGGCATGTAT TTAGATACCT AGATATGACA GAACATATGA CAAGCTATTG
BDP1 TGGCATGTAT TTAGACACCT AGATATGACA GAACATATGA CAAGCTATTG
BXIO TGGCATGTAT TTAGATACCT AGATATGACA GAACATATGA CAAGCTATTG
EV1 TGGCATGTAT TTAGATACCT AGATATGACA GAACATATGA CAAGCTATTG
7335 *
699
VB6 TGTACAGAGG CCCTTAAGAC ATAATATAAC AGTGGGAAAT GGCACCATAA
DB2 TGTACAGAGG CCCTTAAGAC ATAATATAAC AGTGGGAAAT GGCACCATAA
BX11 TGTACAGAGG CCCTTAAGAC ATAATATAAC AGTGGGAAAT GGCACCATAA
BDP1 TGTACAGAGG TCCTTAAGAC ATAATATAAC AGTGGGAAAT GGCACCATAA
BXIO TGTACAGAGG TCCTTAAGAC ATAATATAAC AGTGGGAAAT GGCACCATAA
EV1 TGTACAGAGG CCCTTAAGAC ATAATATAAC AGTGGGAAAT GGCACCATAA
7385 *
749
VB6 CAGGAAATTG TAGCACAACA AATTGGGATG GATGTAATTG CTCAAGGTCA
DB2 CAGGAAATTG TAGCACAACA AATTGGGATG GATGTAATTG CTCAAGGTCA
BX11 CAGGAAATTG TAGCACAACA AATTGGGATG GATGTAATTG CTCAAGGTCA
BDP1 CAGGAAATTG TAGCACAACA AATTGGGATG GATGTAATTG CTCAAGGTCA
BXIO CAGGAAATTG TAGCACAACA AATTGGGATG GATGTAATTG CTCAAGGTCA
EV1 CAGGAAATTG TAGCACAACA AATTGGGATG GATGTAATTG CTCAAGGTCA
7435
799
VB6 GGAAATCATT TATATAACAG CACCACAGGA GGATTACTAG TAATTATATG
DB2 GGAAATCATT TATATAACAG CACCACAGGA GGATTACTAG TAATTATATG
BX11 GGAAATCATT TATATAACAG CACCACAGGA GGATTACTAG TAATTATATG
BDP1 GGAAATCATT TATATAACAG CACCACAGGA GGATTACTAG TAATTATATG
BXIO GGAAATCATT TATATAACAG CACCACAGGA GGATTACTAG TAATTATATG





VB6 TAGACAAAGC AGAACAATTA GAG GAAT AATGGGAACT AACACAAATT
DB2 TAGACAAAGC AGAACAATTA GAG GAAT AATGGGAACT AACACAAATT
BX11 TAGACAAAGC AGAACAATTA GAG AAAT AATGGGAACT AACACAAATT
BDP1 TAGACAAAGC AGAACAATTA GAG GAAT AATGGGAACT AACACAAATT
BX10 TAGACAAAGC AGAACAATTA GAG GAAT AATGGGAACT AACACAAATT
EV1 TAGACAAAGC AGAACAATTA CAGCAATAAT AATGGGAACT AACACAAATT
7535 ★ * * * *
899
VB6 GGACCACCAT GTGGGAAATA TATAAGAATT GCTCAAGCTG TGAGAACAGC
DB2 GGACCACCAT GTGGGAAATA TATAAGAATT GCTCAAGCTG TGAGAACAGC
BX11 GGACCACCAT GTGGGAAATA TATAAGAATT GCTCAAGCTG TGAGAACAGC
BDP1 GGACCACCAT GTGGGAAATA TATAAGAATT GCTCAAGCTG TGAGAACAGC
BX11 GGACCACCAT GTGGGAAATA TATAAGAATT GCTCAAGCTG TGAGAACAGC











The nucleotide sequence of the MVV strain EV1 gp!35 envC
variants
The nucleotide sequence of each envC variant is shown,
including the published EV1 sequence (EV1, from Sargan
et aj.. , 1991) .
Nucleotide positions variable between clones are marked
by asterisks.
The numbering below each line is derived from Sargan e_t
al., 1991.
The numbering above each line shows the nucleotide




VC1 GGATGTAATT GCTCAAGGTC AGGAAATCAT TTATATAACA GCACCACAGG
DC1 GGATGTAATT GCTCAAGGTC AGGAAATCAT TTATATAACA GCACCACAGG
CX7 GGATGTAATT GCTCAAGGTC AGGAAATCAT TTATATAACA GCACCACAGG
CDP1 GGATGTAATT GCTCAAGGTC AGGAAATCAT TTATATAACA GCACCACAGG
C45 GGATGTAATT GCTCAAGGTC AGGAAATCAT TTATATAACA GCACCACAGG
EV1 GGATGTAATT
7464
GCTCAAGGTC AGGAAATCAT TTATATAACA GCACCACAGG
99
VC1 AGGATTACTA GTAATTATAT GTAGACAAAG CAGAACAATT AGGG GAA
DC1 AGGATTACTA GTAATTATAT GTAGACAAAG CAGAACAATT AGAG GAA
CX7 AGGATTACTA GTAATTATAT GCAGACAAAG CAGAACAATT AGAG GAA
CDP1 AGGATTACTA GTAATTATAT GTAGACAAAG CAGAACAATT AGAG GAA
C45 AGGATTACTA GTAATTATAT GTAGACAAAG CAGAACAATT AGAG GAA
EV1 AGGATTACTA
7514
GTAATTATAT GTAGACAAAG CAGAACAATT ACAGCAATAA
★ ★ * ★ * *
149
VC1 TAATGGGAAC TAACACAAAT TGGACCACCA TGTGGGAAAT ATATAAGAAT
DC1 TAATGGGAAC TAACACAAAT TGGACCACCA TGTGGGAAAT ATATAAGAAT
CX7 TAATGGGAAC TAACACAAAT TGGACCACCA TGTGGGAAAT ATATAAGAAT
CDP1 TAATGGGAAC TAACACAAAT TGGACCACCA TGTGGGAAAT ATATAAGAAT
C45 TAATGGGAAC TAACACAAAT TGGACCACCA TGTGGGAAAT ATATAAGAAT
EV1 TAATGGGAAC
7564
TAACACAAAT TGGACCACCA TGTGGGAAAT ATATAAGAAT
199
VC1 TGCTCAAGCT GTGAGAACAG CACGTTAGAC AGAATAGGGA ATGGTGCGTT
DC1 TGCTCAAGCT GTGAGAACAG CACGTTAGAC AGAATAGGGA ATGGTGCGTT
CX7 TGCTCAAGCT GTGAGAACAG CACGTTAGAC AGAATAGGGA ATGGTGCGTT
CDP1 TGCTCAAGCT GTGAGAACAG CACGTTAGAC AGAATAGGGA ATGGTGCGTT
C45 TGCTCAAGCT GTGAGAACAG CACGTTAGAC AGAATAGGGA ATGGTGCGTT
EV1 TGCTCAAGCT
7614
GTGAGAACAG CACGTTAGAC AGAATAGGGA ATGGCACGTT
* *
249
VC1 AGGAACTGTA AAAAACGTCA ACTGTAGGTT AC CACACAAA AATGAAAGCC
DC1 AGGAACTGTA CAAAACGTCA ACTGTAGGTT AC CACACAAA AATGAAAGCC
CX7 AGGAACTGTA CAAAACGTCA ACTGTAGGTT ACCACACAAA AATGAAAGCC
CDP1 AGGAACTGTA AAAAACGTCA ACTGTAGGTT ACCACACAAA AATGAAAGCC
C45 AGGAACTGTA AAAAACGTCA ACTGTAGGTT ACCACACAAA AATGAAAGCC
EV1 AGGAACTATA CAGAACATCA ACTGTAGCCT ACCTCACAGA AATGAAACAA
7664 * * * * * * * ★ k k k
299
VC1 GGAAGTGGAC ATGTCAGGCT CG CA GGGGAAGAGA CAAAAGAGAT
DC1 GGAAGTGGAC ATGTCAGGCT CG CA GGGGAAGAGA CAGGACAGAT
CX7 GGAAGTGGAC ATGTCAGGCT CG CA GGGGAAGAGA CAGGACAGAT
CDP1 GGAAGTGGAC ATGTCAGGCT CG CA GGGGAAGAGA CAGGACAGAT
C45 GGAAGTGGAC ATGTCAGGCT CG CA GGGGAAGAGA CAGGACAGAT
EV1 ATACTTGGAC CTGTGCAGCA AGAGCAGCAA GTCGAGGAAA CAAAAGAGAT
7714 * * * * * * * * * * ★ * * * * * -k
349
VC1 TCCTTATACA TAGCAGGTAG AGACTTCTGG GGCAGAGTAA AAGCACATTA
DC1 TCCTTATACA TAGCAGGTAG AGACTTCTGG GGCAGAGTAA AAGCACATTA
CX7 TCCTTATACA TAGCAGGTAG AGACTTCTGG GGCAGAGTAA AAGCACATTA
CDP1 TCCTTATACA TAGCAGGTAG AGACTTCTGG GGCAGAGTAA AAGCACATTA
C45 TCCTTATACA TAGCAGGTAG AGACTTCTGG GGCAGAGTAA AAGCACATTA
EV1 TCCTTATACA
7764
TAGCAGGTAG AGACTTCTGG GGCAGAGTAA AAGCACATTA
399
VC1 TAGCTGTGAG AGTAACTTAG GTGGATTAGA TGGAATGATG CATCAACAGA
DC1 TAGCTGTGAG AGTAACTTAG GTGGATTAGA TGGAATGATG CATCAACAGA
CX7 TAGCTGTGAG AGTAACTTAG GTGGATTGGA TGGAATGATG CATCAACAGA
CDP1 TAGCTGTGAG AGTAACTTAG GTGGATTAGA TGGAATGATG CATCAACAGA
C45 TAGCTGTGAG AGTAACTTAG GTGGATTAGA TGGAATGATG CATCAACAGA




VC1 TATTGCTGCA AAAATATCAA ATAATAAGAG TAAGAGCTTA CACATATGGT
DC1 TATTGCTGCA AAAATATCAA ATAATAAGAG TAAGAGCTTA CACATATGGT
CX7 TATTGCTGCA AAAATATCAA ATAATAAGAG TAAGAGCTTA CACATATGGT
CDP1 TATTGCTGCA AAAATATCAA ATAATAAGAG TAAGAGCTTA CACATATGGT
C45 TATTGCTGCA AAAATATCAA ATAATAAGAG TAAGAGCTTA CACATATGGT
EV1 TATTGCTGCA AAAATATCAA ATAATAAGAG TAAGAGCTTA CACATATGGA
7864 *
499
VC1 GTGGTGGATA TGCCTCAATC CTATCTGGAG AAAAATAGAA GAAATGCTTT
DC1 GTGGTGGATA TGCCTCAATC CTATCTGGAG AAAAATAGAA GAAATGCTTT
CX7 GTGGTGGATA TGCCTCAATC CTATCTGGAG AAAAATAGAA GAAATGCTTT
CDP1 GTGGTGGATA TGCCTCAATC CTATCTGGAG AAAAATAGAA GAAATGCTTT
C45 GTGGTGGATA TGCCTCAATC CTATCTGGAG AAAAATAGAA GAAATGCTTT
EV1 GAGGTGGATA TGCCTCAATC CTATCTGGAG AAAAATAGAA GAAATGCTTT
7914 *
537
VC1 TAAGAAAGAA AGAAAGAAGA GGGGCATAGG GTTGGTG
DC1 TAAGAAAGAA AGAAAGAAGA GGGGCATAGG GTTGGTG
CX7 TAGGAAAGAA AGAAAGAAGA GGGGCATAGG GTTGGTG
CDP1 TAAGAAAGAA AGAAAGAAGA GGGGCATAGG GTTGGTG
C45 TAAGAAAGAA AGAAAGAAGA GGGGCATAGG GTTGGTG
EV1 TAAGAAAGAA AGAAAGAAGA GGGGCATAGG GTTGGTG
7964 8000
Figure 3.5a
The predicted amino acid sequence of the MVV strain EV1
gp!35 envA variants
The predicted amino acid sequence of each envA variant
is shown, including the published EV1 sequence (EV1,
from Sargan et al., 1991).
Amino acids variable between clones are marked by
as terisks.
Potential N-linked glycosylation sites are underlined.
The numbering below each line is derived from Sargan e_t
al., 1991.
The numbering above each line shows the amino acid




VA1 MASTKSKPSR ATWADMEPPQ KEKWGQWQE LVTGQQNEER QGLVTGKRKP
DA3 MASTKSKPSR ATWADMEPPQ KEKWGQWQE LVTRQQNEER QGLVTGKRKP
AX11 MASTKSKPSR ATWADMEPPQ KEKWGQWQE LVTRQQNEER QGLVTGKRKP
ADP1 MASTKSKPSR ATWADMEPPQ EEKWGQWQE LVTRQQNEER QGLVTGKRKP
A46 MASTKSKPSR ATWADMEPPQ QEKWGQWQE LVTRQQNEER QGLVTGKRKP
EV1 MASTKSKPSR VTWTDMEPPQ KEKWGQWQE LVTRQQNEER QGLVTGKRKP
1 * *
99
VA1 WVSIEILGTN HDQEKEKVNV WEPCEKWFGQ LVWVTYGYYR LVLWGCLIWE
DA3 WVSIEILGTK HDQEKEKVNV WEPCEKWFGQ LVWVTYGYYR LVLWGCLIWE
AX11 WVSIEILGTK HDQEKRKVNV WEPCEKCVGQ LLWVTLWYYR LVLWGCLIWE
ADP1 WVSIEILGTN HDQEKEKVNV WEPCEKWFGQ LVWVTLWMLQ LVLWGCLIWE
A46 WVSIEILGTK HDQEKEKVNV WEPCEKWFGQ LVWVTLWMLQ LVLWGCLIWE
EV1 WVSIEILGTK HDQEKEKVNV WEPCEKWFGQ LVWVTSRYIR LVLWGCLIWE
* ******
149
VA1 MQKENKGQCQ AEEVIALIDD PGGFQRVRQV ETVPVTCVTR HFTQWGCQPE
DA3 MQKESKGQCQ AEEVIALIDD PGGFQRVRQV ETVPVTCVTR ULTQWGCQPE
AX11 MQKESKGQCQ AEEVIALIDD PGGFQRVRQV ETVPVTCVTR MFTQWGCQPE
ADP1 MQKESKGQCQ AEEVIALIDD PGGFQRVRQV ETVPVTCVTR MFTQWGCQPE
A46 MQKESKGQCQ AEEVIALIDD PGGFQRVRQV ETVPVTCVTR MFTQWGCQPE
EV1 MQKESKGQCQ AEELIALIDD PGGFQRVRQV ETVPVTCVTR ULTQWGCQPE
101 * *
199
VA1 GAYPDPEIEY RMISKEILEQ VDGRDWPWNT YHWPLWQLEN MKSWMKENEK
DA3 GAYPDPEIEY RMISKEILEQ VDGRDRPWNT YHWPLWQLEN MKSWMKENEK
AX11 GAYPDPEIEY RMISKEILEQ VYGRDWPWNT YHWPLWQLEN MKSWMKENEK
ADP1 GAYPDPEIEY RMISKEILEQ VYGRDRPWNT YHWPLWQLEN MKSWMKENEK
A46 GAYPDPEIEY RNISKEILEQ VYGRDRPWNT YHWPLWQLEN MKSWMKENEK
EV1 GAYPDPEIEY RNISKEILEQ VYGRDRPWNT YHWPLWQLEN MKSWMKENEK
151 * *
249
VA1 ENKGRTMKTK EDIDDLLAGR IRGRFCVPYP YALLKCEEWC WYPTDINEET
DA3 ENKGRTMKTK EDIDDLLAGR IRGRFCVPYP YALLKCEEWC WYPTDINEET
AX11 ENKGRTMKTK EDIDDLLAGR IRGRFCVPYP YALLKCEEWC WYPTDINEET
ADP1 ENKGRTMKTK EDIDDLLAGR IRGRFCVPYP YALLKCEEWC WYPTDINEET
A46 ENKGRTMKTK EDIDDLLAGR IRGRFCVPYP YALLKCEEWC WYPTDINEET
EV1 ENKGRTMKTK EDIDDLLAGR IRGRFCVPSP YALLKCEEWC WYPTDVNEET
201 * *
299
VA1 GHAQKIKIMC TKAKAVSCTE KMPLAGVQRV YWEKEDEESM KFMNIEACTE
DA3 GHAQKIKIMC TKAKAVSCTE KMPLAGVQRV YWEKEDEESM KFMNIEACTE
AX11 GHAQKIKIMC TKAKAVSCTE KMPLAGVQRV YWEKEDEESM KFMNIEACTE
ADP1 GHAQKIKIMC TKAKAVSCTE KMPLAGVQRV YWEKEDEESM KFMNIEACTE
A4 6 GHAQKIKIMC TKAKAVSCTE KMPLAGVQRV YWEKEDEESM KFMNIEACTE










The predicted amino acid sequence of the MVV strain EV1
gp!35 envB variants
The predicted amino acid sequence of each envB variant
is shown, including the published EV1 sequence (EV1,
from Sargan et^ al. , 1991).
Amino acids variable between clones are marked by
asterisks.
Potential N-linked glycosylation sites are underlined.
The numbering below each line is derived from Sargan et^
al., 1991.
The numbering above each line shows the amino acid




VB6 EETGHAQKIK IMCTKAKAVS CTEKMPLAGV QRVYWEKEDE ESMKFMNIKA
DB2 EETGHAQKIK IMCTKAKAVS CTEKMPLAGV QRVYWEEEDE ESMKFMNIEA
BX11 EETGHAQKIK IMCTKAKAVS CTEKMPLAGV QRVYWEKEDE ESMKFMNIEA
BDP1 EETGHAQKIK IMCTKAKAVS CTEKMPLAGV QRVYWEKEDE ESMKFMNIEA
BX10 EETGHAQKIK IMCTKAKAVS CTEKMPLAGV QRVYWEKEDE ESMKFMNIEA
EV1 EETGHAQKIK IMCTKAKAVS YTEKMPLAGV QRVYWEKEDE ETMKFMNIEA
248 * k
99
VB6 CMASQLRCEK EDKSPGGCVQ GYPIPSRTEI IPESMKHLRG KKSPYGGIKD
DB2 CTESKLRCAQ DEKSPGGCVQ GYPIPVGTEI IPESMKHLRG KKSPYGGIKD
BX11 CTESKLRCAQ DEKSPGGCVQ GYPIPVGTEI IPESMKHLRG KKSPYGGIKD
BDP1 CTESKLRCAQ DEKSPGGCVQ GYPIPVGTEI IPESMKHLRG KKSPYGGIKD
BXIO CTESKLRCAQ DEKSPGGCVQ GYPIPVGTEI IPESMKHLRG KKSPYGGIKD
EV1 CTESKLRCAQ DEKSPGGCVQ GYPIPSRTEI IPESMKHLRG KKSPYGGIKD
298 k k k * * * * k k
149
VB6 KNGELKLPLT VRVWVRMAML SGWVMGTPPY WSARMMGSTG IMGTRWYGIG
DB2 KNGELKLPLT VRVWVRMAML SGWVMGTPPY WSARMMGSTG IMGTRWYGIG
BX11 KNGELKLPLT VRVWVRMAML SGWVMGTPPY WSARMMGSTG IMGTRWYGIG
BDP1 KNGELKLPLT VRVWVRMAML SGWVMGTPPY WSARMMGSTG IMGTRWYGIG
BXIO KNGELKLPLT VRVWVRMAML SGWVMGTPPY WSARMMGSTG IMGTRWYGIG
EV1 KNGELKLPLT
348
VRVWVRMAML SGWVMGTPPY WSARMMGSTG IMGTRWYGIG
199
VB6 SLHHLGFMIS SNPEQGICMF TKEVLVGGEK FEYQYTPSWM CSKMWTGHPV
DB2 SLHHLGFMIS SNPEQGICMF TKEVLVGGEK FEYQYTPSWM CSKMWTGHPV
BX11 SLHHLGFMIS SNPEQGICMF TKEVLVGGEK FEYQYTPSWM CSKMWTGHPV
BDP1 SLHHLGFMIS SNPEQGICMF TKEVLVGGEK FEYQYTPSWM CSKMWTGHPV
BXIO SLHHLGFMIS SNPEQGICMF TKEVLVGGEK FEYQYTPSWM CSKMWTGHPV
EV1 SLHHLGFMIS
398
SNPEQGICMF TKEVLVGGEK FEYQYTPSWM CSKMWTGHPV
249
VB6 WHVFRYLDMT EHMTSYCVQR PLRHMITVGM GTITGMCSTT NWDGCMCSRS
DB2 WHVFRYLDMT EHMTSYCVQR PLRHMITVGM GTITGMCSTT NWDGCMCSRS
BX11 WHVFRYLDMT EHMTSYCVQR PLRHMITVGM GTITGMCSTT NWDGCMCSRS
BDP1 WHVFRHLDMT EHMTSYCVQR SLRHMITVGM GTITGMCSTT NWDGCMCSRS
BXIO WHVFRYLDMT EHMTSYCVQR SLRHMITVGM GTITGMCSTT NWDGCMCSRS
EV1 WHVFRYLDMT





VB6 GNHLYMSTTG GLLVIICRQS RTIRG IMGT NTMWTTMWEI YKMCSSCEMS
DB2 GNHLYMSTTG GLLVIICRQS RTIRG IMGT NTMWTTMWEI YKMCSSCEMS
BX11 GNHLYMSTTG GLLVIICRQS RTIRE IMGT NTMWTTMWEI YKMCSSCEMS
BDP1 GNHLYMSTTG GLLVIICRQS RTIRG IMGT NTMWTTMWEI YKMCSSCEMS
BXIO GNHLYMSTTG GLLVIICRQS RTIRG IMGT NTMWTTMWEI YKMCSSCEMS
EV1 GNHLYMSTTG GLLVIICRQS RTITAIIMGT NTMWTTMWEI YKMCSSCEMS









The predicted amino acid sequence of the MVV strain EV1
gp!35 envC variants
The predicted amino acid sequence of each envC variant
is shown, including the published EV1 sequence (EV1,
from Sargan e_t ad.., 1991).
Amino acids variable between clones are marked by
asterisks.
Potential N-linked glycosylation sites are underlined.
The numbering below each line is derived from Sargan e_t
al., 1991.
The numbering above each line shows the amino acid




VC1 GCNCSRSGNH LYNSTTGGLL VIICRQSRTI RG IMGTNTH WTTMWEIYKH
DC1 GCNCSRSGNH LYNSTTGGLL VIICRQSRTI RG IMGTNTH WTTMWEIYKH
CX7 GCNCSRSGNH LYNSTTGGLL VIICRQSRTI RG IMGTNTH WTTMWEIYKii
CDP1 GCNCSRSGNH LYNSTTGGLL VIICRQSRTI RG IMGTNTE WTTMWEIYKH
C45 GCNCSRSGNH LYNSTTGGLL VIICRQSRTI RG IMGTNTU WTTMWEIYK&
EV1 GCNCSRSGNH
491




VC1 CSSCENSTLD RIGNGALGTV KNVNCRLPHK HESRKWTCQA RRGR DKRD
DC1 CSSCEMSTLD RIGNGALGTV QNVNCRLPHK NESRKWTCQA RRGR DRTD
CX7 CSSCEHSTLD RIGNGALGTV QNVNCRLPHK HESRKWTCQA RRGR DRTD
CDP1 CSSCEESTLD RIGNGALGTV KNVNCRLPHK JSESRKWTCQA RRGR DRTD
C45 CSSCE&STLD RIGNGALGTV KNVNCRLPHK HESRKWTCQA RRGR DRTD
EV1 CSSCEESTLD RIGHGTLGTI QNINCSLPHR iiETNTWTCAA RAASRGNKRD
541 * * * * * * * * * * ********
149
VC1 SLYIAGRDFW GRVKAHYSCE SNLGGLDGMM HQQILLQKYQ IIRVRAYTYG
DC1 SLYIAGRDFW GRVKAHYSCE SNLGGLDGMM HQQILLQKYQ IIRVRAYTYG
CX7 SLYIAGRDFW GRVKAHYSCE SNLGGLDGMM HQQILLQKYQ IIRVRAYTYG
CDP1 SLYIAGRDFW GRVKAHYSCE SNLGGLDGMM HQQILLQKYQ IIRVRAYTYG







VC1 VVDMPQSYLE KNRRNAFKKE RKKRGIGLV
DC1 VVDMPQSYLE KNRRNAFKKE RKKRGIGLV
CX7 VVDMPQSYLE KNRRNAFRKE RKKRGIGLV
CDP1 VVDMPQSYLE KNRRNAFKKE RKKRGIGLV
C45 VVDMPQSYLE KNRRNAFKKE RKKRGIGLV
EV1 EVDMPQSYLE KNRRNAFKKE RKKRGIGLV
641 * 669
within a particular group ie envA, envB and envC was
calculated using the Bestfit local homology algorithm
(Smith & Waterman, 1981). The percentage identity which
is calculated excludes variations due to deletions. The
results of this calculation are shown in figure 3.6
(identity at the nucleotide level) and figure 3.7
(identity at the amino acid level). The nucleotide data
in figure 3.6 demonstrates that the envA fragments all
differ more from the published EV1 sequence than from each
other. A similar but more pronounced pattern is apparent
for envC. For envB however the fragments are all more
similar to each other and to EV1 than they are to VB6.
Similar relationships can be observed at the amino acid
level (figure 3.7).
Predicted secondary motifs, including hydrophilicity,
beta sheets and N-linked glycosylation sites are shown in
figure 3.8a-c for the first clone in each group to be
generated and analysed, that is A46, BX10 and C45. There
was no major difference in the plots for the variants
(data not shown). These were prepared using the
Peptidestructure program on GCG version 7.0.
3.4 Discussion
In this chapter 15 clones were generated from PCR
amplification of viral Hirt DNA and sequenced to obtain
information on the general variability of the gpl35 region
of MVV strain EV1.
In the published sequence of strain EV1 (Sargan e_t
al., 1991) almost the entire gpl35 region was cloned and
sequenced following the same basic protocol as in this
chapter; the env gene regions were obtained by PCR from
viral DNA. Although there are drawbacks to this method it
is appropriate that the same strategy was used in these
comparisons.
In order to interpret the data it is necessary to
obtain an estimate of the fidelity of the initial PCR
- 98 -
Figure 3.6
Sequence identity at the nucleotide level between the
MVV strain EV1 gp!35 variants
The percentage identity for each sequence pair was
calculated by the Bestfit local homology algorithm of
Smith & Waterman (1981).
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Sequence identity at the amino acid level between the
MVV strain EV1 gp!35 variants
The percentage identity for each predicted amino acid
sequence pair was calculated by the Bestfit local
homology algorithm of Smith & Waterman (1981).
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Predicted structural motifs for EnvA
The predicted structural motifs for envA variant A46
were obtained using the Peptidestructure program of GCG
version 7.0.
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Predicted structural motifs for EnvB
The predicted structural motifs for envB variant BX10
were obtained using the Peptidestructure program of GCG
version 7.0.
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Predicted structural motifs for ErivC
The predicted structural motifs for envC variant C45




































step. DNA from the clones A46, BX10 and C45 was used as
template for the PCR under identical conditions to those
used for generating the initial clones. By comparing the
sequence of the "template" fragment, and the fragment
cloned after the subsequent PCR it is possible to estimate
the fidelity of the PCR.
As shown in figure 3.4a-c A46 and ADPl differ at 2
out of 936 bases. BX10 and BDP1 differ at 1 out of 917
bases and C45 and CDP1 are identical, over 537 bases. In
total therefore the error rate of the PCR in these
experiments is 3/2390, which is equivalent to
approximately 1 in 800, or 0.126%. Any variations between
cloned fragments of 0.126% or less may therefore simply
reflect inaccuracies in the initial PCR step. This error
rate is higher than that previously reported for the PCR
of 1 in 1500 (Perrin & Gilliland, 1990) to approximately 1
in 3000 (Meyerhans e_t _al. , 1989) and may be a consequence
of the template structure or the precise PCR conditions
used. The disparity demonstrates the importance of
determining the error rate for the system in use, rather
than relying upon published data from other models.
In the following discussion of the differences
observed for the fragments obtained following
amplification of various viral DNA templates, the data for
the "duplicate" clones , that is ADPl, BDPl and CDPl will
generally be excluded as these fragments do not reflect
variations in the viral templates.
There are no single base deletions or insertions in
any of the fragments and a consistent reading frame is
maintained throughout. None of the fragments sequenced
contain premature stop codons.
There are no deletions or insertions in any of the
envA fragments. A 3 base pair deletion is found in every
envB fragment, when compared with the EV1 sequence (EV1
positions 7558-7560). This occurs in the region of envB
which overlaps the region contained in the envC fragments,
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and the same deletion is also found in all the envC
fragments sequenced. This deletion results in the loss of
an isoleucine residue (EVl position 523) in the encoded
protein.
A six base pair deletion is present in all the envC
fragments when compared with the EVl sequence (EVl
positions 7736-7741). This deletion results in the loss
of an arginine residue and a glycine residue in the
encoded protein (EVl positions 585 and 586). In HIV small
deletions are commonly observed between the env genes of
different isolates, but are uncommon in the other
structural genes (Starcich e_t al^. , 1986)
The codons for the 24 cysteine residues in the gpl35
region of the env gene of EVl have been retained in every
fragment sequenced. In every envA fragment an additional
cysteine residue is encoded at EVl amino acid position
268. This lies within the region which overlaps with envB
and the same mutation is found in all the envB fragments.
The 4 potential N-linked glycosylation sites in the
envA region of EVl have been maintained in all the envA
fragments sequenced. There are 17 potential N-linked
sites in envB of EVl, and these have been conserved in all
the envB fragments sequenced. Fragment VB6 contains an
additional site at residue 299 of the EVl sequence.
There are 8 potential N-linked glycosylation sites in
the envC region of EVl. 2 of these have been lost in all
the envC fragments sequenced (residues 554 and 564 of the
EVl sequence). At EVl residue 573 a threonine to serine
amino acid change results in the maintenance of a
potential glycosylation site, despite the change in amino
acid sequence.
This data therefore suggests that in the env
fragments analysed in this work changes have been
relatively minimal, and generally would be expected to
have little effect on the potential for disulphide bonding
or N-linked glycosylation. They are unlikely to have a
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major effect on the overall three-dimensional structure of
the protein. This is consistent with the high degree of
conservation of cysteine residues and glycosylation sites
previously observed between different MVV isolates (Querat
et al., 1990).
In many of the sequences in figure 3.4 it can be
shown that at many of the residues identified as variable
between the different fragments the variability is limited
(the "duplicate" fragments are excluded from this
analysis). In envA 3 different nucleotides are found
between the 5 sequences (that is, including EV1) at only 3
positions. In 27 positions 4 of the 5 fragments all
encode the same base, and in 8 positions 2 bases are used,
more than once each between the 5 fragments. A similar
pattern is present for envB where at only 1 position are 3
different bases used by the 5 fragments. In 20 positions
4 of the 5 fragments all use the same base, and in 7
positions 2 bases are used, more than once each between
the 5 fragments. The most extreme example of this pattern
of nucleotide usage is provided by envC where in 32
positions only 1 fragment out of 5 is variable. This is
predominantly the EVl sequence which varies, leading to
the nucleotide homology pattern seen in figure 3.6 where
the fragments cloned in this chapter all resemble each
other more than they resemble EVl.
The distribution of nucleotide changes in the env
gene fragments does not appear to be entirely random. In
envA there is a cluster of 14 nucleotide changes between
residues 6249 to 6263. The remainder of the nucleotide
changes occur singly, or at most as a pair and appear to
be relatively randomly distributed. The envB fragments
also show clustering of certain nucleotide changes, there
are 5 nucleotide changes for example between residues 6959
to 6963, and there also appears to be non-random
distribution of other changes. Over the 50 residues 6885
to 6934 for example there are 12 nucleotide changes, but
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over the 380 residues from 6965 to 7344 no changes were
detected. In envC 31 nucleotide changes (excluding
deletions) were found between residues 7658 to 7763 (106
residues), while the remaining few changes were
relatively randomly distributed.
In envA and envB approximately 40% to 50% of the
nucleotide changes which were not tightly clustered result
in amino acid alterations. In envC the majority of
nucleotide changes are relatively clustered and too few
unclustered changes are present to determine reliably the
percentage alteration in amino acid sequence. Clustering
of point mutations has been reported in the env genes of
HIV isolates, but not in the other structural genes
(Starcich e_t a_l, 1986).
In the comparison of the sequential MVV isolates 1514
and LV1-1 (Braun e_t al. , 1987) it was reported that
transitions outnumbered transversions by nearly 6 to 1.
In the data reported in this chapter such a pattern has
not been found. For positions which use 1 of 2
nucleotides it can be seen that in envA there are 16
transitions and 18 transversions, in envB there are 15 and
12 respectively and in envC there are 14 transitions and
23 transversions. There therefore appears to be no bias
amongst the EV1 variants sequenced towards transitions,
and in envC it is possible that the opposite may be
occurring.
At least 50% of the predicted amino acid
substitutions result in no alteration in charge. In the
envA encoded sequences only 4 out of 17 substitutions show
a change between positively charged and uncharged amino
acids, and in one case there is a substitution of a
negatively charged residue for an uncharged residue. In
envB encoded sequences 7 out of 14 residues remain
uncharged, 4 vary between uncharged and positively charged
and 3 between uncharged and negatively charged. In envC
encoded sequences 10 out of 20 substitutions remain
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uncharged, 8 result in a change between uncharged and
positively charged residues and 2 vary between negatively
charged and uncharged. This pattern of conservative
substitutions suggests constraints on the amino acid
substitutions tolerated by gpl35.
The major sites of amino acid variability of each
fragment when compared with EV1 are shown in figure 3.9a-
e. These were generated using the Compare program on GCG
version 7.0, with windows and stringencies of 10 in all
cases. The plots for A46, DA3 and VA1 were identical, as
were the plots for BX10, BX11 and DB2, and all the EnvC
plots. Representative examples are presented. The
identified regions can be compared with the predicted
secondary structure graphs (figure 3.8a-c) to determine if
they lie within predicted regions of high antigenicity,
and if they are likely to adopt a surface configuration.
The major site of variation in the EnvA isolates lies
between amino acids 80 to 90 (figure 3.9a,b). This is not
predicted to be highly immunogenic nor to be on the
surface of the protein.
The major consistent site of amino acid variation in
the EnvB isolates lies between amino acids 518 to 528 (of
the EV1 sequence) (figure 3.9c,d). This region is not
predicted to be highly immunogenic nor to be on the
surface of the protein. The additional site of high
diversity identified in VB6 (figure 3.9d) lies between
amino acids 298 to 308 (of the EV1 sequence) in a region
of predicted high antigenicity.
The major sites of amino acid variation in the EnvC
isolates (figure 3.9e) lie between amino acids 521 to 531
and between amino acids 571 to 591. The first is the same
as the major consistent site of variation in EnvB. The
second is a predominantly surface structure which is
predicted to be antigenic.
All the major sites of variability between the
different EV1 isolates identified in this chapter coincide
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Figure 3.9a
Major regions of variability within gp!35 of MVV strain
EV1
The predicted amino acid sequence of A46 (x-axis) was
compared with the published EV1 sequence (Sargan e_t a_l. ,
1991) (y-axis) using the Compare program of GCG version
7.0. Sequences were compared over a 10 amino acid
window, at a stringency of 10, and regions of extensive
divergence are shown by gaps in the plotted line.
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DOTPLOT of: a46.pnt Density: 356.82 October 25. 1992 11:39
COMPARE Window: 10 Stringency: 10.0 Points: 297
Figure 3.9b
Major regions of variability within gp!35 of MVV strain
EV1
The predicted amino acid sequence of AX11 (x-axis) was
compared with the published EV1 sequence (Sargan et al.,
1991) (y-axis) using the Compare program of GCG version
7.0. Sequences were compared over a 10 amino acid
window, at a stringency of 10, and regions of extensive
divergence are shown by gaps in the plotted line.
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DOTPLQT of: axil.pnt Density: 356.82 October 25. 1992 11:40
COMPARE Window: 10 Stringency: 10.0 Points: 302
Viprov.Pep ck: 3,946, 1 to 3i2























Major regions of variability within gp!35 of MVV strain
EV1
The predicted amino acid sequence of BX10 (x-axis) was
compared with the published EV1 sequence (Sargan e_t al. ,
1991) (y-axis) using the Compare program of GCG version
7.0. Sequences were compared over a 10 amino acid
window, at a stringency of 10, and regions of extensive
divergence are shown by gaps in the plotted line.
-Ill-
POTPLOT of: bxiO.pnt Density: 350.00 October £5. 199£ 11:41
COMPARE Window: 10 Stringency: 10.0 Points: £92
Vlprov.Pep ck: 7, 29B. 1 to 306
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Figure 3.9d
Major regions of variability within gp!35 of MVV strain
EV1
The predicted amino acid sequence of VB6 (x-axis) was
compared with the published EV1 sequence (Sargan e_t aT. ,
1991) (y-axis) using the Compare program of GCG version
7.0. Sequences were compared over a 10 amino acid
window, at a stringency of 10, and regions of extensive
divergence are shown by gaps in the plotted line.
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POTPLQT of: vb6.pnt Density: 350.00 October 25. 1392 11:42
COMPARE Window: 10 Stringency: 10.0 Points: 289
Vlprov.Pep ck: 7,298, 1 to 306
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Figure 3.9e
Major regions of variability within gp!35 of MVV strain
EV1
The predicted amino acid sequence of C45 (x-axis) was
compared with the published EV1 sequence (Sargan j2t al.,
1991) (y-axis) using the Compare program of GCG version
7.0. Sequences were compared over a 10 amino acid
window, at a stringency of 10, and regions of extensive
divergence are shown by gaps in the plotted line.
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DOTPLOT of: c45.pnt Density: 205.68 October 25, 1992 11: 43
COMPARE Window: 10 Stringency: 10.0 Points: 148
Vlprov.Pep ck: 5,354, 1 to 179
with the regions of variability identified between strains
by Sargan e_t al. (1991). An additional variable region at
approximately amino acid 400 (Sargan ejt a_l. , 1991) was not
detected in this work. The second major site of variation
in the EnvC isolates (amino acids 571-591) was also
identified as highly variable by Querat e_t _al. (1990).
This work therefore confirms and extends the previous
published data, as it shows that the majority of the
regions of gpl35 which are variable between geographically
isolated strains of MVV are also variable between isolates
from a single (but non-clonal) strain. It is not possible
to determine if the changes observed have arisen in an
antibody-dependent or independent manner. Selection of
antigenic variants may have occurred in vivo prior to the
isolation of the EVl viral strain. It appears possible
that there may be conserved and variable domains of MVV
gpl35, analogous to those reported for HIV gpl20 (Starcich
et al. , 1986) although these may not be restricted to
regions of high predicted antigenicity.
The majority of the sequenced fragments usually show
more than 98% to 99% sequence identity to each other,
which may suggest that there is relatively little
variation between the env genes of different isolates of
the MVV EVl strain. However it is possible that this
under-represents the range of env variants which exist
under in vitro conditions. If the initial binding of
primers to template in the PCR is a random event then it
is likely that the more copies of a particular template
that are present in a reaction, the more likely it is that
the primers will amplify this template preferentially.
However, by chance it is possible that occasionally it
will be a template present at a lower frequency which is
amplified and cloned (the differences between for example
A46 and AX11, which are cloned products of the same PCR,
ligation and transformation show that more than one
species is amplified by the methodology of these
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experiments).
It is possible that the envC sequence published for
EV1 (Sargan e_t ail., 1991) represents one of these lower
frequency templates, as all the fragments generated and
cloned in these results for envC markedly resemble each
other more than they resemble EV1.
A similar situation may also have occurred for VB6,
the envB fragment which shows the most variability from
the other envB regions studied. This is particularly
marked when the VB6 envB region which overlaps with the
VA1 envA region is analysed. VB6 and VA1 were generated
from the same Hirt DNA template. The 3 nucleotide changes
(from the published EV1 sequence) found in VAl in this
region are also found in VB6. However VB6 also contains
an additional 14 nucleotide changes from the EV1 sequence
which are not found in VAl. Minor differences in the
"overlaps" between many of the clones generated from one
template are present, suggesting a multiplicity of
possible env sequences in vitro.
Although certain of the fragments were described as
generated from Hirt DNA from in vitro low passage and high
passage EV1 it is not possible to determine that any of
the nucleotide variations observed are actually a
consequence of in vitro culture. The amino acid
similarity data may suggest that the observed changes do
not necessarily represent a consequence of extensive in
vitro passage. A46 and AX11 for example show a percentage
similarity of 97.735% whereas DA3 and VAl show a
percentage similarity of 99.029%. This suggests there may
be as much variability within a viral stock as there is
between stocks. To investigate thoroughly the effect of
repeated in vitro passage would require the generation of
a replication-competent full-length molecular clone of EV1
which is not currently available.
It cannot be shown that the env sequences analysed in
this chapter actually represent "viable" forms of the env
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gene which are utilised by the virus. It is possible
that they represent aberrant forms, generated as a
consequence of the error rate of the viral reverse
transcriptase. As there are no stop codons in any of the
sequences, and the overall structure has probably been
maintained in each encoded molecule it is likely that if
the gpl35 encoded from these genes was non-functional this
would be a consequence of relatively subtle destruction or
distortion of important regions. To investigate this
fully a replication-competent molecular clone would be
required, which could be altered to the env sequences
analysed in this chapter either by site-specific
mutagenesis, or by the construction of chimeric molecules.
Although all sequences analysed in this chapter were
initially compared with the published EV1 sequence of
Sargan e_t ail., (1991) this is an arbitrary decision, as
the EV1 sequence was also derived from PCR from Hirt DNA.
With the exception of the replication-competent molecular
clones which were variants of 1514 (Staskus e_t a_l. , 1991)
no full-length functional clones of MVV have been
sequenced. There are therefore currently still
difficulties in determining if changes observed in vitro
relate to phenotypic alterations observed in vivo, or if
relevant sequences are actually being detected. This is a
problem which has been encountered in much of the work in
the lentiviral field.
It has been shown for example that for HIV tat there
are major differences between the quasispecies identified
in vitro and in vivo (Meyerhans e_t al. , 1989) and that
viral isolation by in vitro culture can bias the detection
of certain molecular species over others. To minimise
such effects other workers have used direct PCR
amplification and sequencing of patient-derived HIV
sequences (Balfe £t al. , 1990) but in this case it is
difficult to ensure that all the relevant sequences have
been amplified, and to determine if changes observed over
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time represent true evolution of a new sequence or
outgrowth of a previously sequestered variant.
The sequencing of more variants of the EVl strain of
MVV than had previously been reported will allow selection
of certain regions for further investigation. These
include the identification of highly conserved regions,
and regions where there is relatively poor homology
between variants. By comparing these regions with the
predicted structure of the final protein it may be
possible to select protein sequences which may be
predicted to have important structural roles or may be an
appropriate site for targeting immune responses. This
will be discussed further in chapter 7.
3.5 Summary
This chapter reports the comparison of env gene
sequences (restricted to the gpl35 region) from MVV strain
EVl. Homology between different isolates for a selected
region of gpl35 ranged from 93.182% to 99.811% and regions
of high and low variability were distinguished. This data
provides basic background information on the in vitro
variability of EVl env which was not previously available,
and which may be used for more closely targeted analysis
of env gene variants in the future.
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4. The Generation And Characterisation Of Recombinant MVV
gp!35 Fragments - The Yeast Ty-VLP System
4.1 Introduction
Investigations of the structure and function of the
env gene product of MVV have been hampered by the paucity
of high-quality reagents of known provenance. Previous
work with purified MVV gpl35 has relied upon lectin-based
affinity chromatography of viral preparations (Stanley e_t
ad., 1987) but large-scale culture of MVV-infected cells
is necessary to obtain useful yields. Not only is this an
expensive procedure it is also unsatisfactory in terms of
reproducibility, for even if the initial infecting virus
stock is clonal viral replication will almost certainly
generate variants. This is due in part to the relatively
high error rate of retroviral reverse transcriptases, and
it has been shown that the env gene in particular is prone
to accumulation of mutations, some of which may affect
antigenic epitopes, neutralisation epitopes and various
structural features of the glycoprotein (sections 1.15 and
1.16). Therefore in order to obtain high yields of
envelope glycoprotein of known amino acid sequence it was
decided to produce recombinant protein.
The data presented in this chapter describes the
generation of fragments spanning the entire gpl35
glycoprotein and is the first report of expression of
recombinant MVV gpl35 polypeptides.
The yeast Ty-VLP expression system was initially
selected as the method for producing the recombinant
protein as it has previously been reported to produce high
yields of recombinant proteins in an easily purifiable,
immunologically relevant form.
The Ty-VTLP expression system is a derivative of the
Tyl retrotransposon element of yeast. Most Ty elements
are approximately 5.9kb in size and contain 5' and 3' LTR-
related sequences and two orfs, TYA and TYB. The TYA gene
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is an analogue of retroviral gag genes and the TYB gene is
an analogue of the retroviral pol genes, encoding a
reverse transcriptase, an integrase and a protease. The
TYA and TYB genes are expressed as a fusion protein via a
frame-shifting event which is probably analogous to the
gag/pol frame-shifting observed in retroviruses (Mellor e_t
a_l. , 1985b). The proteins encoded by these orfs can self-
assemble into virus-like particles (VLPs) containing
reverse transcriptase activity and Ty RNA (Mellor e_t a_l. ,
1985b) but which lack any equivalent of the retroviral
envelope protein. The majority of the structural core
proteins of the Ty-VLPs are generated by proteolytic
cleavage of the primary protein product of the TYA orf, pi
(Adams et al., 1987a).
If over-expressed a truncated form of the pi protein
has been shown to self-assemble into VLPs containing
approximately 300 pi units in the absence of other Ty-
encoded proteins (Adams e_t a_l. , 1987a) and expression
vectors have been developed which permit the production of
fusion proteins expressed by read-through from the TYA
gene into the inserted gene sequence. Hybrid VLPs are
formed by the fusion proteins and their particulate nature
allows them to be separated from other yeast proteins.
Proteins which have been expressed in this system
include alpha2~interf eron (Mellor e_t al., 1985a),
fragments of HIV-1 gpl20 (Adams e_t al. , 1987b; Griffiths
et al. , 1991), HIV-1 p24 (Gilmour et al. , 1989), MVV p30
(Reyburn e_t £1^, 1992a), HIV-1 Nef (Gilmour et a_l. , 1990),
fragments of HIV-1 gp41 and HIV-2 gp36 (Gilmour e_t al^. ,
1990) and HIV-1 Tat (Braddock e_t al. , 1989). The fusion
proteins are immunogenic (Adams ejt a_l. , 1987b; Griffiths
et al. , 1991) and the Tat protein and alpha2~interferon
expressed in this system were shown to be functionally
active.
The maximum size of polypeptide which has been fused
to the pi gene without significantly disrupting formation
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Figure 4.1
The pOGS expression vectors
The 3 pOGS expression vectors are shown. The major
restriction enzyme sites are marked and the diagram also
shows the hybrid promoter element and the TYAd gene
which encodes the truncated pi protein.
The cloning site of each vector is shown below the
diagram, and the BamHI restriction site is underlined.
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pOGS40 : p1—AAA GCC GGA TCC AAA TAA—
pOGS41 : p1—AAA GCC GGA TCA AGG ATC CGA TCC GGG AAA TAA
POGS42 : P1—AAA GCC GGA TCG GAT CCG ATC CGG GAA ATA A
of the Ty-VLP is 43kDa (Burns e_t al. , 1992). As this is
significantly smaller than the predicted pre-glycosylation
size for gpl35 of approximately 77.4kDa (derived from
Sargan e_t a_l. , 1991) the polymerase chain reaction was
used to generate overlapping fragments of the gpl35 coding
region. These gene fragments were predicted to encode
proteins of molecular weights of 37.1kDa (EnvA), 34.2kDa
(EnvB) and 20.1kDa (EnvC) all of which therefore lie
within the size range of fusion proteins which have been
successfully expressed in the Ty-VLP system. In order to
preserve possible domain structures which could be
functionally significant in native gpl35, overlaps of 63
or 64 amino acids were introduced between the three
fragments (chapter 3, figure 3.1).
Expression vectors with either constitutive or
inducible promoters are available for the Ty-VLP
expression system. It was not known if the expressed
gpl35 fusion proteins would be toxic in the transformed
cell and therefore it was considered appropriate to use a
vector in which fusion protein expression was inducible
rather than constitutive. The pOGS family of vectors
(Gilmour e_t a_l. , 1989), (figure 4.1) are high copy number
shuttle vectors, that is they can replicate in both E.coli
and S.cerevisiae. They are derivatives of the pMA5620
vector (Adams e_t a^. , 1987b) in which the constitutive
phosphoglycerate kinase (PGR) promoter has been replaced
by a hybrid PGK-GAL promoter which is galactose-inducible.
In all three pOGS vectors the TYA gene has been truncated
at the 3' end to encode the first 381 amino acids of pi
(predicted molecular weight 42kDa). The members of the
pOGS family differ only in the reading frame of the BamHI
cloning site at codon 381 . Stop codons are present in
all three reading frames after the BamHI site and the
plasmids contain an ampicillin resistance gene, allowing
selection in E.coli.
The BJ 2168 strain of S.cerevisiae is phenotypically
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leu", ura" and trp" and therefore unable to grow on
minimal media in the absence of these amino acids. The
strain can be transformed to leucine independence by any
pOGS-based plasmid due to the LEU2 gene in the vector. It
is also partially protease deficient, a feature which is
important in protecting fusion proteins from host cell
proteases.
Although the strain contains a mutation in the GAL2
galactose permease gene some galactose can enter the cell
by a constitutive pathway, and therefore induce fusion
protein expression from the PGK-GAL promoter. Expression
from the GAIL promoter in yeast is critically dependent on
the relative levels of the GAIL4 and GAIL80 proteins. GAIL4
activates expression from the promoter by binding to a
specific DNA site and GAE80 antagonises the action of
GAIL4, either by interacting with the GA1L4, the GA1L4
binding site on the DNA or both (reviewed in Schultz e_t
al. , 1987). As GAL4 levels are often the rate-limiting
factor in galactose induction helper plasmids have been
developed in which the GAL4 gene has been inserted under
the control of the GA1L1 or GAIL10 promoter (Laughton e_t
al. , 1984; Schultz e_t a_l. , 1987). These preserve the
inducibility of the galactose promoter, while increasing
the level of expression from it by overcoming the rate-
limitation of low GA14 levels. The low copy number helper
plasmid pUG 41S (figure 4.2) can be used with the pOGS
plasmids to co-transform S.cerevisiae and so increase the
efficiency of induction of the fusion protein. The URA 3
gene of pUG 41S renders the host cell uracil independent
allowing selection of double transformants by their uracil
and leucine prototrophy.
The env fragments initially generated by the
polymerase chain reaction from MVV-infected cell DNA
(chapter 3) were inserted into the pOGS expression
vectors. After initial selection of positive clones in
the JM83 strain of E.coli the expression constructs were
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Figure 4.2
The pUG 41S helper plasmid
The pUG 41S helper plasmid which incorporates the GAL4
gene under the control of the GAL1/GAL10 promoter is
shown. The major restriction enzyme sites are marked.
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co-transformed with pUG 41S into S. cerevisiae and the
fusion proteins were expressed and characterised.
S.cerevisiae was also co-transformed with pUG 41S and a
native pOGS plasmid to obtain a control transformant which
expressed the truncated pi protein alone. The effects of
expression of the env gene sequences on the growth of the
transformed S.cerevisiae were monitored and compared with
the expression of the various fusion proteins at different
intervals post-induction. Transformed S.cerevisiae were
examined by electron microscopy to investigate any
intracellular structural variations in the hybrid-VLPs
formed by the different constructs and the fusion proteins
were also analysed to determine the extent of
glycosylation. Sera from MVV-infected sheep were tested
against the fusion proteins to confirm that antigenically
relevant polypeptides had been expressed and the fusion
proteins were also used as immunogens in rabbits and mice.
4.2 Generation Of Recombinant pOGS/Env Plasmids
The pTZ-env clones A46, BX10 and C45 (see chapter 3)
were selected as the env sequences to be expressed in the
Ty-VLP system. To maintain the correct reading frame the
envA fragment was inserted at the BamHI site of pOGS42 and
the envB and envC fragments were separately inserted into
the BamHI site of p0GS40.
Initially the fragments were excised from the pTZ
plasmids by digestion with BamHI and gel-purified.
Insertion of these excised fragments into the appropriate
pOGS vector which had been digested with BamHI and treated
with CIP was attempted. The ligated DNA was then
transformed into competent E.coli JM83. However several
attempts using this approach were unsuccessful.
245 colonies were screened for the envA fragment, of
which 18 hybridised to an envA-specific probe by colony
screening. Gel analysis of the DNA from minipreps showed
that the fragment was inserted in pTZ, not pOGS42.
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386 colonies were screened for the envB fragment, of
which 19 hybridised to the envB-specific probe by colony
screening. These envB fragments were also found to be
inserted into pTZ.
187 colonies were screened for the envC fragment, of
which 6 hybridised to the envC-specific probe by colony
screening. The fragments were all found to be inserted in
pTZ.
Various stages in the preparation of the env
fragments were varied in attempts to exclude the
contaminating pTZ DNA. Excised DNA was subjected to two
rounds of gel purification, with an additional intervening
digestion step with BamHI. The DNA was also digested with
Pvul; pTZ19R contains Pvul sites at positions 42 and 1855
but there are no Pvul sites in the env gene fragments.
Therefore this procedure should digest within the plasmid
sequences lessening the chances of contamination by intact
plasmid sequences, while leaving the env sequences intact.
However, none of these procedures resulted in the
isolation of pOGS plasmids containing the desired
fragments.
In order to overcome this problem A46, BX10 and C45
plasmid DNA was used as the template for the polymerase
chain reaction, using the original primers. The resulting
DNA was digested with BamHI and ligated into the
appropriate pOGS plasmid (ligation into pTZ to check the
fidelity of the PCR was also performed - chapter 3. The
sequences which were therefore used in the ligations into
the pOGS vectors are represented by ADP1, BDP1 and CDP1)
and E.coli JM83 were transformed.
50 colonies were screened for the envA/pOGS42
ligation by colony screening and 12 hybridised to the
envA-specific probe. Gel analysis of plasmid DNA
demonstrated that all the positive colonies contained a
pOGS plasmid from which a single insert of the appropriate
size could be excised with BamHI. The DNA was also
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digested with Hindlll; pOGS42 contains Hindlll sites at
positions 1 and 6070 and envA has one Hindlll site at
position 896. Insertion of the envA coding sequence in
the 5' to 3' orientation at the BamHI site at position
2650 would be predicted to yield fragments of 3320, 3460
and 3542 base pairs after digestion with Hindlll.
Insertion in the opposite orientation would be predicted
to yield fragments of 2690, 3320 and 4316 base pairs. By
gel analysis nine clones were found to have a Hindlll
digestion pattern consistent with 5' to 3' insertion and 3
clones to have a pattern consistent with the opposite
orientation. Double-stranded DNA sequencing of one of the
clones (Ap6) confirmed that the envA fragment had been
inserted into the vector in the correct orientation and
the correct reading frame. Ap6 was therefore selected as
the pOGS42/envA clone to be used to transform
S.cerevisiae.
383 colonies were screened after ligation of a PCR
envB product into p0GS40, of which 4 hybridised to the
envB-specific probe. Restriction digestion of three of
these samples resulted in excision of a band of the
correct size for envB with BamHI but the plasmid DNA was
neither p0GS40 nor pTZ18R/19R (the DNA in these samples
was not characterised any further). The restriction
pattern of the remaining clone, Bpll was consistent with a
fragment the size of envB ligated into pOGS40. The envB
fragment contains a Hindlll site at position 145 (the
Hindlll sites in pOGS40 and p0GS42 are in the same
positions) and the digestion pattern with this enzyme was
consistent with the bands of predicted sizes 3320, 3422
and 3565 for an envB fragment inserted 3' to 5' in the
BamHI site. Plasmid DNA was extracted from the clone,
digested with BamHI, re-ligated and transformed into
E.coli JM83. 184 colonies were screened and 3 reacted
with the B-specific probe. Restriction digestion analysis
demonstrated that 2 of the clones contained the fragment
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in the 3' to 5' orientation while a third, BpllR/3 had a
Hindlll restriction pattern consistent with the band sizes
of 2795, 3320 and 4192 predicted for an insertion in the
5' to 3' orientation. BpllR/3 was therefore selected as
the p0GS40/envB clone to be used to transform
S.cerevisiae.
10 colonies were analysed by restriction digestion
analysis after ligation of an envC PCR fragment into
pOGS40. 8 of the clones were p0GS40 with no inserted DNA
but BamHI digestion of the DNA from the remaining 2 clones
excised a fragment of the expected size for envC. No
diagnostic restriction digestion was available to
determine the orientation of the C fragment in p0GS40 and
therefore double stranded sequencing was performed. This
demonstrated that one of the clones, Cp3 contained the
envC fragment in the 5' to 3' orientation. Cp3 was
therefore selected as the pQGS40/envC clone to be used to
transform S.cerevisiae.
4.3 Transformation Of S.cerevisiae With pOGS/Env Plasmids
Purified DNA from pUG 41S and the pOGS/env clones
were used to transform S.cerevisiae. A range of DNA
concentrations were tested and approximately 3.0ug of the
pOGS-based plasmids were co-transformed with l.Oug of pUG
41S. Double transformants were initially selected on Sc-
Glc/Trp plates and then re-streaked onto fresh selection
plates. Double transformations (leu+, ura+) are rare
events (approximately 1 in 10^) and 2 transformants were
initially obtained with Ap6, 6 with BpllR/3 and 1 with
Cp3. For A and B each transformant was screened for
fusion protein expression, using a small-scale culture,
and no obvious difference was apparent between the
transformants (data not shown). Therefore one of each was
chosen arbitrarily and the S.cerevisiae double
transformants were designated A2.2, B2.2 and C3.1.
4 double-transformants containing pUG 41S and pOGS40
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were also generated. There was no obvious difference in
pi protein expression between these transformants and one
was chosen arbitrarily as a control and designated pp8.1.
4.4 Protein Expression From The S.cerevisiae pOGS/Env
Transformants
Figure 4.3 shows the pl:Env fusion proteins detected
by western blotting with a polyclonal rabbit anti-VLP
serum (a kind gift of M. Fotheringham, Department Of
Veterinary Pathology, University Of Edinburgh) after
induction of the cultures with galactose. It should be
noted that the bands shown were obtained after large-scale
purification of the VLPs, and the loading has been varied
for each track. They do not reflect the relative yields
of each protein. The pi protein migrates with an apparent
molecular weight of approximately 55kDa-60kDa in the gel
system used, higher than its predicted molecular weight
(42kDa). This is consistent with previous data (Adams e_t
al., 1987b). plrEnvA migrates at approximately 94-98kDa,
pl:EnvB at approximately 85kDa and pl:EnvC at
approximately 76kDa. A number of other bands are visible
on the western blots of the pi and pl:Env fusion protein
preparations. These are contaminants of the purification
procedure which are reactive with the polyclonal anti-VLP
serum.
No obvious bands were visible for the fusion proteins
from small-scale protein purifications on Coomassie-
stained gels but the pi band in clone pp8.1 could be
distinguished (data not shown). This suggested that the
pl:Env fusion proteins might be low-yielding.
Two-litre cultures of the transformants were induced
and large-scale protein purification performed.
Approximately 20ml of packed cells were obtained from each
culture and these were processed in 7.5ml batches.
Figure 4.4 shows western blots and Coomassie-stained gels
for the large-scale purification of protein from pp8.1.
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Figure 4.3
Western blot of pl/pl:Env fusion proteins
Sucrose gradient purified proteins were separated on a
10% SDS-PAGE gel and blotted onto nitrocellulose. The
blot was developed with rabbit anti-VLP serum @ 1 in
1500 and anti-rabbit alkaline phosphatase @ 1 in 1000.
The pl:Env bands are indicated by dots. The pi doublet
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The western blots showed that the pi material was
concentrated in fractions 8 to 13 (where fraction 1 is the
top of the gradient and fraction 19 is the bottom).
Similar results were apparent on the Coomassie-stained
gel, with a visible pi band most apparent in fractions 8
to 11. The band consistently ran as a doublet with few
contaminating bands present. 5ul from each 2ml fraction
were analysed. A BioRad protein dye-binding assay was
used (manufacturer's protocol) to estimate the protein
concentration of the purified pi preparations, and the
yield of pi protein was thereby estimated as 2.5mg/L (data
not shown).
Figure 4.5 shows the western blot for the fractions
obtained after sucrose gradient purification of the pl:Env
fusion proteins. The pl:EnvA fusion protein is
concentrated in fractions 18 and 19, pi:EnvB in fractions
17 and 18 and plrEnvC in fractions 14 to 17. Other bands
are also visible, suggesting the presence of contaminating
proteins in the fractions which react with the anti-VLP
serum.
Figure 4.6 shows the silver-stained gel for the peak
fractions of each of the large-scale purifications. The
pi band from pp8.1 is clearly visible and a band is also
visible for pl:EnvA. However despite overloading the gel,
and allowing it to become overdeveloped, no pl:EnvB or
plrEnvC bands were visible. It should also be noted that
only lul was loaded of the protein from pp8.1, but 5ul
were loaded for each pl:Env construct. It is therefore
apparent that yields of the fusion proteins were much
lower than the native pi protein. Contaminating proteins
were also present to a much greater extent in the fusion
protein preparations; if equal volumes of the peak
fractions from the pi and pl:Env fusion protein
preparations were separated by SDS-PAGE the level of
contaminating proteins in the pi preparation was much
lower than for the fusion proteins, while the pi band
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Figure 4.4
Western blot and Coomassie-stained gel of pi
Proteins from the peak fractions of sucrose gradient
purified pi were separated on a 10% SDS-PAGE gel and
either Coomassie-stained (b), or blotted onto
nitrocellulose (a) and developed with rabbit anti-VLP
serum @ 1 in 1500 and anti-rabbit alkaline phosphatase @
1 in 1000. The pi doublet is indicated by dots.
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Figure 4.5
Western blot of pl:Env fusion proteins
Proteins from the peak fractions of sucrose gradient
purified pl:Env were separated on a 10% SDS-PAGE gel,
blotted onto nitrocellulose and developed with rabbit
anti-VLP serum @ 1 in 1500 and anti-rabbit alkaline
phosphatase @ 1 in 1000. The fusion protein bands are
indicated by arrows. Sucrose gradient fraction numbers































SDS-PAGE gel of pl/pl:Env fusion proteins
Proteins from the peak fractions of sucrose gradient
purified pl/pl:Env were separated on a 10% SDS-PAGE gel
and developed by silver staining. The pi and pl:EnvA
bands are indicated by dots. Sucrose gradient fraction
numbers are shown above the tracks.
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itself was greatly overloaded (data not shown). As it was
not possible to achieve high purification of the fusion
proteins no attempt was made to estimate yield by protein
assay systems.
4.5 Growth Characteristics Of S.cerevisiae pOGS/Env
Transformants
The growth characteristics of induced and uninduced
S.cerevisiae transformants were performed to determine if
the low yields of the fusion proteins were a consequence
of a toxic effect on the yeast cells. Transformants were
grown in Sc-glc/Trp until an OD^qq of 0.1-0.3 was reached,
the cells pelleted and resuspended in fresh pre-warmed Sc-
glc/Trp or Sc-glc-gal/Trp and the incubation continued.
OD&oo values were recorded at six-hourly intervals for the
first twenty four hours, and finally at forty eight hours
post-induction. Small-scale protein preparations were
made at 12, 24 and 48 hours post-induction.
Figures 4.7 to 4.10 show the growth profiles for the
four transformants, based on the mean of two experiments.
Although slight differences are apparent between the
induced and uninduced cultures at 12 or 18 hours post-
induction these may not be particularly significant, given
the large standard deviations of the samples. (The large
standard deviations in the early stages of the B2.2 growth
curves reflect the different OD^qq values at which
induction was initiated in two separate experiments). By
24 hours post-induction there was no significant
difference in the 0^600 values for the induced and
uninduced cultures.
Figure 4.11 shows a comparison of the results for the
four induced cultures. No significant differences in the
growth characteristics were observed when comparing the
Env-expressing transformants with pp8.1 which expresses
only pi. Phase contrast microscopy of the cultures
revealed no obvious differences in the morphology of the
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Figure 4.7
Growth profile of A2.2
An A2.2 transformed yeast culture was induced @ t=0, and
the OD^qq of the culture monitored, and compared with
the values for an uninduced culture. The standard
deviation of each reading (between 2 separate
experiments) is shown.
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Growth Profile For A2.2
Time post-induction/Hrs
Figure 4.8
Growth profile of B2.2
A B2.2 transformed yeast culture was induced @ t=0, and
the OD600 of the culture monitored, and compared with
the values for an uninduced culture. The standard
deviation of each reading (between 2 separate
experiments) is shown.
-136-
Growth Profile For B2.2
Time post-induction/Hrs
Figure 4.9
Growth profile of C3.1
A C3.1 transformed yeast culture was induced @ t=0, and
the ODgQQ of the culture monitored, and compared with
the values for an uninduced culture. The standard






Growth profile of pp8.1
A pp8.1 transformed yeast culture was induced @ t=0, and
the OD^qq of the culture monitored, and compared with
the values for an uninduced culture. The standard
deviation of each reading (between 2 separate
experiments) is shown.
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Growth Profile For pp8.1
Time post-inductiori/Hrs
Figure 4.11
Growth profiles of induced yeast transformants
All cultures were induced @ t » 0, and the ODgQQ
monitored. The standard deviation of each reading
(between 2 separate experiments) is shown.
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Growth Profiles Of Induced Clones
Time post-induction/Hrs
various induced and uninduced cultures (data not shown).
Recombinant protein expression was monitored by
western blotting with the rabbit anti-VLP serum. Figure
4.12d shows that expression of pi from clone pp8.1 rose
over the time-course of the experiment, although
expression was apparent from 12 hours post-induction (the
first time-point at which protein expression was
analysed). For expression of the pl:EnvA fusion protein
from clone A2.2 the pattern was very different (figure
4.12a) with very little recombinant protein detectable at
12 or 48 hours post-induction, but appreciable detection
at 24 hours post-induction. Figure 4.12b shows that low
level expression of pl:EnvB fusion protein was detectable
at 12 hours post-induction, had risen markedly by 24 hours
post-induction, and possibly had increased slightly
further by 48 hours post-induction. Figure 4.12c shows
that production of the pl:EnvC fusion protein from clone
C3.1 was very poor, as determined by western blotting.
Fusion protein could be detected at 12 and twenty-four
hours post-induction, but not after 48 hours. The four
transformants therefore although showing similar growth
characteristics differed markedly in the pattern of
recombinant protein production.
4.6 Electron Microscopy Of S.cerevisiae Expressing pl:Env
Fusion Proteins
In order to investigate the intracellular morphology
of the hybrid and non-hybrid VLPs cultures of the 4
transformants were induced for 24 hours and the cells
analysed by transmission electron microscopy. Western
blotting with the anti-VLP serum was used to confirm that
the transformants were expressing the proteins (data not
shown). Control uninduced cultures of the same
transformants were also analysed by western blotting and
transmission electron microscopy.
In figure 4.13d VLPs are visible in the cytoplasm of
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Figure 4.12
Variation in expression of pl/pl:Env proteins with
induction time
The proteins from induced and uninduced transformed
yeast cultures were separated on a 10% SDS-PAGE gel,
blotted onto nitrocellulose and developed with rabbit
anti-VLP serum @ 1 in 1500 and anti-rabbit alkaline
phosphatase @ 1 in 1000. The pl/pl:Env bands are
indicated by arrows. The time intervals post-induction
are shown above each blot.
Key
a = transformant A2.2
b = transformant B2.2
c = transformant C3.1
d = transformant pp8.1
+ = induced culture
- = uninduced culture
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Figure 4.13
Transmission electron micrographs of induced pl/pl:Env
transformants
Transformed yeast were grown under inducing conditions
for 24 hours and sections of fixed cells prepared for
transmission electron microscopy. VLPs are indicated by
solid arrows.
Key
a = transformant A2.2
b = transformant B2.2
c = transformant C3.1
d = transformant pp8.1
Scale bar = 200nm
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induced pp8.1 cells as approximately circular structures
with an electron-dense outer region, approximately 15 to
35nm in diameter.
Figure 4.13a demonstrates that the VLPs formed after
induction of the pl:EnvA protein were much larger than the
control VLPs (approximately 70 to 150nm diameter) and very
heterogeneous in morphology. The particles were
cytoplasmic and appeared to be circumscribed by two layers
of electron-dense material with an intervening layer of
electron-light material.
Figures 4.13b and 4.13c show the VLPs present in
induced cultures of B2.2 and C3.1 respectively. They were
similar in size, cellular location and morphology to the
control VLPs formed by clone pp8.1 but were present at
much lower levels in the cytoplasm.
No VLPs were found in uninduced cells and there were
no obvious major changes in cellular morphology between
the various cultures (data not shown).
4.7 Glycosylation Of pl:Env Fusion Proteins
In order to determine if the fusion proteins were
glycosylated samples from the peak fractions of sucrose
gradient purification were incubated in the presence or
absence of N-glycosidase F or endoglycosidase F. N-
glycosidase F hydrolyses almost all N-linked carbohydrate
residues at the aspartylglycosylamine linkage.
Endoglycosidase F hydrolyses the diacetylchitobiose
linkage of N-linked high-mannose oligosaccharides, hybrid
and to some extent biantennary complex carbohydrates.
Figure 4.14 is a representative example of the
results obtained after treatment of pi and pl:Env fusion
proteins with N-glycosidase F. The experiment was
repeated four times, using either Triton-X 100 or
octylglucoside as a detergent, and similar results were
obtained on each occasion.
There was no change observed in the mobilities of the
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Figure 4.14
Glycosylation of pl/pl:Env fusion proteins
Proteins from the peak sucrose gradient fractions of
pl/pl:Env were treated with N-glycosidase F, separated
on a 10% SDS-PAGE gel and blotted onto nitrocellulose.
Blots were developed with rabbit anti-VLP serum @ 1 in
1500 and anti-rabbit alkaline phosphatase @ 1 in 1000.
The pl/pl:Env protein bands are indicated by arrows.
Key
+ = N-glycosidase F treatment









pi, pl:EnvB and pl:EnvC bands after N-glycosidase F
treatment but the pl:EnvA band was altered, with the band
becoming "sharper" and less diffuse in appearance,
although with no detectable alteration in the position of
the "leading edge" of the band. This suggests N-linked
glycosylation of the pl:EnvA fusion protein.
No alteration in the mobility of pi alone, or any of
the pl:Env fusion proteins was observed when the samples
were treated with endoglycosidase F (data not shown).
4.8 Reactivity Of Sera From MVV-Infected Sheep With The
pl:Env Fusion Proteins
In order to confirm that the fusion proteins
contained MVV gpl35 sequences, and to determine if MVV-
infected sheep differed in their responses to gpl35
western blots of the fusion proteins were analysed using
sera from infected sheep.
In order to standardise the amount of fusion protein
on each blot peak fractions were diluted to varying
degrees in TEN, separated by SDS-PAGE and blotted onto
nitrocellulose. The rabbit anti-VLP serum was used to
assess the comparative amounts of the pi:fusion proteins
present. Loading of the native pi protein and the fusion
proteins was adjusted so that native pi was present in
slight excess compared with the pl:Env fusion proteins.
The same blots were then used to screen sera from MVV-
infected sheep.
Sheep 754N and 848A had been experimentally infected
with the MVV EV1 strain approximately 22 months before the
serum samples were obtained, at which point the sheep were
asymptomatic. Sheep 2, 68, 74 and G027 had been naturally
infected with MVV for an unknown period. The serum
samples were obtained at post-mortem and all 4 sheep
displayed classical maedi lesions. All sera were used at
a dilution of 1 in 20, at which they detected gpl35 in
western blots of in vitro MVV-infected cell lysates (data
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not shown). Pooled normal sheep serum (Scottish Antibody
Production Unit) was used as a negative control.
Figure 4.15 demonstrates that sera from infected
sheep differed in the extent to which they reacted with
the fusion proteins. Sera from sheep G027, 74 and 754N
reacted with all three fusion proteins, with 754N the most
strongly reactive. Sera from sheep 848A reacted only
against the plrEnvC fusion protein - no reactivity was
detected against plrEnvA or pl:EnvB. Sera from sheep 2
reacted only with the plrEnvB and plrEnvC fusion proteins
- no reactivity was detected against plrEnvA.None of these
sera reacted against pi alone. Sera from sheep 68 showed
very faint reactivity against pi alone and also against
all three fusion proteins. In view of the relative
amounts of pi on the blots, and the intensities of the
bands detected with the sera from sheep 68 it was
considered that this sample was genuinely reactive against
the Env regions of the fusion proteins. Normal sheep
serum reacted very weakly with pi alone but did not react
with any of the fusion proteins.
4.9 Immunisation Of Rabbits And Mice With pi:Env Fusion
Proteins
1 rabbit and 3 mice were immunised with each plrEnv
fusion protein using the protocol described in section
2.23. Two weeks after the third immunisation the sera
were screened by western blotting for reactivity with a
whole cell lysate of MVV-infected cells. The presence of
Env protein on the blots was confirmed using sera from the
MVV-infected sheep 848A, 754N and G027 (data not shown).
No anti-Env activity was observed for any mouse serum
diluted 1 in 100, or for rabbit sera diluted between 1 in
10 and 1 in 150.
All the sera from the immunised animals were reactive




Reactivity of MW-infected sheep sera with pl/pl:Env
fusion proteins
Proteins from the peak sucrose gradient fractions of
pl/pl:Env were separated on a 10% SDS-PAGE gel and
blotted onto nitrocellulose. The blots were developed
with either rabbit anti-VLP serum (Rbl94) @ 1 in 1500 or
various sheep sera @ 1 in 20, followed by anti-species
alkaline phosphatase (3 1 in 1000. The pl/pl:Env protein
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Figure 4.16
Reactivity of pi:Env-immunised rabbit and mouse sera
with pi
Proteins from the peak fractions of sucrose gradient
purified pi were separated on a 10% SDS-PAGE gel and
blotted onto nitrocellulose. The blots were developed
with sera from mice or rabbits immunised with pi: Env
proteins, and anti-species alkaline phosphatase (? 1 in
1000. Arrows indicate the pi protein band(s).
Key
Mouse A3 - immunised with pl:EnvA
Mouse B2 - immunised with plrEnvB
Mouse C3 - immunised with pl:EnvC
Rabbit 210 - immunised with pl:EnvB
Rabbit 211 - immunised with pl:EnvC
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This chapter has reported the generation of
recombinant proteins which span the entire gpl35 molecule,
and the characterisation of these proteins.
The four transformants generated, pp8.1, A2.2, B2.2
and C3.1 differed only in the coding sequence which was
inserted 3' to the pi gene and therefore the differences
observed in the expression and characteristics of the
fusion proteins must be a consequence of the Env
sequences.
It is not clear why so many difficulties were
encountered in sub-cloning the env gene fragments from the
pTZ-based clones into pOGS vectors. Part of the
difficulty was probably due to the significantly larger
size of the shuttle vector (9.4kb cf. 2.9kb for pTZ) as
smaller plasmids are known to transform at a higher
efficiency than larger plasmids (Hanahan, 1983). It was
also suspected that low levels of undigested pTZ plasmids
containing the env sequences co-migrated with the excised
fragment on a gel, probably by a process of physical
entrapment. In order to circumvent this problem
procedures such as double digestion and double rounds of
gel purification were employed, but these proved to be
unsuccessful, possibly because yields of the desired
fragment were very low after these multiple steps.
Experiments with the bacterial expression system pGEX
(chapter 5) demonstrated that expression of the env gene
fragments in E.coli resulted in a significant reduction in
cell growth. If a basal level of expression from the PGK-
PAL promoter occurred after transformation of E.coli the
resulting toxicity of the expressed fusion proteins could
also result in a reduced effectiveness of transformation
by pOGS-based plasmids
One of the most obvious characteristics of the
transformants which express the pl:Env fusion proteins was
the low expression of the fusion protein compared to that
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of pi alone. On large-scale preparations it became
apparent that this was accompanied by extensive
contamination of the fractions which contained the fusion
proteins with other yeast proteins. This was not merely a
technical problem (eg with cell breakage or sucrose
gradient formation) as much cleaner preparations were
obtained when purifying pi alone by the same technique.
It was noticeable that after sucrose gradient
centrifugation the fractions which contained the highest
levels of the fusion proteins also contained a large
amount of aggregated material, readily visible in the
centrifuge tubes. The extensive degree of contamination
in these preparations may suggest that the expression of
the fusion proteins can lead to the formation of
aggregates, either with or between other cellular proteins
during the purification stages.
The low level of expression of the fusion proteins
was not a consequence of any directly toxic effect upon
the host cells. Although induction in all four
transformants led to an initial slowing down of cell
division this is not an unusual phenomenon, and occurred
for both the fusion proteins and pi alone. Coomassie
stained gels from crude lysates of all 4 transformants,
harvested at different times post-induction, did not
demonstrate any major difference in the level of
expression of cellular proteins during induction (data not
shown). Although this was only a very crude technique it
indicated that expression of the fusion proteins did not
result in any massive overall decline in host cell protein
synthesis.
The results for the time-course of fusion protein
expression suggested differences in the stability of the
various fusion proteins. The increasing expression of the
pi protein alone throughout the entire period of the
experiment indicated that the protein was stable within
the cell, and that expression of the protein could
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continue to be induced even in the presence of high
intracellular concentrations of pi. The pl:EnvB fusion
protein appeared to be the most stably expressed of the
Env fusion proteins as it could still be detected at 48
hours post-induction, albeit at levels much lower than for
pi. The pltEnvA and pl:EnvC fusion proteins were
detectable at 24 hours post-induction but not at 48 hours,
the most likely interpretation being that the proteins had
been degraded within the cell and this degradation had not
been followed by a significant further degree of fusion
protein expression. The alternative possibility of
extracellular export appears to be unlikely as there are
no reports of a mechanism by which VLPs are transported
from a cell. It is not clear how this loss of fusion
protein arises, or why it should only become apparent more
than 24 hours post-induction. It may be that there is a
time-lag in the production of cellular protease activity
in the BJ 2168 cells (which are protease-defective) such
that initially production of the fusion protein outpaces
degradation but that with increasing time there is a
relative fall in fusion protein expression such that the
degradative process outweighs the synthesis of the pl:Env
species. The EnvA and EnvC sequences may also have an
inhibitory effect on cellular protein synthesis (either of
all cellular proteins or just the fusion proteins) which
was not detectable by Coomassie staining of SDS-PAGE gels.
However the process must be influenced by regions in EnvA
and EnvC (and presumably not in the parts of the molecules
which overlap with EnvB) as the same pattern of expression
was not apparent for pi or pl:EnvB.
Electron microscopy revealed that while the VLPs
formed by pi, pl:EnvB and pl:EnvC were broadly similar in
size, shape and morphology they differed dramatically from
those formed by pl:EnvA. The presence of the EnvA protein
sequence therefore must exert a major effect during the
formation of the VLPs. This is unlikely to be a simple
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reflection of the size of the EnvA fragment in the fusion
protein as its predicted molecular weight is only slightly
greater than that of EnvB and the relative sizes of the
monomers of the EnvA and EnvB fusion proteins have been
shown by SDS-PAGE and western blotting to be similar. It
is therefore likely that a structural feature of the EnvA
amino acid sequence leads to this altered assembly of VLPs
in the cell.
Treatment of the fusion proteins with N-glycosidase F
indicated that only the plrEnvA fusion protein was
glycosylated. N-glycosidase F cleaves the N-glycan
linkage of glycoproteins between the carbohydrate chain
and the asparagine residue to which it is attached and the
results with the pl:EnvA fusion protein indicated that a
limited amount of N-linked glycosylation had occurred.
The shift in mobility of the band observed after treatment
suggested that the pi:EnvA fusion protein produced in this
system may be relatively heterogeneous in the degree of
glycosylation as the position of the leading edge of the
band did not alter after N-glycosidase F treatment. If
all molecules of the fusion protein had been
deglycosylated to the same extent it would have been
expected that the entire band on the western blot would
have increased in mobility.
Analysis of the DNA sequence data for the Env clones
(see chapter 3) shows that EnvA contains 4 potential N-
linked glycosylation sites, EnvB 17 and EnvC 6 so the
difference in glycosylation is unlikely to be a
consequence of the number of such sites. It is possible
that the putative signal sequence in the EnvA fragment
(section 1.15) may act to target the fusion protein to the
lumen of the endoplasmic reticulum, the cellular site for
glycosylation. Signal sequences are normally found at the
extreme N-terminus of proteins and it would therefore be
unusual for an internal signal sequence to be operational.
However, in native MVV gpl35 the putative signal sequence
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is not N-terminal. If this internal signal sequence is
functional during the normal replicative cycle of MVV (and
the extracellular expression of gpl35 in infected cell
cultures suggests that it is) then it is conceivable that
it could continue to function as a signal sequence when
positioned internally in a fusion protein. However,
further experiments using deletion mutants or chimeric
proteins would be required to confirm this hypothesis.
Glycosylated recombinant proteins have been produced
previously using S.cerevisiae expression systems. These
include glycoproteins El and E2 of Sindbis virus (Wen &
Schlesinger,1986), the VSV glycoprotein (Wen &
Schlesinger, 1986) and the influenza virus haemagglutinin
(Jabbar e_t a_l. , 1985). The recombinant proteins were
glycosylated in a manner analogous to that of the native
proteins and this was dependent on the presence in the
coding regions of sequences which control these events eg
when the sequence coding for the signal sequence of the
influenza haemagglutinin gene was deleted the recombinant
product was no longer glycosylated (Jabbar e\ a_l. , 1985).
However in all of these cases the recombinant proteins
were not expressed as fusion proteins.
The retrotransposon element from which the pi coding
sequence is derived is an entirely intracellular molecule
and the Ty-VLPs are believed to remain endogenous (Mellor
et a_l. , 1986). As the pi protein therefore does not
traverse cellular membranes, and is almost certainly not
glycosylated it is unlikely that under normal
circumstances polypeptides fused C-terminal to pi would
enter such pathways either.
The results demonstrated that the pl:EnvA fusion
protein was glycosylated but they did not indicate which
region of the fusion protein had been modified. If the
presence of the EnvA sequence altered the pathways into
which the fusion protein was transported it is conceivable
that the glycosylation could have occurred on the pi
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region of the protein (which contains 6 potential N-linked
glycosylation sites), the EnvA region or both. It is also
possible that the glycosylation detected for the plrEnvA
fusion protein does not accurately mimic that found in
native gpl35. Endoglycosidase F treatment can remove all
the N-linked carbohydrate residues on HIV gpl20 (Putney e_t
al. , 1986) and FIV envelope glycoprotein (Stephens et al.,
1991). It is possible that native MVV gpl35 is
glycosylated in a similar manner to the glycoproteins of
HIV and FIV. If this is the case (no direct evidence is
currently available) the lack of digestion of pl:EnvA by
endoglycosidase F observed in the experiments reported in
this chapter may indicate that the glycosylation of the
fusion protein in the Ty-VLP system does not accurately
reflect that seen in native MVV gpl35.
Although there is no direct evidence it is possible
that the presence of carbohydrate residues on the pl:EnvA
fusion protein may contribute to the difference in the
structure of the VLPs observed by electron microscopy.
Despite the lack of normal glycosylation of the Env
polypeptides all three Env regions were recognised by sera
from sheep naturally or experimentally infected with MVV,
demonstrating that immunologically relevant regions were
present in the recombinant proteins and were conserved
between MVV strains. Two sheep (G027 and 754N) reacted
against all three recombinant proteins. At the very
minimum therefore these sera recognised epitopes present
in the regions where the N and C terminal portions of EnvB
overlapped EnvA and EnvC respectively. Sera from sheep
848A only reacted with the EnvC fusion protein and sera
from sheep 2 failed to react with EnvA. It would appear
therefore that MVV-infected sheep can raise antibodies
against a minimum of three epitopes spread throughout
gpl35, that is one epitope in EnvC recognised by 848A, one
epitope probably in EnvB recognised by all sera except
848A and one epitope probably in EnvA recognised by all
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sera except 2 and 848A. This is the minimum number of
epitopes predicted by the data, but it may be an
underestimate.
The fusion proteins were therefore shown to contain
regions of immunological relevance as assessed by their
ability to react with antibodies from MVV-infected sheep.
As both experimentally and naturally infected sheep had
raised antibodies which were reactive with the fusion
proteins it is likely that the fusion proteins contained
epitopes which are conserved between different MVV
isolates, and which therefore may be functionally
significant in viral activity, in binding to a cellular
receptor for example or in post-receptor binding events.
Attempts to use these fusion proteins to raise
antisera which reacted with Env glycoprotein from MVV-
infected cells were unsuccessful. Since antisera from
infected sheep reacted with the recombinant protein it
would seem unlikely that the failure to detect anti-Env
specific antibodies after immunisation of rabbits and mice
with the fusion proteins was due to differences in the Env
sequences of the "natural" gpl35 and the fusion proteins.
It is also unlikely that the failure is due to the
predominantly unglycosylated nature of the Env fragments
as antisera can be raised to unglycosylated HIV gpl20
which react by western blotting with gpl20 purified from
infected cell lysates, and which can neutralise viral
infectivity (Putney e_t a_l. , 1986).
The immunised animals all raised a readily detectable
anti-pl response, which indicated that sufficient antigen
had been administered to elicit a response. EnvA and EnvB
are similar in molecular weight to pi, and EnvC is just
under half its size. All three would therefore be
expected to be present in sufficient quantities to act as
immunogens. However, pi appears to be highly immunogenic
and it is possible that the Env sequences were
intrinsically less so and that therefore more antigen
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would be required to elicit an Env-specific response.
It is possible that the response to pi detected in
the immunised animals represented the outcome of a
secondary immune response to a preciously encountered
antigen, rather than a primary response. Section 5.5
reports the detection of an anti-pl response in a rabbit
which had been immunised with a GST:EnvC fusion protein
preparation, but which had not been immunised with pi or a
pi fusion protein. This suggests that laboratory animals
may encounter pi proteins naturally, possibly as a result
of exposure to yeast. Although at the time of initial
immunisation with the pl:Env fusion proteins no anti-pl
response was detectable as shown by using pre-immunisation
sera from these animals, this does not exclude the
possibility of previous exposure. Consequently
immunisation with a pl:Env fusion protein may stimulate a
secondary immune response to the pi region of the fusion
protein, and the response elicited to the remainder of the
fusion protein may be low.
Hybrid VLPs have been used successfully as immunogens
(Adams e_t al. , 1987b; Gilmour e_t aX_. , 1989 ; Griffiths e_t
al. , 1991) but there are two possible reasons why they may
not have been effective in the experiments reported in
this results chapter. Higher doses of antigen may be
required to promote a fusion protein-specific response
than were available here. For example, in raising
antisera to the HIV-1 gpl20 V3 loop region in this system
rabbits were immunised five times with 500ug of VLPs,
estimated to contain 50ug of the HIV-specific polypeptide
(Griffiths e_t al^. , 1991). The low yields of the fusion
proteins in the experiments reported here precluded using
antigen at these concentration levels. Many fusion
proteins in the Ty-VLP system are now produced with a
factor Xa cleavage site between the pi and inserted
protein, allowing the foreign protein to be purified away
from the pi (Gilmour et^ a_l. , 1989) and this purified
-156-
protein can be used to boost the non-pl response of the
immunised animal. It has been discovered that this may be
essential for eliciting a strong antibody response to the
non-pl component of the fusion protein (Reyburn e_t a_l. ,
1992 (MVV Gag)) (I.Green (ovine tumour necrosis factor
alpha) Department Of Veterinary Pathology, University Of
Edinburgh, personal communication). As the fusion
proteins generated in the experiments reported in this
chapter did not contain a factor Xa cleavage site this
option could not be followed. However, given the
difficulties encountered in purifying the hybrid VLPs it
is likely that factor Xa cleavage would not have been a
viable option as the level of contaminating proteins was
so high that digestion with factor Xa would almost
certainly have led to considerable cleavage of these
cellular proteins, rendering purification of the cleaved
Env polypeptide impossible.
4.11 Summary
The yeast Ty-VLP expression system was used to
generate fusion proteins of pi with fragments of the MVV
env gene and the proteins were characterised. The Env
sequences markedly influenced the expression of the fusion
proteins and the assembly of the VLPs, but had no
obviously toxic effect on the cells. Although
glycosylation was shown to be either limited or negligible
the Env fragments were reactive with sera from MVV-
infected sheep and indicated that recognised antigenic
epitopes are present in at least three sites on gpl35.
Attempts to use the recombinant proteins as immunogens
were unsuccessful.
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5. The Generation And Characterisation Of Recombinant MVV
gp!35 Fragments - The Bacterial pGEX System
5.1 Introduction
Chapter 4 described the production of recombinant MVV
gpl35 fragments in the yeast Ty-VLP expression system.
Although expression of pl:Env fusion proteins was achieved
certain difficulties were encountered which could limit
the applications of these recombinant proteins, including
low yield, unsatisfactorily high levels of contaminating
yeast proteins and no detectable antibody response to the
gpl35 region of the fusion protein following immunisation
of mice and rabbits. In an attempt to overcome some of
these difficulties it was decided to express the env gene
fragments in an alternative system.
The E.coli pGEX expression system was chosen as it
possesses a number of features advantageous when
generating recombinant proteins for subsequent use as
immunogens. The fusion proteins produced in this system
are generally soluble in aqueous solution, they are
purified easily from lysed cells under non-denaturing
conditions by an affinity reaction and have been used
successfully as antigens (Smith & Johnson, 1988).
Although fusion proteins expressed in E.coli are not
usually glycosylated this was not expected to present a
major problem in terms of the antibody response.
Unglycosylated fragments of HIV gpl20 have been used
successfully as immunogens for the production of
neutralising antisera (Putney et al. , 1986).
The pGEX plasmids used to generate the fusion
proteins are shown in figure 5.1. The coding sequences
for the recombinant protein are inserted at the 3' end of
the glutathione S-transferase (GST) gene of Schistosoma
japonicum (Smith ej: a^L. , 1988) under the control of the
strong tac promoter (Smith & Johnson, 1988). The promoter
is repressed in the absence of the inducing agent (IPTG)
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Figure 5.1
The pGEXl Expression Vector
The pGEXl expression vector is shown in the diagram,
with the cloning site of each vector reproduced
underneath. Single restriction enzyme sites on the
plasmid are also marked. The protein cleavage sites for
thrombin and factor Xa in the sequences for pGEX2T and
pGEX3X respectively are shown.
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Pro Lys Ser Asp Pro Ara Glu Phe lie Val Thr Asp STOP
pGEXt CCA AAA TCG GAT CCC CGG GAA TTC ATC GTC ACT GAC TGA CGA TCT G
i 1 i ,
I I
BamHI Sma I EcoRI
thrombin
I ' 1 1
Pro Lys Ser Asp Leu Val Pro Arg-r-Gly Ser Pro Gly lie His Arg Asp STOP
pGEX2T CCA AAA TCG GAT CTG GTT CCG CGT GGA TCC CCG GGA ATT CAT CGT GAC TGA CTG
i i t i
I I
BarnHi Sma I fcoRI
factor Xa
i i
Pro Lys Ser Aso Leu lie Glu Gly Arg-*Gly lie Pro Gly Asn Ser Ser STOP




by the product of the lacl^ allele on the plasmid.
Transformants are selected by ampicillin resistance.
Each pGEX vector contains a BamHI site at the 3' end
of the gst gene and the reading frame at this cloning site
is different in each vector. pGEX2T and pGEX3X also encode
a thrombin cleavage site and a factor Xa cleavage site
respectively at the insertion site of the foreign sequence
(figure 5.1). These allow proteolytic cleavage of the
fusion protein into the carrier protein and the expressed
protein of interest.
Native GST protein is not sequestered into inclusion
bodies after production in transformed E.coli. Following
ultrasonic disruption of the cells the protein can be
purified by affinity binding to glutathione cross-linked to
agarose beads. Bound protein can be eluted in an excess of
reduced glutathione.
Proteins which have been successfully expressed in the
pGEX system include leukaemia inhibitory factor (Gearing e_t
a_l. , 1989), human pyruvate dehydrogenase Elalpha (iwayama
et al., 1991), a species-specific tegument protein of
Echinococcus multilocularis larvae (Frosch e_t a_l. , 1991),
part of the 77kDa merozoite protein of Babesia bovis
(Tetzlaff e_t aJL. , 1992), and the gag proteins of HIV-1,
HIV-2 and SIV (Mills e_t al. , 1992). The fusion proteins
have been successfully used as antigens (Frosch e_t a_l. ,
1991; Mills e_t al. , 1992 ; Tetzlaff e_t a_l. , 1992) and the
antisera raised all reacted with the relevant native
proteins. The B.bovis merozoite antigen has also been
shown to stimulate proliferation of T lymphocytes from
B. bovis-infected cattle (Tetzlaff e_t a_l. , 1992). Therefore
proteins expressed in the pGEX system have been shown to
resemble the native proteins in the immune responses which
they stimulate.
The GST expressed from the pGEX plasmids has a
molecular weight of 27.5kDA and fusion proteins with
overall molecular weights ranging from 32kDa to 84kDa have
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been expressed (Smith & Johnson, 1988). The major
technical problem encountered with the expression system is
low yields of proteins which contain highly hydrophobic
regions. These appear to lead to the formation of
insoluble fusion proteins and sequestration into
intracellular inclusion bodies.
The env gene fragments were excised from the pOGS-
based plasmids into which they had been cloned (chapter 4),
ligated into the appropriate pGEX plasmid and transformed
into E.coli JM83. Clones which contained an insert of the
correct molecular size were further screened by diagnostic
restriction digestion and analysed for recombinant protein
expression. The effect of expression of the fusion protein
on the growth of E.coli was monitored and the expression of
the fusion protein compared with production of native GST.
Serum from an MVV-infected sheep was used to confirm that
antigenically relevant MVV gpl35 fragments had been
expressed and the fusion proteins were used as immunogens
in rabbits and mice.
5.2 Generation Of Recombinant pGEX/Env Plasmids
The pOGS-based clones were chosen in preference to the
pTZ-based clones as a source of the env gene fragments in
order to minimise cloning difficulties caused by
contamination with plasmids during the purification of the
desired fragment (section 4.2). As the pOGS plasmids are
larger than pGEX (9.4kb and 4.9kb respectively) the
probability of contamination by pOGS plasmids during the
cloning procedure would be reduced.
The env fragments were excised from the recombinant
pOGS-based plasmids with BamHI, gel-purified and ligated
into the appropriate pGEX vector which had been digested
with BamHI and treated with CIP. In order to maintain the
env sequences in the correct reading frames envA was
inserted into the BamHI site of pGEXl and envB and envC
were separately inserted into the BamHI site of pGEX2T.
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The recombinant DNA was then transformed into competent
E.coli JM83.
484 colonies were screened for the envA fragment, of
which 13 hybridised to an erivA-specific probe by colony
hybridisation. The DNA from all 13 clones was screened by
restriction digestion and gel analysis. All 13 contained a
single insert of the expected molecular weight which could
be excised with BamHI. Digestion with Bgll was used to
determine orientation of the insert. pGEXl contains Bgll
sites at nucleotides 2009 and 4652 and envA contains a Bgll
site at nucleotide 565. Insertion of the envA fragment
into the BamHI site at nucleotide 914 of PGEXl in the 5' to
3' orientation results in predicted Bgll frgaments of 1476,
1759 and 2643 base pairs. Insertion of the fragment in the
opposite orientation results in a predicted restriction
pattern of 1575, 1660 and 2643 base pairs after digestion
with Bgll. All the clones analysed by Bgll restriction
digestion analysis had a restriction pattern consistent
with insertion of the envA fragment in the 3' to 5'
orientation. DNA from one clone was digested with BamHI
and then re-ligated in an attempt to generate recombinant
molecules containing the envA fragment in the 5' to 3'
orientation. The resulting DNA was used to transform
E.coli JM83 and of the 97 colonies screened 2 hybridised to
an envA-specific probe by colony screening. Both clones
contained a single insert of the expected molecular weight
which could be excised with BamHI, but in each case
restriction digestion analysis with Bgll demonstrated that
the envA fragment was inserted in the 3' to 5' orientation.
Therefore from a total of six separate ligations and
transformations no clone was obtained containing envA
inserted in the 5' to 3' orientation in pGEXl. Possible
reasons for this inability to obtain transformants which
contain a suitable recombinant pGEXl/envA plasmid are
considered in section 5.6.
32 colonies were screened for the envB fragment, of
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which 18 hybridised to an envB-specific probe by colony
screening. The DNA from 4 clones was screened by
restriction digestion and gel analysis. All 4 contained a
single insert of the expected molecular weight which could
be excised with BamHI. Digestion with EcoRV was used to
determine orientation of the insert. pGEX2T contains an
EcoRV site at nucleotide 4070 and envB contains an EcoRV
site at nucleotide 214. This results in predicted sizes
of 1979 and 3868 base pairs for an insert in the 5' to 3'
orientation and 2466 and 3381 base pairs for an insert in
the opposite orientation after EcoRV digestion. 2 of the
clones had a restriction pattern with EcoRV consistent with
3' to 5' orientation, one clone cut very poorly with EcoRV
and the digestion pattern of the remaining clone, gB52, was
consistent with insertion in the 5' to 3' orientation.
gB52 was therefore selected as the clone for expression of
the GST:EnvB fusion protein.
60 colonies were screened for the envC fragment of
which 34 hybridised to an envC-specific probe by colony
screening. The DNA from 4 clones was screened by
restriction digestion and gel analysis. All 4 contained a
single insert of the expected molecular weight which could
be excised with BamHI. Digestion with HincII was used to
determine orientation of the insert. pGEX2T contains
HincII sites at nucleotides 184, 1585 and 4137 and envC
contains a HincII site at nucleotide 216. This results in
predicted sizes of 966, 972, 984 and 2552 nucleotides for
an insert in the 5' to 3' orientation, and 887, 972, 1063
and 2552 nucleotides for an insert in the opposite
orientation after HincII digestion. 3 of the clones had a
HincII digestion pattern consistent with an insert in the
3' to 5' orientation while the pattern for one clone, gC53,
was consistent with insertion in the 5' to 3' orientation.
gC53 was therefore selected as the clone for expression of
the GST:EnvC fusion protein.
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5.3 Protein Expression From The pGEX/Env Clones in E.coli
Transformed cultures were induced under identical
conditions (section 2.17.2.2), the cells harvested and the
fusion proteins purified. Purified material from each
culture was separated by SDS-PAGE and the gel silver
stained. The results are shown in figure 5.2. There was
an obvious difference in the relative yields of GST,
GST:EnvB and GST:EnvC. The highest yields were obtained
for native GST and the lowest for GSTrEnvC. Native GST
migrated with an apparent molecular weight consistent with
the predicted molecular weight of 27.5kDa. The GST:EnvB
fusion protein migrated with an apparent molecular weight
of 59kDa and the GST:EnvG fusion protein migrated with an
apparent molecular weight of 45.5kDA. These were broadly
consistent with the predicted molecular weights of 61.7kDa
and 47.6kDa for the GST:EnvB and GSTrEnvC fusion proteins
respectively.
Contaminating bands were also visible in silver
stained gels. These varied slightly between preparations,
probably due to minor differences in steps in the
purification procedure such as lysis, affinity binding or
washing of the glutathione-agarose beads. A cluster of
bands migrating at approximately 30kDa were routinely
observed and are shown in the GSTrEnvB track in figure 5.2.
These possibly represent endogenous E.coli GST proteins
(eGST). In some preparations bands with apparent molecular
weights of 61kDa to 72kDa were also visible (data not
shown). Similar contaminating bands have also been
observed in GST:fusion protein preparations by other
authors (Tetzlaff et al., 1992).
It was not possible to estimate the protein
concentrations of the GST:Env fusion proteins by a dye
binding assay when the proteins were bound to the
glutathione-agarose beads, as poor results are obtained in
such assays when the proteins are in a particulate form.
Although an assay would have been feasible using eluted
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Figure 5.2
Purified native GST and GSTrEnv fusion proteins
Purified native GST and GSTrEnv fusion proteins were
separated on a 10% SDS-PAGE gel and detected by silver
staining. The native GST and GST:Env fusion protein




protein it would have been necessary to introduce various
estimations into the final calculation of fusion protein
yield, including the proportion of the protein either
uneluted or lost during elution, and the proportion of the
total protein represented by the fusion protein itself.
As such estimates could introduce large errors into the
final values obtained the approximate yields were simply
estimated from the silver stained gels, and were in the
range of ug/L for the GSTrEnv fusion proteins and mg/L for
GST.
Western blotting with serum from sheep 754N was used
to confirm that the fusion proteins contained gpl35-
specific sequences. Sheep 754N was experimentally
infected with MVV strain EV1 and sera from this sheep
reacts with gpl35 in MVV-infected cell lysates, and with
the pl:Env fusion proteins (section 4.8). The reactivity
of this serum with the GSTrEnv fusion proteins is shown in
figure 5.3. Although the relevant bands are difficult to
see clearly on the photograph of the blots (due to the
strong cross-reacting bands migrating with apparent
molecular weights similar to those of the fusion proteins)
specific reactivity of serum 754N with the fusion proteins
was demonstrated. The GSTrEnvB band migrates in the
expected position, just below a more heavily staining band
which is also detected by NSS. The GSTrEnvC band also
migrates in the expected position, just below a band
detected by serum 754N in the GST preparation. There was
no detectable reactivity of serum 754N with the native GST
protein despite overloading of this protein relative to
the fusion proteins, as determined by silver staining of a
gel (data not shown). A number of contaminating bands
were also detected by both the 754N sera and NSS. These
probably represent contaminating bacterial proteins to
which the sheep have raised antibody responses during
normal exposure to E.coli.
The fusion proteins could be successfully eluted from
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Figure 5.3
Reactivity of MW-infected sheep serum with GST;Env
fusion proteins
Purified GST and GST:Env fusion proteins were separated
on a 10% SDS-PAGE gel and blotted onto nitrocellulose.
Strips were developed with normal sheep serum (NSS) or
MVV-infected sheep serum (754N), @ 1 in 20 and anti-
sheep alkaline phosphatase @ 1 in 1000. The GST:Env
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the glatathione-agarose beads in the presence of an excess
of reduced glutathione. The relative levels of
contaminating proteins fell with sequential elution steps
leading to increased purity of the eluted protein, albeit
with a concomitant decrease in overall fusion protein
concentration (data not shown).
It is apparent that the yields of the fusion proteins
were considerably lower than the yields of native GST.
This appears to reflect a relative decrease in the
production of the fusion proteins when compared with the
native GST, rather than an indirect effect such as reduced
affinity of the GST region of the fusion protein for the
glutathione-agarose in the presence of Env fragments.
This is demonstrated in figure 5.4 in which crude extracts
of the various clones, obtained by pelleting cells from
induced cultures and resuspending these in PBS were
analysed by SDS-PAGE. The non-recombinant GST band is
clearly visible in a Coomassie-stained gel, but a band
corresponding in position to GST:EnvB is only barely
visible, and no discrete GST:EnvC band can be
distinguished. This suggested that expression of the
fusion proteins from the recombinant plasmids was less
efficient than expression of GST from the non-recombinant
pGEX plasmid alone.
5.4 Growth Characteristics Of E.coli Clones Transformed
With pGEX/Env
In order to determine if the low yields obtained for
the fusion proteins were a consequence of a toxic effect
of the constructs on the growth of E.coli a time-course of
cell growth after fusion protein induction was performed.
Triplicate cultures were induced when the optical
densities at 600nm (OD^qq) of the cultures were between
0.35 and 0.5, and growth of the cultures was monitored at
30 minute intervals for 3 hours. At the end of the time-
course a protein sample was analysed by SDS-PAGE and
-168-
Figure 5.4
Crude extracts from E.coli expressing native GST or
GST:Env fusion proteins
Crude extracts were made from cells expressing native
GST or GST:Env fusion proteins, separated on a 10% SDS-
PAGE gel and detected by Coomassie blue staining.
Native GST and GST:EnvB fusion protein bands are
indicated by arrows. The expected position of GST:EnvC
is indicated by a bracket.
-169-





silver staining to confirm that expression of the fusion
proteins had been induced (data not shown).
Figure 5.5 summarises the growth characteristics of
the different cultures. The clone transformed with the
non-recombinant pGEX plasmid continued to grow vigorously
after induction of GST but growth of clones gB52 and gC53
was dramatically reduced following protein induction.
This reduction in growth was apparent within one hour
post-induction and suggests that expression of the fusion
proteins has a toxic effect upon cell growth.
In an attempt to improve the yields of the
recombinant proteins cultures were induced at different
cell densities. The cultures were either induced at an
ODsoo 0.45 or of 0.6 to 0.7. After induction the
cultures were incubated for a further 3 hours, the cells
harvested and the fusion proteins purified. The purified
proteins from equivalent volumes of each culture were
analysed by SDS-PAGE. Figure 5.6 shows the result of
varying the cell density at which expression of the fusion
protein was induced. Expression of native GST from the
pGEX2T plasmid fell when the culture was induced at the
higher OD^qq reading but the opposite effect was apparent
for the GST:EnvB and GST:EnvC fusion proteins. Therefore
by varying the point in the growth curve at which fusion
protein expression is induced in these clones the yields
(per volume) of the recombinant proteins have been
significantly improved.
5.5 Immunisation Of Rabbits And Mice With GST;Env Fusion
Proteins
In an attempt to raise anti-gpl35 specific antisera
rabbits and mice were immunised with the fusion proteins.
Initially mice were immunised at 2 sites subcutaneously
with approximately 150ng of eluted fusion protein in
Complete Freund's Adjuvant. After 4 weeks the mice were
boosted with a similar amount of eluted fusion protein in
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Figure 5.5
Time course of cell growth after induction of E.coli
clones expressing native GST or GST:Env fusion proteins
0D600 values were monitored for cultures of E.coli
clones pGEX2T (ie transformed with the plasmid pGEX2T),





The effect of cell density on the induction of native
GST and GST:Env fusion proteins
Cultures of E.coli clones pGEX2T (ie transformed with
the plasmid pGEX2T), gB52 and gC53 were induced at the
0D600 values shown at the top of the figure. Purified
native GST and GSTrEnv fusion proteins were separated on
a 10% SDS-PAGE gel and detected by silver staining. The




Incomplete Freund'a Adjuvant, and this was repeated once
more for GST:EnvB. Rabbits were immunised at 2 sites
subcutaneously with 450ng of eluted fusion protein in
Complete Freund's Adjuvant - immunisations Bl and CI
(ig-plQ^), and this was repeated once for the GST:EnvC
fusion protein (lc2^ an<z twice for the GSTrEnvB fusion
protein (lg2> ^B3^» with the Complete Freund's Adjuvant
replaced by Incomplete Freund's Adjuvant. lug of the
appropriate uneluted fusion protein (that is where the
fusion protein was still attached to the glutathione-
agarose beads) in Incomplete Freund's Adjuvant was then
used to boost the immune response in each rabbit (Ib4>
ZC3^ *
Only a limited number of tail bleeds can be obtained
from a mouse and therefore the rabbits alone were screened
initially for a gpl35-specific response. When a strongly
positive anti-gpl35 response was obtained from the rabbits
screening of the mouse sera would follow. The fusion
proteins had not been cleaved into GST and Env regions
therefore to distinguish anti-EnvB/EnvC responses from
anti-GST responses the sera were screened against the
yeast-derived pl:Env proteins. The sera were also
screened against native GST to determine whether a
response had been elicited to the "carrier" protein. The
reactivity of the sera against protein blots of MVV-
infected cell lysates was also analysed.
Figure 5.7a shows that the sera from the immunised
rabbits at a dilution of 1 in 100 reacts with a band on a
western blot of an eluted GST preparation which had a
molecular weight consistent with that of GST. Sera from
rabbit 216 which was immunised with the GSTrEnvC antigen
also recognised a band of unknown identity with an
apparent molecular weight of approximately 68kDa.
Figure 5.7b-d shows the results obtained after
western blotting of pi, pl:EnvB and pl:EnvC with sera from
the immunised rabbits 11 days after Ig^ and 1^3. The
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Figure 5.7
Reactivity of sera from rabbits immunised with GST:EnvB
and GST:EnvC fusion proteins
Purified proteins were separated on a 10% SDS-PAGE gel
and blotted onto nitrocellulose. Strips were developed
with normal rabbit serum (NRbS), rabbit serum 215
(Rb215) (immunised with GST:EnvB) or rabbit serum 216
(Rb216) (immunised with GST:EnvC), all @ 1 in 100, or
rabbit anti-VLP serum (Rbl94) @ 1 in 1500, followed by
anti-rabbit alkaline phosphatase @ 1 in 1000. The
relevant bands are indicated by arrows.
a blot of purified native GST
b blot of purified plrEnvB
c blot of purified pl:EnvC

























results with rabbit serum 194 (the polyclonal rabbit anti-
VLP serum) show that pi was loaded in excess on the blots
in comparison to pl:EnvB and pl:EnvC. Normal rabbit serum
did not react with any of the antigen preparations. Serum
from rabbit 215 which was immunised with the GSTrEnvB
preparation reacted with plrEnvB but showed no detectable
reactivity with pi alone. Rabbit 215 therefore had raised
antibodies specific to the EnvB region of the fusion
protein. No reactivity was detected with the gpl35 on a
western blot from an MVV-infected cell lysate (data not
shown).
When the serum from rabbit 216 (which was immunised
with the GSTrEnvC fusion protein) was screened 14 days
after Iq2 it was found to be strongly reactive with pi,
suggesting possible exposure of the rabbit to yeast
proteins. The same serum was also faintly reactive with
pl:EnvC but given the cross-reactivity observed with pi
alone this could not be considered as gpl35-specific (data
not shown). When serum from the same rabbit was screened
11 days after the anti-pl response had decreased, and
no band is visible on the pi blot in figure 5.7d. No
reactivity was apparent with pl:EnvC (figure 5.7c) or
with the gpl35 on an MVV-infected cell lysate (data not
shown). It was concluded that rabbit 216 had not mounted
a significant humoral immune response to the EnvC portion
of the fusion protein. At the time of this negative
screening rabbit 216 had a respiratory infection and had
developed a large solid mass under its jaw. It was
therefore decided that euthanasia was the most appropriate
action for this animal.
Rabbit 215 was again boosted with uneluted GST:EnvB
and all the mice were boosted with the appropriate
uneluted fusion protein. Immunisation of a new rabbit
with GSTrEnvC was also initiated. The results of these




This chapter describes the successful generation of
clones which express the envB and envC regions of the MVV
env gene as fusion proteins with GST. Expression of the
fusion protein from these clones has been analysed and
conditions determined which improve the yield of these
proteins. The proteins have also been employed as
immunogens to generate Env-specific antibodies.
Although GST:EnvB and GST:EnvC fusion proteins were
successfully expressed the yields of these were low
compared with the native GST protein. The poor yields
appeared to be predominantly a consequence of low
expression of the fusion proteins, rather than a
purification problem such as sequestration of the fusion
protein into inclusion bodies or steric hindrance of
binding of the GST moiety of the fusion protein to
glutathione-agarose. The barely detectable levels of the
fusion proteins in crude cell lysates indicated that the
induced cells only expressed the fusion proteins to a
limited extent and the growth curves for induced cultures
suggested that expression of the fusion proteins had a
toxic effect upon E.coli growth. This is in contrast to
the results obtained with S.cerevisiae expressing pl:Env
fusion proteins, in which yields of the fusion proteins
were low, but this was not a consequence of any detectable
toxic effect of the fusion proteins upon cell growth.
This implies that the toxicity of the env-encoded regions
of the fusion proteins is very dependent on the cell type
in which the protein is expressed.
It may be possible to increase the yields of the
fusion proteins from clones gB52 and gC53 by altering
certain conditions. The data presented in this chapter
clearly shows that the yields can be improved by inducing
the cultures at a relatively high cell density. As the
fusion proteins appear to exert a toxic effect upon cell
growth it is advantageous to induce expression of the
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fusion proteins when the number of cells present in the
culture is high, as this will lead to the greatest
production of fusion protein in the absence of effective
cell division. It is interesting that the opposite trend
was observed for the native pGEX plasmid, suggesting that
for proteins which are not toxic the greatest yields can
be obtained by inducing the cultures at a relatively low
cell density, and allowing the cells to grow and divide
while expressing protein.
It may be possible to increase the yields of the
fusion proteins by transforming the recombinant plasmids
into a different strain of E.coli. In comparative studies
using pGEX-based plasmids expressing the human 68kDa (Ul)
ribonucleoprotein antigen (Frorath £t al. , 1991) or rat
interleukin-6 (Frorath et a_l. , 1992) the highest
expression of the fusion proteins in each case was
observed in E.coli strain LE392. Although E.coli strain
JM83 was not used in these studies this may be a means by
which expression of the GST:EnvB and GST:EnvC fusion
proteins could be improved. The authors presented no data
on the magnitude of the differences in yield between the
strains, or the mechanism for the variation.
The yields of the fusion proteins may also be
affected by the concentration of IPTG used to induce the
cultures. In contrast to the O.lmM concentrations used to
induce the fusion proteins reported in this chapter other
workers have used higher levels of the inducing agent,
ranging from 0.5mM (Frorath e_t a_l. , 1991; Frorath e_t a_l. ,
1992) to lOmM (Frosch e_t a_l. , 1991; Iwayama £jt a_l. , 1991).
The fusion protein yields may also be influenced by the
length of time for which the cultures are induced. Due to
lack of time it was not possible to investigate these
aspect of the fusion protein expression.
The reactivity observed for sheep serum 754N with the
GST:EnvB and GST:EnvC fusion proteins by western blotting
confirmed that these fusion proteins contained MVV
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epitopes against which infected sheep raise antibodies.
Although it would be possible to repeat the studies of
sera from infected sheep which were detailed in section
4.8 the GST:Env fusion proteins are probably less suited
to this work than the pl:Env fusion proteins. This is
because there is currently no anti-GST antisera available
and therefore it is difficult to confirm that different
blots all contain sufficient and equivalent amounts of the
GST/GST:Env fusion proteins. Although this can be checked
by silver staining this is not as satisfactory as being
able to assay the amount on the actual blot which is to be
tested, as is possible when the anti-VLP antisera is used
with the pl:Env fusion proteins. An indirect check by
silver staining has the disadvantages that it relies on
precision when loading the relevant samples on separate
gels (or different parts of the same gel) and it may be
difficult to predict from a silver stained gel if
sufficient antigen has been loaded to be detectable by
western blotting.
Immunisation of a rabbit with GST:EnvB resulted in
the production of anti-EnvB antibodies, as shown by their
ability to react with pl:EnvB on a western blot. The
time-scale of production was long, and the response did
not appear to be strong. This was probably a consequence
of the relatively low doses of the fusion protein used to
immunise the rabbit. In other experiments it has been
reported that rabbits have been immunised with lOOug of
fusion protein, of which approximately 30% was the non-GST
moiety (Oettinger e_t aj.. , 1992) in order to raise specific
antisera. This is approximately fifty times greater than
the estimated amount of purified EnvB with which rabbit
215 was immunised in the results reported in this chapter.
No reactivity was observed against gpl35 on a western blot
of an MVV-infected cell lysate. This was possibly due to
a combination of the low titre of the rabbit serum and the
relatively low levels of this antigen on the blot.
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Alternatively the rabbit may only have raised detectable
antibodies against a very limited number of epitopes at
this point in its immune response. There is a possibility
that the epitopes could be masked by carbohydrate residues
in the cell-derived MVV gpl35, or that they may be
epitopes which vary between MVV isolates. DNA sequencing
of envB has shown areas of high amino acid variability
between different isolates (chapter 3). It is likely that
with further immunisations the response to the EnvB region
of the fusion protein will increase and under such
circumstances it would be expected that reactivity with
MVV gpl35 from infected cells would be observed.
The failure to raise rabbit antisera specific to EnvC
may also be a consequence of the low doses of the
immunogen, especially as EnvC forms a smaller percentage
of the total mass of the fusion protein than EnvB (42% and
55% respectively). However the results obtained with
GST:EnvB suggest that it will be possible to elicit an
antibody response to the fusion protein, especially if
uneluted fusion protein is used as the immunogen. This
has been shown to be an efficient mechanism for provoking
an antibody response (Oettinger e_t a_l. , 1992) in this
system. This may be because by using the uneluted
material decreases in final yield due to non-elution of
some of the fusion protein, dilution of the sample during
elution, and losses during any subsequent concentrating
procedures (eg acetone precipitation of the protein) are
minimised. Additionally the fusion protein bound to the
glutathione-agarose beads may act as a polymeric antigen.
Polymeric antigens are generally more immunogenic than
monomeric antigens, and therefore may stimulate a stronger
antibody response.
Sera from both rabbit 215 and rabbit 216 reacted with
a band of the expected molecular weight for native GST by
western blotting. However, this does not necessarily
indicate that these animals had been immunised with
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sufficient of the GST:Env fusion proteins to stimulate an
immune response to the GST portion of the fusion protein.
The fusion protein preparations which were used to
immunise the animals usually contained contaminating
proteins with molecular weights of approximately 30kDa,
which were believed to represent the endogenous GST
protein (eGST) produced by E.coli. It is possible that
the anti-GST response observed in the immunised rabbits
was originally stimulated by eGST protein, but that there
was enough conservation of epitopes between this and the
native GST encoded by the pGEX plasmid to allow cross-
reactivity of the antisera on a western blot.
Although no data was available on the response of the
mice to immunisation with the GST:Env fusion proteins
whilst writing this thesis it is likely that if a response
can be stimulated in rabbits it will also be possible to
use the fusion proteins as effective immunogens in mice.
If subsequent tail bleeds from the immunised mice reveal
an anti-Env specific response of good titre the spleens
from these mice will be used for the production of
hybridomas to generate monoclonal antibodies. In order to
maximise the number of clones which produce anti-Env
antibodies the mice will be boosted intravenously 3 to 4
days prior to sacrifice. The GSTrEnvB and GSTrEnvC fusion
proteins each contain a thrombin cleavage site and if
successful cleavage can be achieved (this has not been
attempted in the work presented in this thesis) the
cleaved material will be used for this final immunisation.
If sufficient quantities of cleaved material cannot be
obtained the mice will be immunised with eluted uncleaved
fusion protein.
The data presented in this chapter suggests that the
pGEX system will be suitable for the expression and
purification of proteins which can be used to stimulate a
response to MVV gpl35. Such antisera will be used in a
variety of functional and mapping studies (see chapter 7).
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For this purpose the pGEX expression system has a number
of advantages over the yeast Ty-VLP expression system.
Although the yields of the GST:EnvB and GST:EnvC fusion
proteins are relatively low (ie ug/L rather than the mg/E
observed for the native GST) they are at least comparable
with the yields obtained in the Ty-VLP expression system
for the same gpl35 regions. However the GST-based fusion
proteins are of much higher purity than the pl-based
fusion proteins and can be produced more rapidly and using
simpler and more reliable techniques.
The most obvious problem encountered in the work
reported in this chapter was the inability to generate a
pGEXl:envA-specific clone. Of 484 colonies screened 13
contained a recombinant pGEXl plasmid in which the envA
fragment had been inserted in the 3* to 5' orientation,
and attempts to reverse the orientation by excising the
fragment and religating the molecules were unsuccessful.
Calculating from a Poisson distribution (see appendix 2)
the observed difference between 13 clones in one
orientation, and no clones in the opposite orientation is
significant at the 0.1% level (d=3.6). This suggests that
in the cloning system used in these experiments there was
selection against clones which contained the envA fragment
in the 5' to 3' orientation.
Such a result may suggest that the GST:EnvA fusion
protein is toxic to the E.coli JM83 cells into which the
plasmid was transformed. Although expression of the
pl:EnvA fusion protein did not affect growth of
S.cerevisiae (section 4.5) the data presented in figure
5.5 of this chapter demonstrates that toxicity of the env-
encoded sequences in one expression system cannot
necessarily be used to predict toxicity in another system.
Expression of the plrEnvB and pl:EnvC fusion proteins did
not have any significant effect on the growth of
transformed S.cerevisiae but expression of the GST:EnvB
and GST:EnvC fusion proteins markedly affected the growth
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of E.coli JM83. Therefore it cannot be concluded that the
lack of an obviously toxic effect of pl:EnvA on the growth
of S.cerevisiae would necessarily imply a non-toxic effect
of expression of GST:EnvA on the growth of E.coli JM83
transformants.
It may therefore be postulated that the inability to
generate any clones transformed with a recombinant pGEX
plasmid containing the envA sequence in the 5' to 3'
orientation may be a consequence of extreme toxicity of
the recombinant protein, such that cells which contain
such a plasmid fail to grow on the selection plates. In
order for this to be the mechanism leading to the failure
to isolate the required clones it is necessary to suggest
that there is a degree of constitutive expression of the
fusion protein. It is therefore important to consider
why E.coli clones containing plasmids into which the envA
sequence has been inserted in the 5' to 3' orientation
with respect to a promoter have been successfully
generated in other experiments.
In chapter 3 envA sequences derived from various MVV
preparations were inserted into the pTZ plasmids and used
to transform E.coli JM101. The pTZ vectors are not used
as a fusion protein expression system but they do have the
potential to express low levels of a fusion protein. The
foreign DNA is inserted into the beta-galactosidase gene
which is inducible by IPTG and it is possible that foreign
DNA inserted in the correct reading frame could encode low
levels of protein. Although in all cases the envA
sequences were found to be in a 3' to 5' orientation with
respect to the promoter when initially ligated using the
BamHI site, the orientation could be reversed by using a
unidirectional cloning strategy. This indicates that
although there may be an initial bias towards plasmids
with a 3' to 5' orientation of the inserted fragment this
can be overcome fairly readily.
In chapter 4 the same envA sequence used in the pGEX
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experiments was successfully inserted in the 5' to 3'
orientation into a pOGS plasmid, and used to transform
E.coli JM83.
These results indicate that the failure to obtain a
pGEX-based plasmid in which the envA fragment was inserted
in the correct orientation may be the result of the
combination of the pGEX plasmid and the bacterial host.
Successful cloning of the envA fragment 5' to 3' in the
pOGS expression vector into E.coli JM83 may suggest that
the sequences encoded by envA are not toxic to E.coli when
present as fusion proteins with pi. Alternatively there
may be no expression of the plrfusion protein in E.coli
if the yeast promoter on the pOGS plasmid fails to
function in the bacterial host.
The successful insertion of envA sequences into pTZ
plasmids, and transformation of E.coli JM101 could suggest
that the JM101 strain tolerates the envA-encoded sequences
better than the JM83 strain of E.coli. However, when
inserting the envA sequence into pTZ plasmids no effort
was made to ensure that the coding sequence was inserted
in the correct reading frame. Therefore the clones
isolated which contained the envA sequence in the 5* to 3'
orientation may simply reflect the insertion of the
sequence in a reading frame in which it does not encode
the EnvA protein, and hence it does not have a toxic
effect on cell growth.
If the failure to isolate an appropriate pGEX-based
envA clone of E.coli is due to extreme toxicity of the
fusion protein (or theoretically the mRNA encoding the
protein) this must imply some degree of constitutive
expression of the fusion protein sequences from the
plasmid. This is perhaps surprising, as the product of
the laclq allele of the plasmid should function as a tight
repressor of expression from the tac promoter of the
plasmid. Constitutive expression from the promoter would
indicate some breakdown in this control. In experiments
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in which the entire MVV EV1 env gene was inserted into the
pRc/RSV plasmid and then transformed into E.coli JM83 and
JM101 it was found that in 80 clones which contained the
env gene the orientation of the gene was 3' to 5' in all
cases (R.G.Dalziel, Department Of Veterinary Pathology,
University Of Edinburgh, personal communication)
suggesting selection of clones which could not encode the
Env protein. This occurred even though no constitutive
expression was anticipated from this vector. As the full-
length env gene also encoded the gp46 region of Env it
cannot be inferred from this data that the envA region was
responsible for the failure to obtain any clones which
contained the env gene in the 5' to 3' orientation. It is
also not possible to determine from the data in this
chapter which region of envA was responsible for the
observed failure to obtain any clones in which the gene
fragment was inserted 5' to 3'. The region which encodes
the first 40 amino acids of Rev is not a likely candidate,
as Rev expression has been shown to have little toxic
effect in this system (M. Fotheringham, Department Of
Veterinary Pathology, University Of Edinburgh, personal
communication). It is also unlikely that the region of
EnvA which overlaps EnvB ie amino acids 247 to 311 is
responsible for the presumed toxicity, as envB was
successfully cloned in the 5' to 3' orientation into
pGEX2T. The hydrophobic signal sequence contained in EnvA
is a possible candidate, particularly as strongly
hydrophobic regions adversely affect the success of fusion
protein expression in the pGEX system but to address this
problem more fully it would be necessary to generate
truncated envA fragments and attempt to clone these into
the same expression system.
It may be possible to increase the chances of
obtaining a clone which can encode GST:EnvA by altering
the manner in which the recombinant plasmid is generated.
As shown in figure 5.1 pGEXl contains a BamHI site and an
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EcoRI site at the cloning site at the 3' end of the gst
gene. There are no BaraHI or EcoRI sites in the envA
sequence. By redesigning the 3' PCR primer for envA, such
that the BamHI site is replaced by an EcoRI site and then
generating a PCR product in the same way that was used to
obtain env fragments for insertion into the pOGS vectors
(section 4.2) an envA fragment could be created with a
BamHI site at its 5' end and an EcoRI site at its 3' end.
If the pGEXl was similarly digested prior to ligation with
envA this would ensure that the envA fragment could only
be ligated into the plasmid in the 5' to 3' orientation.
Although the number of clones containing such a
recombinant plasmid would be expected to be very low given
the inferred toxicity of such a construct, screening for
such clones should be greatly simplified by the reduced
numbers of transformants obtained after a ligation and
transformation and therefore the likelihood of isolating
an appropriate clone would be improved.
5.7 Summary
The bacterial pGEX system was used to generate fusion
proteins of GST with the EnvB and EnvC regions of MVV
gpl35. The expression of these fusion proteins was shown
to be toxic to the host cells but fusion proteins could be
produced which were of at least comparable yield to those
expressed in the Ty-VLP system, and of greatly improved
purity. The GST:EnvB fusion protein was an effective
immunogen in the production of a polyclonal anti-EnvB
response and by increasing the doses of the GST:EnvC
fusion protein it is anticipated that this will also prove
to be an effective immunogen. Attempts to obtain a clone
which expressed a GST:EnvA fusion protein were
unsuccessful, but alterations in the cloning strategy may
overcome this problem.
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6. Functional Studies Of MVV gp!35 Using Recombinant gp!35
Fragments
6.1 Introduction
There is currently little information available on
the role of different regions of gpl35 in the life cycle
of MVV. It is not known for example which regions of
gpl35 bind to the cellular receptor(s), whether sequences
within gpl35 are important in cell-cell fusion and if
neutralising antisera act by blocking gpl35-receptor
interactions, blocking fusion or perhaps by some other
mechanism.
The lentivirus for which there is the most
substantial amount of data on the relationships between
the structure of the external envelope glycoprotein and
its functions is HIV. Some of this data was briefly
discussed in section 1.14 and the most apparent conclusion
to be drawn is that many different regions of gpl20
interact functionally within this molecule. Although a
detailed discussion of the HIV gpl20 literature cannot be
attempted in this chapter a brief description of some of
the most salient features will be presented, as this well-
characterised molecule may indicate possibly fruitful
lines of investigation for MVV gpl35.
A major role of HIV gpl20 is interaction with CD4,
the primary cellular receptor for HIV (McDougal e_t al. ,
1986). Antibodies to the amino acid region 397-439 of
HIV-1 gpl20 block binding to CD4 (Lasky e_t al., 1987) and
this may represent the protein-protein interaction site of
the two molecules. However alterations to amino acids 363
and 437 (Kowalski e_t al. , 1987) and 257, 368 and 370
(Olshevsky e_t a^l. , 1990), and deletion of the C-terminal
44 amino acids of gpl20 (Linsley ^_t a_l. , 1988) also
influence gpl20/CD4 binding. A role for amino acids
between residues 42 to 129 of HIV gpl20 has also been
identified (Syu et al., 1990). Therefore the interaction
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of gpl20 with its major ligand appears to be dependent on
a number of residues spread throughout the glycoprotein,
probably as a consequence of the three dimensional
configuration of the molecule.
This multiple-site interplay of residues in the
function of gpl20 is not restricted to its interaction
with CD4. Regions critical for the interaction of gpl20
with gp41 have been identified in one study in the N-
terminal 31 amino acids of gpl20 (ivey-Hoyle e_t a_l. , 1991)
and other reports have shown an involvement of amino acids
36 to 45 and amino acids 491-501 (Helseth e_t al. , 1991).
Virus neutralisation can be achieved by antisera
directed against epitopes which are not involved in the
interaction with CD4, in particular the PND which lies
within the V3 loop formed by the cysteine residues at
positions 296 and 331 (Goudsmit e_t al. , 1988).
Mutations within different regions of gpl20 have been
shown to "compensate" for one another in conferring
infectivity on a HIV clone. It was reported that a non¬
infectious clone which contained a mutation at residue 267
of gpl20 was rendered infectious by a subsequent
spontaneous mutation at residue 128 (Willey £t a_l. , 1988).
Following in vitro mutagenesis of this second residue
(resulting initially in a non-infectious clone) a further
infectious clone was subsequently isolated with a mutation
at residue 308, which lies within the PND (Willey e_t al,
1989). This suggested the interaction of at least three
regions in a critical early event in HIV infection.
In order to begin to investigate the potential roles
of different regions of MVV gpl35 the recombinant proteins
described in chapters 4 and 5 were generated and
characterised. Initially it had been anticipated that
antisera raised against these recombinant proteins would
be used to investigate the roles of different regions of
gpl35. Due to the technical difficulties described
previously suitable antisera were not available to
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undertake this work at the time of writing. However the
recombinant proteins themselves were employed in attempts
to begin to relate function to different regions of gpl35.
Although work with HIV gpl20 has shown that residues
throughout the protein may interact functionally during
viral infection of a cell, useful data has also been
obtained using fragments of the glycoprotein. For
example, proteolytically cleaved gpl20 has been used
successfully to investigate regions of gpl20 which bind to
CD4 (Nygren e_t al. , 1988). Truncated versions of gpl20
generated in a vaccinia virus expression system have also
been used for similar purposes (Linsley e_t al. , 1988).
In an attempt to investigate the interaction of MVV
gpl35 with cellular molecules the recombinant Env fusion
proteins generated in the yeast Ty-VLP expression system
(chapter 4) were used in a variety of tests. The
recombinant pl:Env fusion proteins were used in preference
to the GST:Env fusion proteins (chapter 5) because no
pGEXl:envA clone had been successfully generated at the
time of writing, and because the availability of an anti-
pi antiserum formed the basis of the detection system in
certain of the experiments. These studies involved
attempting to block infection in vitro with the
recombinant proteins, detection of interactions with
cellular molecules by binding the fusion proteins to
intact cells and cell lysates, and analysing possible
interactions with MHC class II molecules, which have been
identified as a component of a cellular receptor for MVV
(Dalziel e_t a_l. , 1991).
6.2 The Interaction Of The pi;Env Fusion Proteins With
Fixed Skin Cell Culture Monolayers
In order to investigate if any of the pl:Env fusion
proteins interact with a cellular molecule experiments
were performed in which the fusion proteins were added to
fixed cell monolayers. The aim of these experiments was
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to determine if specific binding of one or more of the
pl:Env fusion proteins could be detected as this would
indicate that a possible binding site for a cellular
molecule was present within the particular region of
gpl35.
The cell monolayer was fixed using ice-cold acetone
in PBS as cells fixed by this method maintain the
antigenicity of surface markers. The fusion proteins were
added to the cells under non-denaturing conditions to
increase the probability of physiologically relevant
interactions between the various cellular and non-cellular
molecules.
The fixed 848 skin cell monolayers were incubated at
4°C for 16 hours with a 1 in 100 dilution of the peak
fractions from sucrose gradient purification of the pi or
pl:Env fusion proteins. Using a standard dilution of the
peak fractions resulted in a large relative excess of pi
protein in the pi control compared with the pl:Env fusion
proteins. This was demonstrated by SDS-PAGE and silver
staining (data not shown). The monolayers were developed
with either polyclonal rabbit serum 194 (anti-VLP) or
normal rabbit serum (NRbS) and a donkey anti-rabbit FITC
conjugate. After washing the monolayers were examined by
fluorescence microscopy.
As a control for the fixation and washing procedures
and the anti-rabbit FITC conjugate, cytospins of ovine
efferent lymphocytes were stained with NRbS or rabbit
anti-MHC class II serum. Approximately 15-20% of the
efferent lymphocytes were stained by the anti-MHC class II
serum, as expected.
There was little non-specific reactivity of the anti-
VLP serum (figure 6.1a) or NRbS (figure 6.1b) with the 848
skin cells alone. There was also very little reactivity
of NRbS with skin cells pre-incubated with pl:EnvA (Figure
6.2). Similar low reactivity of the NRbS was observed
when the cells were pre-incubated with the pi, plrEnvB or
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Figure 6.1
Immunofluorescence of 848 skin cells incubated with
normal rabbit serum or rabbit anti-VLP serum
Acetone fixed 848 skin cell monolayers were incubated
with rabbit anti-VUP serum (a) or normal rabbit serum, @
1 in 250. Staining was developed using an anti-rabbit




Immunofluorescence of 848 skin cells incubated with
Ei :EnvA and developed with normal rabbit serum
Acetone fixed 848 skin cell monolayers were incubated
with sucrose gradient purified pl:EnvA. Staining was
developed using normal rabbit serum @ 1 in 250 and anti-
rabbit FITC conjugate @ 1 in 200.
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pl:EnvC preparations (data not shown).
However, as shown in figure 6.3a-d a very different
pattern of staining is apparent when cells pre-incubated
with pi or the pl:Env preparations were stained using
rabbit serum 194. A very high level of particulate
staining was observed. This was so intense that great
difficulties were encountered in obtaining photographs in
which the cellular morphology could be clearly seen. This
is a consequence of an automatic exposure meter on the
camera used to record these results. For monolayers such
as the NRbS controls a long exposure is set and
consequently the cells are visible on these prints. Where
high levels of staining are present a short exposure is
selected. Unfortunately this results in only the intense
staining becoming visible, and is too short for the cells
themselves to be distinguishable on the photographs.
Examination of the same fields by light microscopy
demonstrated that the general cellular appearance had not
been altered by the addition of the pi or pl:Env fusion
proteins (data not shown).
The high level of particulate staining was noticeable
for pi and all the pl:Env fusion proteins, but was
especially marked for pi and plrEnvA. The data suggests
the presence of one or more species in the gradient
purified fractions which can interact with both the fixed
cells and the anti-VLP serum. As this staining is most
marked for pi and plrEnvA it suggests these preparations
contain the highest levels of the appropriate molecule(s).
As all the preparations including pi alone resulted
in high level staining of the monolayers it was not
possible to determine if there was a specific interaction




Immunofluorescence of 848 skin cells incubated with
pl/pl:Env and developed with anti-VLP serum
Acetone fixed 848 skin cell monolayers were incubated
with sucrose gradient purified pl:EnvA (a) or pl:EnvB
(b). Staining was developed using rabbit anti-VLP serum




Immunofluorescence of 848 skin cells incubated with
pl/pl;Env and developed with anti-VLP serum
Acetone fixed 848 skin cell monolayers were incubated
with sucrose gradient purified pl:EnvC (c) or pi (d).
Staining was developed using rabbit anti-VLP serum @ 1
in 250 and anti-rabbit FITC conjugate @ 1 in 200.
-194-
 
6.3 The Interaction Of The plrEnv Fusion Proteins With
Skin Cell Hysates
In the report suggesting an involvement of the MHC
class II molecule as a component of the cellular receptor
for MVV (Dalziel e_t a_l., 1991) an interaction was
initially demonstrated in vitro, between MVV and cellular
proteins by a virus overlay protein blot assay (VOPBA)
(Boyle et a_l. , 1987). In this system a protein blot of a
lysate from a susceptible cell line was incubated with
MVV. The complex of cellular components and virus was
then localised using an anti-MVV polyclonal antiserum.
This putative cell-virus interaction was therefore
maintained even where the cellular component was present
in a denaturing system.
The plrEnv fusion proteins were used in a similar
system to determine if any of the recombinant gpl35 sub-
regions could be shown to interact with cellular molecules
in the same way as observed with intact virus in the
VOPBA. This potentially could act as a means of
identifying regions of gpl35 which interact with cellular
molecules.
848 skin cells were lysed when just sub-confluent and
the cellular proteins were separated by SDS-PAGE and
blotted onto a nitrocellulose membrane. Membrane strips
were incubated at 4°C for 18 hours with the peak fractions
from sucrose gradient purified pi or pl:Env preparations,
pi was added to the strips at a dilution of 1 in 50, and
the plrEnv fusion proteins were added at 1 in 10. At
these dilutions the pi protein was present in excess in
the pi control (data not shown). The strips were
developed with rabbit anti-VHP serum followed by an anti-
rabbit alkaline phosphatase conjugate. As a control
strips from a blot of pi alone were developed in the same
system, and the pi band was observed as expected (data not
shown).
Figure 6.4a shows the results of this experiment. A
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Figure 6.4
Western blot of an 848 cell lysate, incubated with
pl/pl:Env fusion proteins
Proteins from an 848 skin cell lysate were separated on
a 5-15% SDS-PAGE gel and blotted onto nitrocellulose.
Strips were incubated with pi or pl:Env fusion protein
preparations and developed using rabbit anti-VLP serum @
1 in 1500, and anti-rabbit alkaline phosphatase @ 1 in
1000. The relevant bands are indicated by arrows.
Molecular weight standards (kDa) are shown at the left
hand side of the figure.
Panel a - incubation with purified preparations.
Panel b - incubation with crude or purified
preparations.
Key
(P) sucrose gradient purified preparations
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band is visible with an apparent molecular weight of 24kDa
when the cell lysates are incubated with each of the
pl:Env preparations, but not after incubation with sucrose
gradient purified pi alone. This suggested either that
each of the regions of gpl35 represented by the fusion
proteins could bind to a cellular molecule, or that a
contaminant present in the pl:Env preparations but not in
the purified pi alone could bind to a molecule in the 848
cell lysate.
In order to investigate the possibility of
comtaminants binding the experiment was repeated using a
crude preparation of pi protein. The cells from an
induced culture of transformant pp8.1 were harvested and
processed as normal up to the stage of centrifuging the
cell lysate onto a 60% sucrose cushion. This preparation
was stored at -20°C, without any subsequent sucrose
gradient purification. Silver staining of an SDS-PAGE gel
demonstrated extensive contamination of the sample with
non-pl yeast proteins (data not shown).
In figure 6.4b it can be seen that pre-incubation of
the strips with the crude pi preparation results in
detection of a band of the same molecular weight as that
observed when the strips are pre-incubated with pl:EnvA.
This demonstrates that the band observed in figure 6.4a is
the result of an interaction with a yeast-derived
contaminant. The results from these experiments therefore
do not demonstrate a detectable reactivity of the Env
regions of the fusion proteins with cellular molecules
present on the protein blots of 848 cell lysates.
6.4 Interaction Of The pi:Env Fusion Proteins With MHC
Class II Molecules
From the original description of an interaction
between MHC class II and MVV (Dalziel e_t a_l. , 1991) it can
be inferred that MVV can interact with class II when this
is denatured (as in the VOPBA) or when the three
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dimensional structure is relatively undisturbed (as in the
class II antigen-binding ELISA). The pl:Env fusion
proteins were used in both types of assay to determine if
they displayed any detectable specific interaction with
MHC class II.
Blots were made of immunopurified ovine MHC class II
antigen and the empty sites blocked. pi or pl:Env fusion
protein preparations were added to the blots as described
in section 6.3, and developed in the same way. The blots
were also incubated with polyclonal rabbit anti-MHC class
II antiserum, to confirm that the blots were positive for
class II.
MHC class II was detectable on the blots using the
polyclonal anti-MHC class II antiserum. The rabbit anti-
VLP serum was reactive with a blot of purified pi. No
bands were detectable with the anti-VLP serum after
incubation of the MHC class II blots with the pi or pl:Env
preparations (data not shown). Therefore no significant
binding of the recombinant gpl35 proteins to MHC class II
was detectable in this assay system.
In order to determine if an interaction could be
observed between the pl:Env fusion proteins and non-
denatured MHC class II molecules two variations of an
ELISA were performed. In the first, plates were coated
with immunopurif ied MHC class II and the pi or pl:Env
preparations were added. The wells were then incubated
with polyclonal rabbit anti-VLP serum, followed by a
horseradish peroxidase-linked anti-rabbit antibody and
developed.
In the second type of experiment plates were coated
with pi or the pl:Env fusion proteins and immunopurified
MHC class II was added. This was followed by a
polyclonal rabbit anti-MHC class II serum, and the rest of
the development of the ELISA was continued as above.
The results for the first type of ELISA are shown in
figure 6.5 It is not possible to determine accurately
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Figure 6.5
EEISA to detect binding of pl:Env fusion proteins to MHC
class II
Wells were coated with MHC class II and the pl/pl:Env
fusion proteins added. Binding was detected using
rabbit anti-VHP serum (Rbl94) @ 1 in 1500 and anti-
rabbit horseradish peroxidase @ 1 in 1000.
The stages up to the addition of the horseradish
peroxidase conjugate can be summarised as follows:
Step 1 Step 2 Step 3 Step 4
cl II block - anti-cl II =Rbl64
pl/Env block - anti-VHP =Rbl94
cl II block pl/Env anti-VLP =x
block pl/Env anti-VHP =y
cl II = class II














the amounts of MHC class II in the immunopurif ied
preparations, due to the presence of triethanolamine in
the solution. From silver stained SDS-PAGE gels the
concentration was estimated as 5-10ug/ml and approximately
30ng were used to coat the wells. Control wells coated
with MHC class II and developed with MHC class II serum
showed that the wells had been successfully coated (figure
6.5). Wells were also coated with the pi or pl:Env
preparations to confirm that the amount of these proteins
added to the coated wells was sufficient to be detectable.
Figure 6.5 shows this to have been the case. The
dilutions of the sucrose gradient purified samples used
were: pi - 1 in 5,000, pl:EnvA - 1 in 20,000, plrEnvB - 1
in 2,500 and pl:EnvC - 1 in 2,500. It had previously been
determined using the same rabbit anti-VLP detection system
that coating the plates with these dilutions of the pi and
pl:Env preparations resulted in final absorbance readings
which lay within the linear range of ELISA values in a
dilution series of each protein (data not shown).
The pi and pl:Env fusion proteins were added to wells
which had been coated with MHC class II. The preparations
were also added to wells which had not been coated with
MHC class II but had been blocked in the same way as these
wells. The values shown in figure 6.5 represent the
difference of the two sets of readings for each sample.
Four replicates were recorded for binding to the MHC class
II coated wells, and two for binding to the control wells.
The standard deviations for the binding to the coated
wells are shown.
The OD492 readings are low for the pi and the pl:Env
fusion proteins, and there is no significant difference
between the values for any of the preparations. Therefore
there was no detectable binding of the recombinant gpl35
proteins to MHC class II in this assay system.
In the second approach to this problem the plates
were coated with the pi or pl:Env preparations. Much
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higher concentrations of the sucrose gradient purified
fractions were used ie pi - 1 in 1000, plrEnvA - 1 in 200,
plrEnvB - 1 in 50 and plrEnvC - 1 in 50. This was to
ensure that the wells were saturated. The OD492 readings
after development with the rabbit anti-VLP serum are shown
in figure 6.6. Wells were also coated with approximately
30ng of MHC class II and developed using the rabbit anti-
MHC class II antiserum, to confirm that detectable amounts
of MHC class II were added in the test wells. MHC class
II was added to pl/pl:Env-coated wells and the ELISA was
developed with the rabbit anti-MHC class II serum. As a
control the same serum was also used in wells which had
been coated with the pi or pl:Env preparations, but to
which MHC class II had not been added. The data shown for
the test samples in figure 6.6 represents the difference
of these two values. Six replicates were made of the test
samples and two of each control. The standard deviations
of the test samples are shown.
The results displayed in figure 6.6 indicate that
there is no significant difference between the results
obtained in the test samples for pi, pl:EnvA and plrEnvB.
There is a slight difference in the results for pi and
plrEnvC but this is unlikely to be significant. The
controls with anti-VLP serum demonstrate approximately 25%
higher reactivity with pl:EnvC over pi alone, suggesting
that at the dilutions used the plrEnvC preparation is
present in relative excess compared with pi, for this
detection system. If the test result for pi was raised by
25% to compensate for this relative inequality there would
be no significant difference between the results for the
samples.
The experiments outlined in this section therefore do
not indicate any detectable binding of the recombinant
gpl35 fragments to immunopurified MHC class II molecules,
and it is consequently impossible to speculate which
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Figure 6.6
EEISA to detect binding of MHC class II to pl:Eriv fusion
proteins
Wells were coated with pl/pl:Env fusion proteins and MHC
class II antigens added. Binding was detected using
rabbit anti-MHC class II serum (Rbl64) @ 1 in 1000, and
anti-rabbit horseradish peroxidase @ 1 in 1000.
The stages up to the addition of the horseradish
peroxidase conjugate can be summarised as follows:
Step 1 Step2 Step3
cl II block -
pl/Env block -
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class II p1 p1:A p1:B p1:C p1 p1:A p1:B p1:C
Rb164 Rb194 - (class M+Rb164)-(Rb164) -
regions, if any, of MVV gpl35 interact with this cellular
molecule in the infective process.
6.5 Attempts To Block MVV Infection Of Skin Cell Cultures
With The pl:Env Fusion Proteins
Under normal circumstances the envelope glycoprotein
is the molecule which first mediates the interaction of
MVV and a susceptible cell. In HIV it has been shown
that preincubation of cells with free gpl20 inhibits the
fusion of CD4-positive cells with HIV-infected cells
(Putney e_t al. , 1986; Matthews e_t a_l. , 1987) by
interacting with the cellular CD4 and thereby preventing
attachment by the cell-associated gpl20.
Experiments were performed in which susceptible skin
cells were preincubated with the pl:Env fusion proteins
prior to infection with MVV. The skin cell cultures were
subsequently analysed to determine if the preincubation
had led to any decline in virally-induced cpe in vitro.
848 skin cells were grown in 96 well plates until just
sub-confluent. The medium was removed and the cells
washed in fully supplemented 2% DMEM. The peak pi or
pl:Env sucrose gradient purified fractions were diluted 1
in 100 in the same medium. At this dilution the level of
yeast cell contaminants in each of the pl:Env
preparations is approximately equivalent, and the level of
pi protein in the control is in excess. The cells were
incubated for 1 hour at 37°C with 50ul of the diluted
fractions. MVV strain EVl was added in a further volume
of 50ul of the same medium. A range of virus
concentrations was used ie 6 TCID^q, 3 TCID^q and 0.6
TCID^q per well. The plates were incubated under the same
conditions for a further hour, the medium was then removed
and the cells washed in lOOul of fully supplemented 2%
DMEM. lOOul of this medium, containing a 1 in 100
dilution of the appropriate pi or pl:Env preparations were
added to each well. The plates were incubated for 7 days
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under standard conditions. At the end of this period the
monolayers were stained with Giemsa and examined
microscopically. Quadruple replicates were performed for
each test. Control wells, which were treated either with
MVV alone, cell-conditioned medium or pl/pl:Env proteins
alone were also included.
Significant cpe, in the form of large quantities of
multi-nucleated syncytia was apparent for all monolayers
incubated with MVV, at each of the viral doses used.
There was no apparent difference between the cultures
incubated with virus in the presence or absence of pi or
the pl:Env preparations. No syncytia were observed in the
wells incubated with conditioned medium. There was no
apparent toxicity of pi or the pl:Env fusion proteins at
the concentrations used in this experiment.
The experiment was repeated under similar conditions
but with YT40 skin cells in place of 848 cells, as the 848
cells available at the time of this repeated experiment
were growing very poorly. In an attempt to increase the
probability of detecting any inhibitory effect of the
fusion proteins on infection some of the assay conditions
were altered. MVV strain EV1 was used at 1.5 TCID^q, 0.6
TCID^q and 0.3 TCID^q per well. The pi preparation was
used at a dilution of 1 in 100 and all the pl:Env
preparations were used at a dilution of 1 in 10.
After incubation and staining it was observed that
the monolayers were no longer confluent but consisted of
individual cells. This was independent of the different
constituents added to the wells. Possibly as a
consequence of this disruption of the monolayers no
virally-induced cpe was detectable in any of the wells.
Therefore no conclusions could be drawn about possible
effects of the fusion proteins upon the outcome of viral
infection in these cells. However, in all wells to which
the pl:EnvC fusion protein had been added there was
complete destruction of the monolayer, with only 3 to 4
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cells remaining per field. This destruction was observed
in both the presence and absence of MVV and indicates that
the pl:EnvC preparation is toxic to these cells when added
at a high concentration.
The data presented in this section therefore do not
show any inhibitory effect of the pl:Env fusion proteins
on MVV infection in vitro. In order to confirm this
further experiments using a wide range of dilutions of
both the virus and the fusion proteins would be required.
This was not possible in the time available for these
experiments.
6.6 Discussion
In an attempt to correlate function of MVV gpl35 with
different regions of the molecule the pl:Env fusion
proteins expressed in the yeast Ty-VEP expression system
were used in a variety of assays. These failed to
demonstrate detectable interactions between the fusion
proteins and cellular molecules and therefore it has not
proved possible to determine which regions of gpl35 are
for example involved in receptor binding and post-binding
entry events. Some of these aspects of the MVV life-cycle
may be addressed more successfully when antisera raised
against the GSTrEnv fusion proteins become available.
However, for the future design of experimental protocols
it is important to consider possible reasons for the lack
of detectable activity observed in the assays reported in
this chapter. These fall into two major classes:
technical problems with the expression and purification of
the fusion proteins, and problems which may arise from
using fragments of gpl35 rather than the whole molecule.
One of the major problems in attempting this work was
the combination of poor yields and low purity of the
pl:Env fusion proteins. This was exacerbated by the use
of a polyclonal anti-VLP serum, which cross-reacted with
yeast cell contaminants, as a detection method in many of
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the experiments. At the time when the experiments were
performed no characterised anti-pl monoclonal antibody was
available. Although controlled for as much as possible in
the experiments this may have created conditions
unfavourable for detecting any interactions which were
relatively low-affinity and/or low frequency.
In section 6.2 it was reported that no specific
interaction could be observed for the pl:Env fusion
proteins with fixed cell monolayers. There was a high
level of non-specific reactivity which was also apparent
after incubation of the monolayers with the pi protein
alone. The intensity of this staining was greatest for pi
and pl:EnvA, and was less intense for pl:EnvB and pl:EnvC.
The pi preparation contained few detectable contaminating
proteins, and those that were present were at much lower
concentrations than in the pl:Env fusion protein
preparations. In the pl:Env fusion protein preparations
the contaminating proteins were present at approximately
equivalent concentrations in all three samples, but levels
of the fusion protein itself were greatest in the pl:EnvA
preparation. As the intensity of staining observed was
greatest with the pi and pl:EnvA fusion protein it is
possible that the molecule which was binding to the fixed
cells was pi. In the absence of a pl-specific monoclonal
antibody it is not possible to confirm this directly and
there is no available data on the cellular molecule which
could mediate such an interaction with pi. It is possible
that pi is binding to a cellular molecule which under
normal physiological conditions interacts with an
unrelated protein. pi is believed to be permanantly
intracellular in yeast and there is no known reason why
ovine skin cells would interact specifically with such a
yeast protein.
Ovine efferent lymph cells were fixed and stained
successfully with a polyclonal anti-ovine MHC class II
serum, suggesting that the protocol used was effective in
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the detection of at least some cellular molecules.
However it was not possible to determine directly that the
cellular receptor for MVV on the skin cells had been
maintained in an intact form. No suitable detection
system was available to confirm this.
No specific interaction was demonstrable for the
pl:Env fusion proteins and a lysate of MVV-susceptible
cells (section 6.3). Where the lysate was incubated with
the pl:Env fusion proteins, or a crude preparation of pi
alone a band was detected, but this was not observed
following incubation with purified pi. This indicated
that a non-pl yeast component was capable of interacting
with a cellular molecule in this assay system. This does
not necessarily contradict the result obtained using fixed
cell monolayers from the same cell line, in which it
appeared likely that the cells were interacting with the
pi component of the fusion proteins. The differences
between the two sets of results are possibly a consequence
of the non-reduced and reduced nature of the cell
preparations in the two systems. The results with the
cell lysate demonstrate the importance in these
experiments of controlling for both the pi and non-pl
components of the fusion protein preparations.
In section 6.4 it was reported that there was no
detectable interaction between MHC class II molecules and
the gpl35 region of the fusion proteins. Technical
problems with the assay system may have contributed to
this failure to observe a specific interaction. In the
first ELISA-based experiment reported in this section the
four pl/pl:Env fusion preparations were used at different
dilutions. These had been previously selected to yield
comparable final readings, within the linear range on a
dilution series when developed with the anti-VLP
antiserum. In order to achieve this the purified pi and
pl:EnvA were used at dilutions of 1 in 5,000 and 1 in
20,000 respectively. However the results in chapter 4
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demonstrated that yields of pi alone were much higher than
pl:EnvA, and therefore to obtain comparable ELISA readings
it would have been expected that pi should be diluted to a
much greater extent than pl:EnvA. The disparity observed
in these experiments highlights the fact that a similar
ELISA reading based on reactivity with the anti-VLP serum
does not directly correlate with absolute levels of pi.
In addition ELISA values were affected by the amounts of
contaminating proteins present which are also detectable
by the anti-VHP serum. However, despite this it might
have been anticipated that if there had been a specific
interaction of the Env regions of the fusion proteins with
MHC class II this might have been preferentially detected,
as coating the plates with MHC class II molecules would
have lent specificity to the molecules which would bind to
the wells. At the concentrations used in this experiment
no such interaction was observed.
No specific interaction was detectable when the
plates were coated with the pi or pl:Env fusion proteins,
and then incubated with MHC class II. Much higher
concentrations of the fusion proteins were used than in
the previous experiment, although this could also result
in higher levels of the contaminating proteins which would
compete for binding sites on the plates. Again it must be
noted that similar ELISA readings for the pi and pl:Env
fusion proteins with the anti-VLP serum do not necessarily
imply that equivalent amounts of pi and pl:Env had coated
each well.
From these ELISA results it remains theoretically
possible that MHC class II and the Env regions of the
fusion proteins do interact but this has been undetected.
This could be due to the combination of the low yields and
poor purity of the fusion protein preparations, and the
polyspecific reactivity of the anti-VLP antiserum which
makes precise quantitation of the relative levels of the
pl:Env fusion proteins difficult.
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No interaction of the pl:Env fusion proteins with MHC
class II was observed when the fusion protein preparations
were incubated with MHC class II immobilised by blotting
onto nitrocellulose after SDS-PAGE. This was despite
using the pl:Env preparations at higher concentrations
than in the ElISA-based experiments.
In none of the techniques used therefore was a
specific interaction between MHC class II and the Env
regions of the fusion proteins demonstrated.
In the experiments in section 6.5 the fusion proteins
were used in an attempt to block infection of susceptible
skin cell lines by MVV. In the first set of experiments
no inhibition of infection was detectable. It is possible
that the fusion proteins may have been causing some
inhibition of infection but that the assay system used
(checking for virally-induced syncytia) was too
insensitive to detect this decrease. An alternative
detection system, based on a p30 assay or monitoring
reverse transcriptase levels (possibly at earlier time
points post-infection) might yield more definitive
results. However, even at the lowest viral dose used (0.6
TCID50) no inhibitory effect of the fusion proteins on
virally induced cpe was apparent.
It is possible that the levels of fusion protein
added to the cells were inadequate to block viral
infection. In HIV concentrations of gpl20 as low as 2-4nM
have been shown to block the fusion process (Matthews e_t
al. , 1987). It is not possible to determine accurately
the amount of fusion protein in the pl:Env preparations
for the reasons described in chapter 4. However, from a
silver stained gel of pl:EnvA it can be estimated that 5ul
of the peak sucrose gradient purified fraction contained
approximately 50ng (from band intensity). Using a
molecular weight of 97kDa for the pl:EnvA fusion protein
it is possible to estimate that a concentration of pl:EnvA
of approximately InM was used in these experiments.
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Although this figure is very much an approximation it may
indicate that the amount of fusion protein added to the
cells was perhaps insufficient to achieve inhibition, had
this been possible with these constructs. This does
assume however that HIV gpl20 can be used as a model for
MVV gpl35.
In an attempt to check that there was no detectable
inhibition of infection by the fusion proteins the amounts
added to the cells were increased by an order of
magnitude. In this experiment it was difficult to detect
MVV-induced cpe in any of the wells, and therefore no
conclusions could be drawn regarding the ability of the
fusion proteins to block infection. It was observed that
at the concentration used pl:EnvG caused almost total
destruction of the cell monolayer. As the pl:Env fusion
proteins appeared from silver staining of SDS-PAGE gels to
contain approximately equivalent levels of contaminating
yeast proteins it is probable that this toxicity was due
to the pl:EnvC protein itself. There is no direct
evidence for the region of plrEnvC which causes this
cellular destruction. EnvC contains highly hydrophobic
regions (chapter 3) which may be possible candidates if
they lead to non-specific interaction with, and disruption
of the cellular membrane. This may be particularly
relevant to the highly hydrophobic C-terminal of EnvC, as
it would be anticipated that this would be external on the
VILPs. It would be necessary to generate deletion mutants
or chimeric versions of the fusion protein to confirm
this.
It is clear that much of the work reported in this
chapter could have been more easily standardised and
controlled with recombinant gpl35 fragments which were
produced with higher yields or at least improved purity
(this will be discussed further in chapter 8). The use of
a more readily quantifiable assay system for some of the
work would also improve the confidence with which these
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negative results are interpreted. There was no indication
with any of the variety of techniques used that the fusion
proteins interacted with any cellular molecules. If it is
assumed that this lack of interaction is genuine, and not
just a consequence of the low levels of the fusion
proteins for example it is important to consider the
possible reasons for this.
It has been assumed throughout this work that the Env
regions of the fusion proteins are accessible in the VLP
preparations. In the formation of hybrid VLPs the pi
molecules are expected to assemble such that the non-pl
fragment of the fusion protein is external on the VLP
(Adams e_t a_l. , 1988). However there was no direct
confirmation of this for the fusion proteins used in these
experiments. If the particles had mis-assembled such that
all the gpl35 fragments were completely sequestered within
the VLP it would be impossible for them to interact with
any cellular molecules, and therefore negative results
would be obtained in all the assays attempted in the
experiments reported in this chapter.
For expression in the Ty-VLP system large overlapping
fragments of gpl35 were chosen. This was to attempt to
maintain, at least partially, the three-dimensional
integrity of the intact protein. There is however no
published data on the secondary, tertiary or quaternary
structure of MVV gpl35. There are 24 cysteine residues in
MVV EV1 gpl35 (Sargan e_t al. , 1991) and therefore there is
the potential for the formation of extensive secondary and
tertiary structure. It is possible that even the use of
relatively large fragments of gpl35 as fusion proteins has
resulted in the loss of structural motifs critical for
interaction with the cellular receptor(s).
It is possible that the lack of any observed
interaction between the fusion proteins and cellular
molecules is due to the relative lack of glycosylation of
the fusion proteins, compared with the glycosylation of
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native gpl35. As described in chapter 4 only the pl:EnvA
fusion protein may be glycosylated, and it is possible
that the glycosylation of this fragment does not mimic
glycosylation of the native protein.
The role of glycosylation in the function of
lentiviral envelope proteins has been most extensively
studied for HIV gpl20 but much of the data is
contradictory. It has been reported that the removal of a
single glycosylation site at amino acid 400 of HIV-2 gpl05
leads to a 50-fold decrease in the efficiency of binding
to CD4 (Morikawa £t _al., 1991). However it is not clear
that the decreased affinity for CD4 was a direct
consequence of the loss of carbohydrate at the residue.
It has been shown that the loss of infectivity observed
when a potential glycosylation site of HIV-1 gpl20 was
mutated was actually due to alteration in the
secondary/tertiary structure of the protein, not the loss
of carbohydrate (Willey ert al. , 1988).
It has been reported that unglycosylated recombinant
full-length and truncated gpl20, and deglycosylated native
gpl20 lose the ability to bind to CD4, and to block
fusion (Putney e_t a_l. , 1986; Matthews e_t ail. , 1987;
Morikawa e_t al, , 1990). It was therefore suggested that
glycosylation of gpl20 was essential for receptor binding.
However similar experiments with recombinant gpl20 and
gpl20 on intact virions has shown a diminuation in binding
to CD4 and infection, but not an abolition of the
interaction (Fenouillet e_t a_l. , 1990). The variation
observed by different workers may reflect differences in
technique, whether in the deglycosylation process or the
subsequent functional assays. The presence of
carbohydrate on gpl20 appears therefore to affect the
interaction of the molecule with its cellular receptor but
the degree of importance of this in the viral life cycle
is currently unclear. A major role of the extensive
glycosylation of gpl20 may be protection in vivo from
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potentially neutralising antisera (Davis e_t a_l. , 1990).
It is therefore possible that the inability to detect
any interaction of the MVV gpl35 fragments with cellular
molecules reported in this chapter is a consequence of the
apparent lack of appropriate glycosylation of the fusion
proteins. Carbohydrate residues may be required for
effective interaction of the virus and its receptor(s).
In order to address this problem it would be necessary to
express the gpl35 fragments in an expression system in
which normal glycosylation could take place.
It is also possible that the lack of interaction
observed with MHC class II molecules may indicate that it
is not gpl35 that interacts with this molecule. The data
of Dalziel e_t a_l. (1991) does not conclusively demonstrate
that the postulated interaction with MHC class II is
dependent on MVV gpl35. If another viral protein for
example gp46 is involved then it would not be expected
that an interaction would be observed with the fusion
proteins used in these experiments. However, this cannot
explain the lack of interaction with skin cell lysates,
which are expected to contain the cellular receptor which
interacts with gpl35.
6.7 Summary
This chapter reports attempts to use the pl:Env
fusion proteins to identify regions of gpl35 which are
functionally involved in interactions with cellular
molecules. It was not possible to demonstrate any
specific binding of these fusion proteins in the variety
of assays used in these investigations. This may have
been due to the rather unsatisfactory yields and purity of
the fusion proteins, or it may have been a consequence of




Each results chapter in this thesis has contained an
extensive discussion of the data presented, and these will
not be repeated substantially in this chapter. This final
discussion will attempt to summarise the major findings of
this study on MVV gpl35, and to indicate new areas of
research which have been suggested by the work reported
here.
There have been no previous reports of the generation
of MVV gpl35 recombinant proteins. In the work reported
here the entire gpl35 protein was expressed in the form of
3 overlapping fragments in the yeast Ty-VLP expression
system, and the C-terminal 60% of the protein has also
been expressed in the bacterial pGEX expression system.
Parameters affecting the success of recombinant fusion
protein production in these systems have been analysed,
and the env gene sequences inserted into the expression
vectors have been shown to exert a major effect on fusion
protein expression. As poor yields were encountered in
both expression systems it is possible that sequences
within MVV gpl35 tend to have a generally deleterious
effect upon fusion protein production. This could not
realistically have been predicted in advance. It may be
possible to improve the yields of recombinant MVV gpl35 by
cloning smaller fragments of the gene into expression
vectors. This could also allow the identification of
those features which appear to lead to poor yields of the
proteins.
Although some of the work reported in this thesis was
hampered by the poor yields and low purity of the fusion
proteins certain interesting observations were made.
Perhaps unexpectedly the plrEnvA fusion protein generated
in the yeast Ty-VLP expression system was shown to be
glycosylated. There have been no previous reports of
glycosylation in this expression system, and it is
possible (although not actually demonstrated) that the
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glycosylation of the fusion protein affected assembly of
the VLPs. By cloning smaller fragments of the envA region
of gpl35 into the same expression system it may be
possible to determine which part of the EnvA protein leads
to this glycosylation. Any candidate region could also be
used to generate a chimeric molecule, for example with one
of the other gpl35 regions, to determine if this leads to
glycosylation of a previously unglycosylated fusion
protein.
By using the recombinant proteins it was demonstrated
that MVV-infected sheep differ in the regions of gpl35 to
which they have mounted a detectable antibody response,
and this observation may lead to interesting subsequent
lines of investigation. A preliminary retrospective
longitudinal study is about to be undertaken in the
Department Of Veterinary Pathology (Dr. R.G. Dalziel,
personal communication) to determine if the response of
individual sheep to different regions of gpl35 varies
during the course of infection. It will also be
interesting to investigate if there is any correlation of
disease progression with the anti-gpl35 responses. It may
also be possible to link the anti-gpl35 response to the
neutralisation capability of sheep sera in vitro and so
begin to identify regions of gpl35 involved in the
infective process. Prior to the generation of the
recombinant proteins this work would not have been
feasible.
Although none of the pl:Env fusion proteins were
found to interact detectably with cellular molecules, or
to inhibit infection in vitro the recombinant proteins may
still be useful novel reagents for functional studies of
MVV gpl35. If an E.coli clone which expressed GST:EnvA
can be successfully generated it would be appropriate to
repeat the experiments reported for the pl:Env fusion
proteins in chapter 6, but using the GST:Env fusion
proteins. This would require an anti-GST antiserum (or
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preferably a monoclonal antibody) and immunisation of
rabbits and mice has begun at the time of writing.
The GST:Env proteins will be useful reagents for
these functional studies, as they can be produced with
much higher purity than the pl:Env fusion proteins. As
there are fewer contaminants it may be possible to use
much higher absolute levels of the fusion proteins
themselves in these experiments, which may improve the
likelihood of detecting interactions with cellular
molecules. It will be interesting to determine if eluted
GST:EnvC shows the same toxicity for skin cell cultures as
pl:EnvC or if this is dependent on assembly into the VLPs.
Both the pl:Env and GST:Env fusion proteins could be
used in inhibition of neutralisation assays. In these
assays neutralising sera are preincubated with the fusion
proteins, before incubation with virus. If any of the
fusion proteins inhibit viral neutralisation this may
indicate regions of gpl35 which are targets in vivo for
neutralising antisera, and which may be important in the
initial stages of viral infection of cells. This would be
best attempted using a sensitive detection system, for
example monitoring reverse transcriptase levels, or p30
antigen detection.
The data reported for GST:EnvB suggested that rabbits
immunised with this protein were beginning to mount an
immune response to the gpl35 region. If the GST:Env
fusion proteins prove to be effective immunogens a wide
range of experiments will become possible, which may begin
to identify regions of gpl35 involved in interactions with
cells.
Both polyclonal antisera and monoclonal antibodies
could be screened to determine if they are able to inhibit
viral infection in vitro. This will allow identification
of regions of gpl35 which are involved in viral infection,
information which does not currently exist for MVV.
Monoclonal antibodies may be particularly informative for
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this purpose. The monoclonal antibodies can be mapped
crudely to different regions of gpl35 rapidly and simply.
For example, a monoclonal antibody raised initially
against EnvA, but which also cross-reacted with EnvB could
be predicted to recognise an epitope in the overlap
between the 2 proteins. Similar mapping will be possible
using the overlap between EnvB and EnvC. The N-termini of
the Rev and gpl35 proteins are coincident, and the
availability of recombinant Rev protein in the Department
Of Veterinary Pathology will allow further mapping of
anti-EnvA monoclonal antibodies.
If any of the antisera are found to be neutralising
it will be of interest to investigate at which point they
interrupt the infection process. It is likely that
antibodies to different regions of gpl35 may affect
different events for example initial binding, or post-
binding entry events.
There still remains considerable interest in the
identity of the cellular receptor(s) for MVV. Antisera
raised against the recombinant proteins may be useful
reagents for analysing this interaction.
Immunoprecipitation of infected cells using the antisera
(pooled polyclonal antisera would be the most appropriate
initial choice) could be used to precipitate viral gpl35
cross-linked with cellular molecules with which it
interacts. These molecules could be analysed by SDS-PAGE.
The data reported in chapter 3 demonstrated that
within the EV1 strain of MVV there appear to be conserved
and variable regions of amino acids. The majority of
these coincide with conserved and variable regions
identified previously in the comparison of different
isolates of MVV. The inherent variability of MVV, which
is characteristic of the lentiviruses may lead to
difficulties of interpretation in some experiments. For
example in longitudinal studies of the response to MVV
strain EV1 the risk is always present that an infected
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animal fails to respond to a particular gpl35 region
because it has never encountered the antigenic sequence of
the recombinant protein. However, although much of the
work could be simplified if an infectious clone was
available the data presented in chapter 3 does suggest
possible further avenues of investigation.
Any neutralising antisera raised against the
recombinant gpl35 fragments could be tested against
different viral strains eg Icelandic variant 1514, and
against sequential isolates of EV1, or British field
isolates of MVV.
It was demonstrated in chapter 3 that there are
variations in the amino acid sequences between certain of
the gpl35 variants. These variants could all be expressed
individually, possibly using an in vitro translation
system and tested with sera from infected sheep. As the
regions of amino acid diversity are already known for
these fragments it would be possible to predict the
regions which resulted in any change in reactivity of
sheep sera with a particular gpl35 variant.
The same approach could also be used to map the
monoclonal antibodies obtained using the GSTrEnv fusion
proteins.
The data in chapter 3 indicated regions of gpl35
which are variable between viral isolates. It will be
interesting to expand this work to investigate the extent
of this variation in vivo, in both experimentally and
naturally infected sheep (again an infectious clone would
be useful for this study). From the data in chapter 3 it
is possible to select PGR primers which would generate
fragments which span regions of high predicted
variability. Rather than introduce selection of viral
variants which grow well under tissue culture conditions
it may be more appropriate to perform the PCR without an
intervening in vitro passage. The generated fragments
could be sequenced directly, and they could also be
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inserted into expression systems for further analysis with
monoclonal antibodies. As controls the same protocol
could be used to generate fragments of predicted high
conservation.
Summary
Reagents have been generated which allow potential
investigation of the interaction of MVV gpl35 with the
host animal, both at the level of infection of individual
virus-susceptible cells, and the host immune response to
this protein. There have been no published reports of the
generation of recombinant MVV gpl35 proteins previously,
and these are reagents which may be critical in
investigating the structural-functional relationships of
this protein. The level of variability of this protein in
vitro has been investigated, and this data will allow the
selection of regions of gpl35 for further study with more
confidence than was previously possible.
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Yeast N2~base (no amino acids) 0.67%
D-glucose 1%
Sc-glc-agar










Yeast ^-base (no amino acids) 0.67%
Glucose 1%
Agar 3%








Fully Supplemented 8% Dulbecco's Modification Of Eagle's
Medium (8% DMEM)
DMEM lx
(with non-essential amino acids)





Fully Supplemented 2% DMEM
DMEM lx
(with non-essential amino acids)





EDTA 5 x 10~4M



























NBT Western Blot Development Solution
Tris-HCl pH9.5 0.1M















d = - X£
/3.TJ nl n2
P 0.05 0.02 0.01
d 1.960 2.326 2.576
0.002 0.001
3.090 3.291
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